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Summary 
Introduction 
The new European Union (EU) Pharmacovigilance, implemented in 2012, aimed to establish a more 
proactive and efficient system for the early detection and prevention of issues related to the safety of 
medicinal products. This goal is reflected by the legal enforcement of Risk Management activities. As 
a consequence, it is necessary to submit a Risk Management Plan (RMP) with each application for a 
new marketing authorisation. This document includes a critical assessment of the known and 
unknown safety profile of the medicinal product and discusses the need to implement 
Pharmacovigilance and risk minimisation activities that go beyond the routine ones.  
A Post-Authorisation Safety Study (PASS) is an additional Pharmacovigilance activity conducted 
with the goal of identifying, characterising or quantifying a safety hazard, confirming the safety 
profile of the medicinal product, or of measuring the effectiveness of risk minimisation measures 
(RMMs). They bridge Pharmacovigilance, which defines the mission, with Pharmacoepidemiology 
which provides the study methods. PASS can be imposed as condition or special obligation to the 
marketing authorisation and may also be requested upon conclusion of a safety related referral.  
The Pharmacovigilance Risk Assessment Committee (PRAC) is a committee of the European 
Medicines Agency (EMA) created by the new Pharmacovigilance legislation. It is responsible for 
the assessment of safety issues at EU level, as well as the monitoring of the Pharmacovigilance 
activities foreseen in the legislation. In addition, as a consequence of the efforts to increase 
transparency of the regulatory processes and decisions, the EMA publishes the PRAC monthly 
minutes on its website. These documents list all the assessed Pharmacovigilance procedures with a 
brief summary of the plenary decisions. The availability of these and other documents provided an 
opportunity to identify the PASS protocols submitted to the PRAC. 
The objective of the current dissertation was to describe the PASS landscape during the first three 
complete years of the new Pharmacovigilance legislation by characterising the purpose and 
methodology of the studies. It also aimed to give a critical perspective on the level of public available 
information on the PASS review process and PRAC feedback. 
Methods 
The minutes of the PRAC meeting minutes held from July 2012 to July 2015 were chronologically 
reviewed to identify and track all PASS protocols and respective rounds of review. The information 
from the minutes was complemented with a review of the European Public Assessment Reports 
(EPARs) for the medicinal products covered in the PASS, which provided information about the 
regulatory background. Moreover, the European Union electronic Register of Post-Authorisation 
Studies (EU PAS) Register available in the European Network of Centres for Pharmacoepidemiology 
and Pharmacovigilance (ENCePP) website was also searched to find information about PASS 
methodology and protocol documents.  
Upon protocol availability, it was possible to retrieve more granular information. Metrics regarding 
the PRAC assessment process were determined among protocols that were considered approved based 
on the following rules: there was information in the PRAC comments text, the PASS was found in the 
EU PAS Register, or more than one year had elapsed since the last assessment of that PASS protocol.  
Descriptive analyses were performed on actual data, with no imputations for missing data. 
Comparisons using chi-square test (with a significance level of 5%) were conducted.  
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Results 
In total, 189 different PASS protocols were identified by reviewing the minutes of the PRAC 
meetings from July 2012 to July 2015, corresponding to 353 PASS protocol submissions to the 
PRAC. The outcome of PRAC assessment was only available in the minutes for approximately one 
third (30%) of the 353 assessments. Only half of the 189 PASS were available in the EU PAS 
Register at the data lock, July 2015. 
The majority of PASS (58%) concerned new marketing authorisations. About one third (31%) of the 
189 PASS were imposed by the regulators.  
The vast majority of PASS (74%) had at least one objective related with investigation of safety 
concerns, while approximately one third (34%) included at least one objective of assessing drug 
utilisation and one fourth (25%) incorporated at least one objective related with assessment of 
effectiveness of RMMs. Almost one third of the PASS (31%) combined objectives of at least two of 
those categories. 
PASS were mainly designed as longitudinal studies (81%). However, the majority of PASS (56%) 
with at least one objective concerning the assessment of effectiveness of RMM had a cross-sectional 
design. Overall, slightly more PASS involved a primary data collection approach (58%). Among 
PASS with at least one objective related with assessment of drug utilisation, 58% leveraged data 
collection schemes already established for other purposes. More than two thirds of PASS (70%) 
focused on a single medicinal product as eligibility criteria (either patient exposure or prescribers of 
the medicinal product of interest), while broader exclusion criteria were less frequent.  
Among the 57 available protocol documents, only one third (33%) mentioned a comparator, such as 
another medicinal product, a non-exposed group or external data sources. All 57 PASS included at 
least one European country. 
The majority of the 18 available protocols in which at least one objective was to assess effectiveness 
of RMM did not specify how success of those measures would be ascertained. One third (33%) of 
these PASS aimed exclusively to assess effectiveness of RMM and were designed as cross-sectional 
studies using a questionnaire to assess knowledge and auto-reported behaviour.  
The most common areas of the protocol referred as responsible for the rejection of the protocols by 
the PRAC were related to inadequate study design (37%) and concerns with study feasibility (30%) 
requiring evidence that bias and limitations were adequately considered. The comments corroborate 
the general insight that the there was a limited level of detail in the PASS protocols. 
PRAC protocol assessment metrics were estimated among 37 imposed PASS considered approved. 
The results suggested a decrease in the median number of rounds of review from 3 to 2 and an 
average decrease of 6 months in overall review time between the first and the third year of the review. 
Discussion 
This was the first comprehensive characterisation of the PASS protocols submitted to the PRAC 
during the first three years under the new Pharmacovigilance legislation.  
Overall, the results showed that despite the unprecedented level of transparency achieved, which 
made this study possible, there is still room for improvement in the level of information provided by 
regulators and MAHs. An increased publication of the outcomes of PRAC assessment and more 
adherence to the EU PAS Register, would increase the pool of knowledge available to further 
improve PASS.  
It was also evident that there is and some lack of communication between different stakeholders, 
which may be worsened by the lack of uniform terminology. The limited level of detail in the 
protocols is not in line with good pharmacoepidemiology and good pharmacovigilance practices 
(GPP and GVP), both emphasising the need to include details on the reasoning behind the 
methodological decisions and feasibility considerations. 
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The recognition of the singularity of PASS, as pharmacoepidemiological studies that have a specific 
mission within the medicinal products’ RMPs, calls for alignment of different parties and cross-
pollination of different skills, including qualitative and quantitative approaches and combined study 
designs, to tailor the best approach for each safety question.  
Conclusion 
Cross-functional collaboration and communication across stakeholders, higher levels of 
transparency and the use of a harmonised terminology would be key to develop innovative methods, 
customised for the singular and multifaceted needs of PASS, an example of which being the 
assessment of effectiveness of RMM. The anticipated result would be the implementation of best 
practices that will certainly contribute to a safer use of medicinal products.  
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Pharmacoepidemiology; Pharmacovigilance Risk Assessment Committee (PRAC)  
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Resumo 
Introdução 
A nova legislação europeia de Farmacovigilância, implementada em 2012, visou o estabelecimento 
de um sistema mais proativo e eficiente para a deteção atempada e prevenção de problemas de 
segurança dos medicamentos. A obrigação de submeter Planos de Gestão do Risco com todos os 
pedidos de Autorização de Introdução no Mercado (AIM) de novos medicamentos reflete esta 
direção. Nestes documentos o titular de AIM deve apreciar o perfil de segurança conhecido e 
desconhecido do medicamento e ponderar a necessidade de implementar atividades de 
Farmacovigilância ativa e medidas de minimização do risco para proteção da saúde pública. 
Os estudos de segurança pós-autorização (Post Authorisation Safety Studies, PASS) são uma 
atividade de Farmacovigilância ativa cujo objetivo é identificar, caracterizar ou quantificar o perfil 
de segurança de um medicamento ou medir a eficácia das medidas de gestão dos riscos. Resultam 
da convergência entre a Farmacovigilância que define a missão e a Farmacoepidemiologia que 
fornece os métodos para o estudo. De acordo com a nova legislação, as autoridades competentes 
podem impor a realização de PASS como condições da AIM ou em sede de AIM concedida em 
circunstâncias especiais.  
Outra novidade da nova legislação de Farmacovigilância foi a criação de um novo comité da Agência 
Europeia do Medicamento, o Pharmacovigilance Risk Assessment Committee (PRAC), que tem 
como objetivo avaliar todos os problemas de segurança de medicamentos ao nível da União Europeia 
e supervisionar todos os processos de Farmacovigilância que a legislação prevê. Como consequência 
dos esforços para aumentar a transparência das decisões e processos regulamentares, as minutas das 
reuniões mensais do PRAC são publicadas no website da Agência e listam todos os processos 
avaliados pelo PRAC, juntamente com um pequeno sumário das decisões tomadas em plenário. A 
disponibilidade destes documentos tornou possível a identificação dos protocolos dos PASS 
submetidos para avaliação do PRAC desde a implementação da nova legislação em Julho de 2012.  
A presente dissertação teve como objectivo a caracterização exaustiva dos protocolos dos estudos 
PASS submetidos ao PRAC durante os primeiros três anos da nova legislação de Farmacovigilância, 
descrevendo o âmbito e a metodologia dos estudos em várias vertentes. Pretendeu-se também 
reflectir sobre o nível de informação que se encontra publicamente disponível. 
Métodos 
Foram revistas todas as minutas das reuniões mensais do PRAC entre os períodos de Julho 2012 e 
Julho 2015 de modo a identificar cronologicamente todos os protocolos de PASS submetidos para 
avaliação do PRAC durante os três primeiros anos da nova legislação de Farmacovigilância.  
Para complementar a informação disponível nas minutas, foram consultados os Relatórios Públicos 
Europeus de Avaliação dos medicamentos em estudo, disponíveis no website da Agência, de forma 
a identificar o contexto regulamentar na origem do PASS. Por outro lado, foi também efetuada uma 
pesquisa no registo eletrónico de estudos de pós-autorização mantido pelo European Network of 
Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) para obter informações mais 
detalhadas sobre a metodologia do estudo incluindo os próprios documentos dos protocolos que, 
estando disponíveis, providenciaram uma fonte de informação mais detalhada e exata.  
O número de rondas de revisão a que os protocolos foram submetidos, assim como a duração do 
processo desde a primeira submissão do protocolo até à aprovação do mesmo, foram calculados para 
os protocolos considerados autorizados no fim do período em análise. Na ausência de informação 
sobre o resultado da última avaliação de um determinado protocolo, foi assumido que o protocolo 
fora aprovado quando se encontrava inserido no registo eletrónico do ENCePP ou quando o 
protocolo não fora novamente mencionado nas minutas do PRAC durante mais de um ano até Julho 
de 2015.  
Foram utilizadas estatísticas descritivas e análises bivariadas recorrendo ao teste de qui quadrado 
com nível de significância de 5%. 
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Resultados 
Da revisão das minutas das reuniões mensais do PRAC entre Julho de 2012 e Julho de 2015 foram 
identificados 189 protocolos de PASS, de um total de 353 submissões para avaliação pelo comité. 
O resultado da avaliação pelo PRAC estava disponível em apenas cerca de um terço (30%) das 353 
avaliações. Somente metade dos 189 PASS (49%) tinha sido inserida no registo eletrónico do 
ENCePP até Julho de 2015.  
A maioria dos 189 PASS (58%) dizia respeito a novas AIMs. Cerca de um terço (31%) dos 189 
PASS foram impostos pelas Autoridades Regulamentares.  
A maior parte dos PASS incluía pelo menos um objetivo relacionados com a investigação de riscos 
ou ausência dos mesmos (74%), enquanto cerca de um terço (34%) continha pelo menos um objetivo 
relacionado com a avaliação de padrões de utilização do medicamento, e um quarto (25%) inseria 
pelo menos um objetivo relativo a avaliar a efetividade de atividades de minimização de risco. Cerca 
de um terço dos PASS (31%) combinava objetivos de pelo menos duas destas categorias.  
A grande maioria dos estudos PASS apresentava um desenho longitudinal (81%). No entanto, a 
maioria dos estudos com pelo menos um objetivo relacionado com avaliação da efetividade das 
medidas de minimização de risco (56%) tinha um desenho transversal. Constatou-se que um número 
ligeiramente superior de PASS (58%) tinha por base a recolha de dados primários (i.e. informação 
recolhida de novo para o estudo). Observou-se um padrão inverso entre os estudos com pelo menos 
um objetivo relativo à avaliação de padrões de utilização do medicamento dado que a recolha de 
dados em 58% destes estudos era baseada em fontes secundárias. No total, mais de dois terços (70%) 
dos estudos visavam a inclusão de uma população exposta exclusivamente ou prescritora do 
medicamento em avaliação. Verificou-se que os estudos com critérios de inclusão mais abrangentes, 
tais como outros medicamentos ou todos os doentes com determinada patologia, eram mais raros. 
A análise mais detalhada dos 57 protocolos disponíveis revelou que apenas um terço (33%) dos 
estudos referia um comparador (quer outro medicamento ou ausência do medicamento em estudo 
quer fontes externas) e que todos os PASS planeavam a inclusão de pelo menos um país europeu. 
Entre os 18 protocolos disponíveis de PASS com pelo menos um objetivo relativo à avaliação da 
efetividade das medidas de minimização do risco, a maioria não referia concretamente a forma como 
o sucesso das mesmas seria avaliado. Um terço desses protocolos (33%) visava exclusivamente
investigar a efetividade dessas medidas através da aplicação de um questionário para avaliar o
conhecimento e o comportamento auto-reportados.
As áreas dos estudos referidas mais frequentemente como responsáveis pela rejeição dos protocolos 
pelo PRAC estavam relacionadas com aspetos do desenho do estudo (37%) e de exequibilidade 
(30%), sendo necessárias considerações adicionais para demonstrar que eventuais viés e limitações 
tinham sido adequadamente ponderados. Estes comentários corroboram a observação geral de que 
o nível de detalhe incluído na maioria dos protocolos era escasso.
A análise das métricas relativas ao número de revisões de cada protocolo e duração total do processo 
de revisão dos 37 protocolos com evidência de terem sido aprovados, sugeriu uma evolução positiva 
entre os PASS submetidos pela primeira vez no primeiro ano em análise e aqueles submetidos pela 
primeira vez no terceiro ano (redução de uma mediana de 3 para 2 revisões por protocolo e uma 
redução média de 6 meses na duração total de revisão). 
Discussão 
Este trabalho permitiu descrever pela primeira vez os protocolos de PASS submetidos ao PRAC 
durante os três primeiros anos da nova legislação de Farmacovigilância.  
Embora o facto deste trabalho ter sido possível reflita um nível de transparência sem precedentes, o 
nível de informação disponível é ainda limitado. Uma maior partilha das recomendações do PRAC 
resultantes da avaliação dos protocolos, uma maior adesão ao registo de PASS no portal eletrónico 
do ENCePP e o desenvolvimento de uma terminologia mais consistente, será importante para a 
partilha de boas práticas de modo a fomentar o desenvolvimento de PASS mais robustos. 
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Por outro lado, o limitado nível de detalhe presente nos protocolos sugere alguma inconformidade 
com as boas práticas de Farmacoepidemiologia e Farmacovigilância, as quais enfatizam a 
fundamentação e descrição crítica dos métodos selecionados. Adicionalmente a articulação entre os 
objetivos dos PASS enquanto medidas adicionais de Farmacovigilância e os métodos empregues 
poderá beneficiar de uma maior colaboração entre os peritos de diferentes áreas.  
Conclusão 
Uma maior colaboração e partilha de informação e conhecimento entre diferentes áreas levará ao 
desenvolvimento de novos métodos customizados para as necessidades singulares dos PASS, tais 
como metodologias multidisciplinares direccionadas para avaliar a efetividade das medidas de 
minimização do risco. O resultado, contribuirá certamente para o estabelecimento de processos mais 
robustos e levará ao uso mais seguro dos medicamentos 
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Preamble 
The historical background in which the current project is inserted is one of alliances. On the one 
hand, Post-Authorisation Safety Studies (PASS) sits in the intersection between 
Pharmacoepidemiology and Pharmacovigilance. On the other hand, the understanding of PASS as a 
public health enabler stands under the umbrella of Regulatory Science which bridges science and 
society, as PASS are also a product of a socioeconomic context at a given period of time.  
The connection between Pharmacovigilance and Pharmacoepidemiology has its roots on drug safety 
tragedies. The infamous thalidomide crisis fostered the development of Pharmacovigilance systems 
and transformed the drug development framework, as new methodologies, such as the ones from the 
epidemiology field were applied to study the benefits and risks of medicinal products used in real-
world practice.  
However, both areas followed distinct paths. Within the pharmaceutical industry, the focus had 
traditionally been on clinical trials to provide evidence to support licensing while having 
Pharmacovigilance as a post marketing lighthouse to detect spontaneous case reports. Conversely, 
Pharmacoepidemiology developed mainly in the academic and institutional research contexts as a 
response to the recognised need to understand the effects of medicinal products in the broader 
population complementing the information from the clinical trials.  
The convergence between the two fields was facilitated by the incorporation of Risk Management 
principles in regulations over the past decade. In the framework of a pharmaceutical Risk 
Management system, the Marketing Authorisation Holders (MAHs) need to proactively consider all 
the evidence about the medicinal product (what is known and unknown about the targeted disease, 
the product efficacy and safety and the expected target population) from pre-marketing research and 
literature sources. By critically assessing all this information, the MAH establishes the safety 
concerns for which Pharmacovigilance activities (collection of data to identify and characterise 
risks) and Risk Minimisation Measures (RMM) (actions to mitigate the harms) may need to be 
implemented to optimise the benefit-risk of their medicinal products. In order to close the loop, it is 
then critical that the MAHs also assess the effectiveness of the Risk Management system in place.  
It is in the process of planning which activities will best address the established safety concerns that 
the pharmacoepidemiological methods emerge as pertinent tools to answer the questions formulated 
in the Risk Management process. Within this context, PASS are a perfect reflection of the bridge 
between Pharmacovigilance and Pharmacoepidemiology and its incorporation in the regulatory 
pharmaceutical practice. 
PASS also represent a clear shift from the traditional passive collection of safety data, by providing 
the means to proactively investigate the most important safety concerns, assessing pattern of drug 
use deemed critical to monitor the safe utilisation of the product and also, assessing the effectiveness 
of RMM.  
The European Union (EU) 2010 Pharmacovigilance legislation, implemented in 2012, further 
endorsed these activities by establishing legal mechanisms to enforce the conduct of Risk 
Management activities. As a consequence, it is necessary to submit a Risk Management Plans (RMP) 
with each application for a new marketing authorisation. 
Four years have passed since the new legislation was implemented. It is now a good time to assess 
what was achieved so far. An initiative from the European Medicines Agency (EMA) is underway 
to measure the impact of Pharmacovigilance activities at EU and Member States level. This is a 
complex task that would need a collaborative approach among all the stakeholders involved.  
This work aims to make a contribution to this important goal by providing a deep dive into PASS 
submitted during the first three years of the new legislation. The review would not have been 
possible without the availability of public data sources, the existence of which reflects another 
cornerstone of the new Pharmacovigilance legislation, an increase in transparency and 
communication from the EMA. 
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 Introduction 
1 A Note on Regulatory Science 
As this work can be viewed under the umbrella of Regulatory Science, it is opportune to start with 
an introduction to this concept.  
According to Irwin et al, “the study of regulatory science can provide an insight into the changing 
conditions of scientific practice-and especially the operation of science within an area of industry-
governmental-academic relations which is also pressured by the need to make potentially far-
reaching decisions (in terms of both public health and economic costs) on a regular basis.”(1) 
In the healthcare field, the need for this new branch of science has evolved and the last decade 
witnessed the integration of Regulatory Science in the core activities of key regulators such as the 
EMA, the United States (US) Food and Drug Administration (FDA), and the Japanese 
Pharmaceuticals and Medical Devices Agency (PMDA).(2-4) 
The EMA defines Regulatory Science as the “range of scientific disciplines that are applied to the 
quality, safety and efficacy assessment of medicinal products and that inform regulatory decision-
making throughout the lifecycle of a medicine. It encompasses basic and applied medicinal science 
and social sciences, and contributes to the development of regulatory standards and tools”.(3) 
Among the numerous fields of application of this science to the pharmaceutical arena, 
Pharmacovigilance is one prominent field given the major changes introduced by the 2010 
legislation.  
A deep dive into the history of Pharmacovigilance and of drug development regulations will reveal 
how the new legal framework has implications that go much beyond the Pharmacovigilance 
activities, appealing for a change in the development, assessment and use of pharmaceutical 
products. 
2 The History of Pharmacovigilance 
2.1 Early Beginnings 
Early publications of the New England Journal of Medicine at the beginning of the 19th century 
described case reports of today’s well known toxic effects of arsenic and mercury; they revealed the 
uncertainty of whether the effects were caused by the chemicals, as a manifestation of the underlying 
disease, or even, a prognostic sign of the substance’s efficacy. It was not until the beginning of the 
20th century that the safety of the medicinal products was fully appreciated.(5)  
The history of pharmaceutical regulation and Pharmacovigilance has been always shaped by crisis: 
impactful adverse drug reactions (ADRs) to medicinal products demanding a reaction from the 
system.  
In the early days of the 20th century, the manufacturers were not required to demonstrate efficacy or 
safety of the medicinal products launched into the market. The first regulatory reaction to drug safety 
incidents may have been implementation of the Pure Food and Drug Act by the FDA in 1906, in 
response to excessive misbranding of food and medicinal products. These rules required 
manufacturers to accurately label the contents of their medicinal products. (5, 6) 
A couple of decades later, in 1937, one of the first episodes with high media impact in the tragic 
history of drug safety took place in the US, when more than 100 people died after being exposed to 
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a new antibiotic, sulphanilamide which was dissolved in diethylene glycol, a lethal solvent. The 
manufacturer of that product was only charged for misbranding as there was no requirement to test 
or even provide evidence that literature had been dully searched before the product was launched. 
(5) As a consequence, stricter regulation was implemented through the 1938 Food, Drug, and
Cosmetic Act. It imposed the requirement for manufacturers to submit evidence of preclinical
toxicity testing and drug safety data to the FDA before the launch of a medicinal product.(6)
It was almost 30 years later, in 1962, that the world’s most infamous tragedy in the history of human 
medicines occurred, the thalidomide disaster. Thalidomide was launched as a sedative and 
antiemetic medicinal product to relieve the discomfort of pregnant women. More than 10,000 
children worldwide were born with phocomelia, a congenital disorder involving malformation of the 
limbs found to be an ADR to thalidomide. This tragedy was the main driver for legislative reforms 
in many health systems and triggered the first systematic international efforts to address drug safety 
issues.(7) 
The Sixteenth World Health Assembly (1963) adopted a resolution that reaffirmed the need for rapid 
dissemination of information on ADRs. This led to the creation of the World Health Organisation’s 
(WHO) Pilot Research Project for International Drug Monitoring in 1968. The purpose of this 
project was to develop an international system to detect previously unknown or poorly understood 
ADRs. As a consequence, WHO advocated the establishment of guidelines and national centres for 
drug monitoring that would contribute to the international system.(7) It was the official birth of 
Pharmacovigilance.  
Pharmacovigilance is defined by the WHO as “the science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects or any other drug-related problem”.(7) 
The goals of Pharmacovigilance are to enhance patient care and patient safety in relation to the use 
of medicines; and to support public health programmes by providing reliable, balanced information 
for the effective assessment of the benefit-risk profile of medicines. (7) 
From these beginnings, systems were developed in the different countries for the collection of 
individual case histories of ADRs and their evaluation. In the early 1980s, the Council for 
International Organizations of Medical Sciences (CIOMS), in close collaboration with the WHO, 
launched its programme on drug development and use. CIOMS provided a forum for policy makers, 
pharmaceutical manufacturers, government officials and academics to make recommendations on 
the communication of safety information between regulators and the pharmaceutical industry. (7) 
Despite the more stringent process for drug regulation, a series of major ADRs leading to the 
withdrawal of medicinal products kept occurring. Several examples of medicinal products and ADRs 
responsible for their removal from the market can be cited, such as: proctalol and 
oculomucocutaneous syndrome cases (1976); phenacetin and nephropathy (1980); benoxaprofen 
and jaundice (1982); tolcapone and trovafloxacin and hepatotoxicity (1998, 1999); cisapride and 
cardiac arrhythmias (2000); cerivastatin and rhabdomyolysis (2001); rofecoxib and valdecoxib and 
thhrombotic events and cardiovascular and cutaneous disorders, respectively (2004, 2005); 
sibutiramine and cardiovascular disorders (2010), among others.(8, 9) 
2.2 Towards the Need for Real-world Evidence: a Parallel with Clinical Research 
Developments 
It is interesting to note that the most infamous tragedy in the history of drug safety has also 
significantly shaped the history of drug research.  
The US Kefauver–Harris Amendments (1962) changed the medicinal products’ legislation as a 
consequence of the thalidomide disaster regardless of the fact that this medicinal product had never 
been approved for use there. The changes strengthened the requirements to submit preliminary 
evidence of drug safety, requiring extensive preclinical pharmacologic and toxicological testing 
even before a medicinal product could be tested in humans. In addition, clinical testing had to 
demonstrate “substantial evidence that the drug would have the effect it claims to have”. “Substantial 
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evidence” was defined as “adequate and well controlled investigations, including clinical 
investigations”.(6) 
In Europe, as reaction to the thalidomide disaster, the First European Directive, known as 
65/65/EEC, was enacted by the Council of the European Economic Community in 1965 stating that 
no medicinal product could be placed into a Member State’s market unless authorisation had been 
issued by the competent authority in that Member State. This included the need to submit results of 
physico-chemical, biological or microbiological tests, pharmacological and toxicological tests and 
clinical trials.(10) 
In the following years, the demonstration of a positive benefit-risk profile through randomised 
clinical trials has been the state of the art method to gather the proof required to submit to the 
regulators when applying for a new marketing authorisation.(8) The attention was turned to patients’ 
rights and protection rather than the scientific methodologies. 
The Helsinki Declaration was published in 1964, adding to the ethical principles embedded in the 
code of Nuremberg from 1949. Later, in 1978 another statement of ethical principles was published, 
the Belmont Report. They established principles regarding moral, ethical, and legal requirements of 
research involving human subjects including the right to give informed consent, the precedence of 
the well-being of individual research subjects over the interests of the research and the following 
principles: (1) respect for persons and their autonomy; (2) beneficence (maximize possible benefits 
and minimize possible harms); and (3) justice (fairness in the selection of subjects for clinical 
research).(11) 
The following historical episodes of interest in the context of this work are the first manifestations 
of patients’ voice in the context of clinical research. Events in the 1980s sharpened the rights of 
research subjects as movements from society started to make pressure on the focus and priorities of 
research. As examples, acquired immune deficiency syndrome activists claimed for earlier access to 
innovative drugs and advocates for women's health began to call for more focused research on health 
problems that directly concerned their lives, such as breast cancer and hormonal replacement 
therapy.(12)  
The active movements from society, requesting to be an active participant on clinical research 
decisions, coincided with the economic changes of the 1990s, frequently known as “globalisation”, 
and the need for a different mindset from the research community, to promote collaboration and 
common grounds for research.(8)  
The industry, at that time, was becoming more international. However the different technical 
requirements from country to country were such that, many time-consuming and expensive test 
procedures needed to be replicated in order to meet the requirements of individual markets. The 
urgent need to rationalise and harmonise regulation was impelled by concerns over rising costs of 
research and development and the need to meet the public demand for early access to innovative 
treatments. This led to the creation of the International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH) in 1990 to harmonise regulatory 
requirements between Europe, US and Japan. ICH's mission has been to achieve greater 
harmonisation worldwide to ensure that safe, effective, and high quality medicines are developed 
and registered in the most resource-efficient manner.(13)  
In the context of clinical research, ICH developed the Good Clinical Practices (GCPs) to provide an 
international ethical and scientific quality standard for designing, conducting, recording and 
reporting clinical trials.(14) In the context of Pharmacovigilance, the ICH has published a great 
number of documents setting standards for safety (clinical and non-clinical).(13)  
By this time there was an increased harmonisation of procedures to develop and register new 
medicinal products and an increased access to medicinal products and knowledge. However, the 
healthcare professionals (HCPs), which are the clinical decision makers, and the patients, which are 
the users of the medicinal products started demanding more evidence of the most appropriate 
treatments. A campaign launched in the 1990s, by a group known as the Evidence-Based Medicine 
Movement, advocated the need to enhance the evidence on which medicine was practiced to improve 
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the outcomes of diagnosis and treatment. This highlighted that there could be a gap between the 
evidence of the adequate benefit-risk profile of medicinal products required by the regulators and 
the clinical decisions made by the HCPs based on their opinion and clinical judgement.(15)  
The concept of evidence-based medicine considered a hierarchy of reliability of evidence for clinical 
decision-making with randomised clinical trials at the top.(15) Therefore, in order to implement 
evidence-based medicine in clinical practice, results of the clinical trials needed to be available to 
the healthcare community. This propelled several initiatives and guidelines to put pressure on the 
industry and regulators to publish the results of research, by incentivising the registration of studies 
in public registries, peer reviewed scientific journals or scientific congresses.(16)  
Despite the major contributions of evidence-based medicine to the publication of evidence and to 
the development of clinical guidelines, it is also acknowledged today that, the strong focus on 
objective data from clinical trials and guidelines has some boundaries. (8, 15)  
Clinical trials are subject to limitations such as: 
• Lack of representativeness of patient populations: the populations studied in clinical trials
are limited in number and quite homogeneous as these studies have clearly defined
eligibility criteria, typically excluding more vulnerable patients such as those severely ill,
those with comorbidities and concomitant treatments, paediatric patients, elderly patients
and pregnant women.
• Long-term therapy: The clinical trials have a limited duration which restricts the knowledge
about benefits and risks to short-term treatment. Some ADRs may manifest after long
periods of use or under certain disease characteristics which may change over time.
Therefore, despite the unquestionable strengths and needs for clinical trials, an over-reliance on these 
studies has proved to be insufficient.(15) 
Scurti et al suggested that the following statement is conceptually widely acknowledged but easily 
disregarded: “drugs (and their use) cannot be considered primarily objects to be studied per se, but 
rather as tracers of health needs and policies, prescribing attitudes, and market exigencies i.e. of the 
way medicine and public health are perceived and pursued in society”.(8) Therefore, the author 
suggested that an evaluation technique or strategy centered on medicinal products outside their 
context of use may not adequately reflect the “registered” benefit-risk profile of a medicinal product 
to the real-world patients and populations.  
By citing Archie Cochrane (1972), Scurti et al, synthesised the need for a renewed culture and 
practice of Pharmacovigilance: “he [Archie Cochrane] anticipated a renewed culture and practice of 
Pharmacovigilance with the present awareness of trials and epidemiology, efficacy and 
effectiveness, risk management and rights of patients and populations as a continuum of 
complementary tools, strategies, and actors to make institutions and health care systems accountable 
to and in dialogue with society”.(8) 
As will be seen further below, these observations are intimately related with the changes 
implemented in the 2010 European Pharmacovigilance legislation and with the  need for real-world 
evidence in general. 
2.3 Towards a Proactive System 
The limitations of the clinical trials in predicting the safety of medicinal products in the “real-world” 
highlight the need for collection of safety data throughout the life cycle of a medicinal product. This 
has been recognised since the creation of Pharmacovigilance in the 1960s but, at the beginning of 
the new millennium, the practice of Pharmacovigilance was still mainly based on the detection of 
spontaneous ADRs and reactive actions to signals or alerts flagged through this system.  
However, in parallel in an academic or instructional research setting, the needs to develop systematic 
approaches to study the effects of drug use in large number of patients motivated the use of 
Epidemiology methods and the creation of a new discipline, Pharmacoepidemiology. The term 
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Pharmacoepidemiology derived from “pharmaco” and “epidemiology” bridging clinical 
pharmacology and epidemiology by applying the methods of epidemiology to the content area of 
clinical pharmacology.(6)  
In fact, during the WHO Consultation Meeting in 1971, an important landmark from the early days 
of Pharmacovigilance, it was recognised that for a Pharmacovigilance system to be effective, it 
would require the systematic monitoring of populations, review of health statistics and of drug 
utilization data, and that effective analysis of input data anticipate the need for systematic data 
collection.(7) 
Therefore, remarkably, the need to act upon the incidence of ADRs was a main contributor to both 
the birth of Pharmacovigilance (studying ADRs at case level) and Pharmacoepidemiology (studying 
ADRs at population level).  
The following decades saw the publication of the first pharmacoepidemiologal studies and the 
creation of the first dedicated Pharmacoepidemiology research units.(6) A recent publication even 
considers that from a “historical perspective, observational studies have shaped second-generation 
Pharmacovigilance”, citing examples of studies from the 1970s that unveiled safety concerns by 
linking voluntary reporting data to consumption data, followed by case population methods, case-
control methods and, in the late 1970s-1980s, the first studies linking prescription records with 
individual patient files.(17) However, until recently, observational research mainly evolved outside 
the context of industry and regulators, which, as explained above, for decades continued to privilege 
the conduct of interventional clinical trials.(6)  
The creation of the International Society of Pharmacoepidemiology (ISPE) in 1984 and of the 
European Society of Pharmacovigilance in 1992 marked the formal introduction of 
Pharmacovigilance into the research and academic world, as well as its increasing integration into 
clinical practice. Specialist medical journals have appeared, and a number of countries have 
implemented active surveillance systems to complement conventional methods of drug 
monitoring.(6, 7) Therefore, outside the Pharmaceutical Industry, Pharmacoepidemiology was 
generating new evidence in the interests of drug safety.  
It was not until the new millennium that regulatory changes reflected the need for industry and 
regulators of medicinal products to supplement the existent methods with more proactive strategies. 
It was recognised that stricter assessment before drug approval and more intensive post-marketing 
surveillance through additional post marketing activities such as randomised clinical trials, 
observational studies and use of registries could have prevented or limited previous incidents.(18)
A more proactive approach towards the identification and quantification of safety concerns was 
targeted by the ICH guideline on Pharmacovigilance planning (ICH E2E, 2004) which introduced 
the notion of Risk Management programs.(19) A new community legislation was implemented in 
2005, introducing additional tools to complement existing legislative requirements. These included 
the submission of RMPs in the context of new/significant change in a marketing authorisation on 
request from a competent authority or by MAH/applicant initiative.(20)  
RMPs (covered in more detail in Introduction Section 4 ) reflect what is known and unknown about 
a medicinal product and proactively plan activities to increase knowledge of the safety specification 
and to minimise risks. PASS are among those activities aiming to investigate uncertainties. PASS 
(covered in more detail in Introduction Section 5) employ pharmacoepidemiological methods at 
Pharmacovigilance’s service and represent the realisation of the needs to bridge Pharmacovigilance 
and Pharmacoepidemiology and integrate them in the regulatory decision-making armamentarium. 
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This chapter described the birth of Pharmacovigilance and its intertwined relations with regulatory 
changes in clinical research. From the thalidomide disaster, regulations for clinical research and 
Pharmacovigilance followed separate pathways but demand from the society, HCPs, regulators and 
industry created the need for a proactive collection of real-world evidence, for instance, through the 
inclusion of Risk Management and Pharmacoepidemiology in the toolkit for Pharmacovigilance. 
The following chapter will further detail the most recent changes in the regulatory framework. 
3 New Pharmacovigilance Legislation 
3.1 The Need for a Regulatory Change 
The growing awareness that the scope of Pharmacovigilance should be extended, led to the initiation 
in 2004, of an assessment on the EU Pharmacovigilance system. On December 2008 the European 
Commission (EC) proposed legislative changes to amend the European legislation on 
Pharmacovigilance.(21) The report published in 2008 is a good starting point to understand the 
rational for the major change in Pharmacovigilance regulation to be witnessed.(22) 
This report cited the following estimates of public health burden of ADRs from the medical and 
scientific literature: 
• 0.12%-0.22% of hospital admissions resulted in death due to an ADR corresponding
to100,800-197,000 deaths annually in the EU (the fifth most common hospital cause of
death);
• 3%-10% of hospital admissions were caused by ADRs corresponding to 2.5-8.4 million
annually in the EU;
• 2.1%–6.5% of hospitalised patients suffer an ADR, corresponding to 1.8-5.5 million
annually in the EU;
• ADR-related costs other than those caused by hospitalisation were estimated at €63.2 billion
annually in the EU;
• €79 billion represented a reasonable estimate of the total societal cost of ADRs occurring in
the EU.
In addition, it was suggested that a weak Pharmacovigilance system adversely impacted innovation 
based on the assumption that, if regulators are confident in the Pharmacovigilance system they will 
more likely allow a product into market and this is of crucial benefit to patients with unmet medical 
needs.  
It was found that, despite the previous introduction of proactive toolkits such as RMPs, they were 
not being effectively used. Several activities proposed in the RMPs were not considered adequate 
for handling the risks of the medicinal products and did not prevent the occurrence of the safety 
concerns which, for instance, in the case of rimonabant led to its withdrawal couple of years after 
the RMP was in place.(18) In addition, although EMA was recommending the conduct of PASS, 
several companies were not implementing those activities.(18, 23) It was considered that under the 
regulatory framework at that time, compliance by the company with the measures in a Risk 
Management system would remain problematic as the legal requirement was to describe the 
measures and not to conduct them, i.e. there was no legal basis to enforce those measures.(23) 
On a different perspective, the Member States were not consistently implementing the 
recommendations made by the EMA’s Pharmacovigilance Working Party.(21) In addition, the 
conclusions of some safety issues being discussed at this Working Party were never made public 
which exacerbated the discrepancy in decision-making and regulatory action. As a consequence to 
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the lack of harmonisation regarding Pharmacovigilance requirements, there was an increased the 
regulatory burden on the industry.(22)
Moreover, the EU committees responsible for Pharmacovigilance did not systematically interact 
with HCPs and patients which did not have a voice in decision-making on safety issues. Thus, 
decisions could be taken without all the relevant experience and information being made available. 
This lack of inclusiveness of stakeholders in the processes of Pharmacovigilance, coupled with the 
lack of transparency was considered a contributor to a lack of trust by patients in the regulation of 
medicinal products and, more generally, in the pharmaceutical industry.(21, 22)  
These findings reflect the socioeconomic, cultural and scientific challenges and changes observed 
in the history of medicinal products described in Introduction Section 2 and culminated in a major 
regulatory change to enforce a more proactive, transparent and inclusive Pharmacovigilance 
system.(22) 
3.2 The New EU Pharmacovigilance Legislation 
The preparation of the new EU Pharmacovigilance legislation took approximately nine years. 
Implemented in July 2012, the 2010 EU Pharmacovigilance legislation was the biggest change to 
the regulation of human medicines in the EU since 1995.(24) A new Directive and Regulation were 
adopted by the European Parliament and the Council of Ministers in December 2010: Directive 
2010/84/EU and Regulation (EU) No 1235/2010 amending Directive 2001/83/EC and Regulation 
(EC) No 726/2004, respectively.(25-28) The legislation was accompanied by the Commission 
Implementing Regulation (EU) No 520/2012 providing details on the operational implementation of 
the legislation.(29) In October 2012, the Pharmacovigilance legislation was further amended by 
Directive 2012/26/EU and Regulation (EU) No 1027/2012 which provided strengthened measures 
for monitoring medicines safety and carrying out reviews at a European level.(30, 31) 
The EMA and Member States have also produced, in consultation with relevant stakeholders, good 
Pharmacovigilance practice guidelines (GVP) for the conduct of the different Pharmacovigilance 
activities and replaced the Volume 9A.(32),(20)  
The implementation of the legislation has been a complex process with significant changes in the 
EMA’s responsibilities and significant implications for applicants and MAHs. The EMA worked 
with the EC, the national competent authorities and a wide range of stakeholders including patients, 
HCPs and industry, to ensure effective implementation and operation of the new Pharmacovigilance 
rules. Priorities were set so that public health activities were implemented first, followed by 
transparency and communication activities and lastly by simplification of activities.(33, 34)  
The new EU Pharmacovigilance legislation aimed to offer better promotion and protection of public 
health through the following objectives(24):
• The collection of better data on medicines and their safety;
• Rapid and robust assessment of issues related to the safety of medicines;
• Effective regulatory action to deliver safe and effective use of medicines;
• Empowerment of patients through reporting and participation;
• Increased levels of transparency and better communication.
3.3 European Regulatory Stakeholders 
3.3.1 The Role of the European Medicines Agency (EMA) 
The EMA has a central role in the EU system, co-ordinating the activities and providing technical, 
regulatory and scientific support to the Member States and industry. It also provides the essential 
infrastructure required by the system and has specific tasks laid down in the legislation in the conduct 
of Pharmacovigilance including signal detection for medicinal products authorised through a 
centralised authorisation procedure (CAP).(35) 
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The new EU Pharmacovigilance legislation established an additional scientific committee, the 
Pharmacovigilance Risk Assessment Committee (PRAC), whose members include experts in 
Pharmacovigilance and regulation working within the national competent authorities of the Member 
States (plus Iceland and Norway), representatives of patients and HCPs, and scientific experts in 
areas such as epidemiology, signal detection, biological medicines and risk communication. The 
PRAC meets monthly and is responsible for the assessment of safety issues at EU level and for the 
monitoring of many of the Pharmacovigilance activities foreseen in the legislation. It works closely 
with other scientific committees, especially the Committee for Medicinal Products for Human Use 
(CHMP) which leads on CAPs, and also with the Co-ordination Group for Mutual Recognition and 
Decentralised Procedures – Human (CMDh), a body representing the national regulators of the 
European Economic Area, which leads on many issues relating to nationally authorised 
medicines.(35) 
3.3.2 Key Interactions between PRAC, CHMP and CMDh 
The different PRAC outputs depend on the existence or not of a formal decision-making phase as 
defined in the Pharmacovigilance legislation. For the processes with a formal decision-making 
phase, the PRAC output is a recommendation and applies to safety referrals, single assessment of 
Periodic Safety Update Reports (PSURs) and PASS assessments. These recommendations are 
transmitted to the CHMP when a procedure concerns at least one CAP. The PRAC recommendations 
lead to CHMP Opinions which are then assessed by the EC which is responsible for issuing a 
decision. When there is no CAP involved, the recommendations are transmitted to the CMDh leading 
to a CMDh consensus that the Member States shall follow, or a CMDh majority that leads to an EC 
Decision. 
Where the position/opinion of the CHMP/CMDh differs from the recommendation of the PRAC, 
the CHMP/CMDh shall attach a detailed explanation of the scientific grounds for the differences 
along with the recommendation. Figure 1 below depicts these interactions. 
Figure 1 – Interaction between the different European Medicines Agency (EMA) committees and the 
European Commission (EC). Source: Arriegas M). Safety, Risk Management and Pharmacovigilance. 
[Presentation] Training Programme in Pharmaceutical Medicine. Universidade de Aveiro. Lisboa. 
March 2013. 
3.3.3 The Role of the Member States 
The national competent authorities supervise the collection of information on suspected ADRs of 
medicinal products, particularly spontaneous reports from patients and HCPs. Equally, they provide 
much of the resource base and knowledge needed to assess signals of possible emerging safety 
issues. Member State experts also take the lead (as the so-called rapporteur and co-rapporteur teams) 
in evaluating and analysing data when a safety issue is assessed at the European level (a referral). 
They play a critical role in tailoring and communicating safety messages to HCPs, patients and the 
public at a national level. 
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Member States also maintain the inspectorates that carry out the work of ensuring that the medicinal 
products marketed in the EU are manufactured appropriately and are of suitable quality, the 
Pharmacovigilance systems of the industry are working as they should, and checking that the clinical 
studies that provide the evidence of the safety and effectiveness of medicines are performed in line 
with appropriate standards.(36) 
3.3.4 The Role of the Commission 
The EC is the competent authority for CAPs and supplies the legal authority that underpins the EU 
Pharmacovigilance system. It provides the legislative framework needed to carry out its functions 
in the most efficient way. 
This chapter described the objective and governance model of the current EU Pharmacovigilance 
legislation. The following chapters will now cover in more detail the object of interest of this study 
by starting with a description of pharmaceutical Risk Management to explain the overarching 
structure in which PASS play a very important role. The understanding of Risk Management is 
essential to understand that PASS, which use Pharmacoepidemiological methodologies, have 
features that make them different from other Pharmacoepidemiology studies as they have a mission 
to accomplish within the strategy planned for a given medicinal product. This mission can be either 
to act as additional Pharmacovigilance activities and/or as tools to assess effectiveness of RMM. 
4 Risk Management 
According to the Pharmacovigilance legislation a “Risk related to the use of a medicinal product” is 
“any risk relating to the quality, safety or efficacy of the medicinal product as regards patients’ health 
or public health and any risk of undesirable effects on the environment”.(27)  
Typically, a medicinal product has multiple risks, varying in terms of severity, effects on individual 
patients and public health impact. The successful identification of the most impactful ones 
(significant safety concerns) before the medicinal product is on the market allows for the planning 
and implementation of preventive or minimising strategies to mitigate them, thus optimising the 
benefit-risk profile of the medicinal product.(37) 
However, not all actual or potential risks would have been identified at the time when an initial 
authorisation is sought and many of those associated with the use of a medicinal product will only 
be discovered and characterised after the medicinal product is on the market. For that reason, in 
addition to activities to prevent and minimise known and suspected risks, it is also important to 
consider activities to detect or further characterise risks for which there are still important 
uncertainties.(37) 
Risk Management has three stages which are inter-related and iterative. The initial two comprise 
risk identification and characterisation and the third, minimisation or mitigation(37): 
1. Characterisation of the safety profile of the medicinal product including what is known and not
known;
2. Planning of Pharmacovigilance activities to characterise and identify new risks and increase the
knowledge in general about the safety profile of the medicinal product;
3. Planning and implementation of risk minimisation and mitigation and assessment of the
effectiveness of these activities.
Figure 2 below presents the steps of a Risk Management cycle representing the phased steps. 
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Figure 2 – The Risk Management Cycle. Source: European Medicines Agency. Guideline on good 
Pharmacovigilance practices (GVP): Module V – Risk Management systems (Rev 1). EMA/838713/2011 
Rev 1.(37) 
4.1 Risk Management Plan 
As previously described, RMPs were introduced in the Pharmacovigilance guidelines in 2005 but 
there was no legal basis for implementing them. The new Pharmacovigilance legislation enforced 
the obligation to submit a RMP with all the applications for a new marketing authorisation, with a 
significant extension of indication, or if there is a public health concern.(37)  
The RMP is the product of executing the three steps described above. In addition, the RMP is 
expected to be a live document, periodically updated as new knowledge about the risks and the 
benefits of the medicinal product arises from the post-marketing experience.(37) 
Characterisation of the medicinal product safety profile(37) 
When developing a RMP, the MAH need to reflect on what is known and unknown about the 
medicinal product taking into consideration the results of pre-marketing research (non-clinical and 
clinical studies) and also conducting extensive literature research on safety findings with medicinal 
products or patients with similar characteristics to those targeted by the medicinal product of 
concern. Therefore, the first sections of an RMP are dedicated to the identification and assessment 
of safety concerns (important identified risks, important potential risks and missing information). 
According to GVP, each of those safety terms is defined as follows(38): 
• An “identified risk” is “an untoward occurrence for which there is adequate evidence of an
association with the medicinal product of interest”;
• A “potential risk” us “an untoward occurrence for which there is some basis for suspicion
of an association with the medicinal product of interest but this association has not been
confirmed”;
• “Missing information” is a “gap in knowledge about a medicinal product, related to safety
or use in particular populations which could be clinically significant”.
Collect Data
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Identify & Analyse
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benefit assessment
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Benefit risk 
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Risk Management activities should not contemplate all the identified and potential risks. Instead, 
they should focus the important safety concerns, which according to GVP are defined those that 
“could have an impact on the risk-benefit balance of the product or have implications for public 
health”. What constitutes an important risk depends upon several factors, including the impact on 
the individual, the seriousness of the risk and the impact on public health.(38) 
Failure to prioritise the safety concerns and target too many of them, could incorrectly flag a 
medicinal product for additional scrutiny, potentially lead to regulatory delays and limiting 
medicinal product uptake. Therefore it could affect the prescription patterns of the physicians, 
potentially leading them to not treat patients in great need of a certain medicinal product by choosing 
instead, alternatives with a poorer benefit-risk profile.(39-41)
Risk Identification and Characterisation(37) 
Upon establishing the important identified/potential risks and missing information (safety concerns), 
the Applicant/MAH needs to reflect on whether there is need for additional Pharmacovigilance 
activities to further detect and characterise safety concerns. 
Pharmacovigilance activities are post-marketing activities designed to detect, identify and 
characterise risks relating to the medicinal product. They can be grouped as routine and additional 
activities:(38) 
• Routine Pharmacovigilance activities include the spontaneous collection, assessment and
reporting of ADRs, signal detection, literature monitoring and submission of PSURs
summarising the benefit-risk profile of the medicinal product throughout the product
lifecycle including a summary of all Pharmacovigilance activities in place. The use of
specific ADR follow-up questionnaires to obtain structured information on reported ADRs
of special interest and collection of additional information of interest (e.g. recording of tests)
would still be considered routine Pharmacovigilance activities, provided the tests were
performed as routine practice and only the recording of the information is an additional
requirement;
• Additional Pharmacovigilance activities are typically non-clinical studies, clinical trials or
non-interventional studies. Situations when additional Pharmacovigilance activities are
needed, can include for instance, a medicinal product intended for chronic, for which there
is only evidence of short term follow-up data at the time of authorisation. Long-term follow-
up of patients (e.g. in a cohort study) may provide additional reassurance on the long term
effects of the medicinal product. PASS are additional Pharmacovigilance activities.
An efficient planning of the necessary Pharmacovigilance activities to characterise the safety profile 
of the medicinal product should be based on specific issues identified from pre- or post-authorisation 
data and from pharmacological principles. Therefore, an accurate a priori identification of 
significant safety concerns of a medicinal product minimises unanticipated ADRs and provides a 
focus for RMM in preventing the occurrence of the significant safety issues. 
Risk Minimisation 
The ultimate objective of risk identification and characterisation is the prevention or mitigation of 
safety concerns.  
Risk minimisation is defined as “an intervention intended to prevent or reduce the probability of the 
occurrence of an ADR associated with the exposure to a medicine or to reduce its severity should it 
occur”.(38) 
The MAH should assess if RMM are required to address each safety concern. In practice, the RMM 
are public health interventions intended to optimise the benefit-risk balance of a medicinal product 
by guiding the use of medicinal product that support the provision of the right drug, at the right dose, 
at the right time, to the right patient and with the right information and adequate monitoring.(42) 
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RMM activities are classified as follows(37): 
• Routine RMMs which include labelling such as, including information about the risks
(appropriate dosing, contraindications, special precautions, known ADRs) in the Summary
of Product Characteristics (SmPC) for HCPs and in the Patient Information Leaflet (PIL)
for patients, respectively. Decisions on the distribution channels and ease of access to the
product (prescription only or over the counter medicinal product), number of units per
package are also typical routine RMM and for the majority of the medicinal products they
are sufficient;
• Additional RMMs may be necessary to optimise the benefit-risk balance of a medicinal
product when it is considered that routine measures are not sufficient. They may consist in
extra communication and education for patients and HCPs (e.g. patient card, Direct
Healthcare Professional Communication and educational materials), controlled distribution
systems or pregnancy prevention programs (e.g. in order for the medicinal product to be
prescribed the patient needs to show the negative results of pregnancy tests).
Key goals of RMM can be the appropriate patient selection to exclude high-risk patients from 
treatment, minimisation of the occurrence of ADRs or optimisation of outcomes by maximising 
benefits.(43) 
It is well recognised that the successful implementation of additional RMMs requires contributions 
and compliance from all stakeholders, including MAHs, patients and HCPs. The performance of 
RMM in the healthcare systems requires an ongoing assessment to ensure that their objectives are 
fulfilled and that the measures in place are proportionate taking into account the benefit-risk balance 
of the medicinal product and the burden of those measures to the HCPs and the patients.(44) 
4.2 Assessing Effectiveness of Risk Minimisation Measures (RMM) 
Monitoring the effectiveness of RMM is an explicit requirement from Directive 2001/83/EC which 
states that the MAH shall “monitor the outcome of RMMs which are contained in the RMP or which 
are laid down as conditions of the marketing authorisation”.(27)
The publication from Pietro et al, which laid the foundation for GVP Module XVI dedicated to the 
assessment of the effectiveness of RMM, justifies the need for that assessment: “in the same way 
that public health interventions aim to minimise risks associated with a pharmaceutical product, it is 
imperative to systematically evaluate the effectiveness of the intervention in order to determine 
whether the intended effect/outcome has been achieved or an alternative activity needs to be 
identified and implemented”.(39, 42)  
Since the introduction of pharmaceutical Risk Management, several programs to minimise risks and 
to assess those measures have been developed.(43, 45) In 2010, the proportion of CAPs with 
additional RMMs in the EU had increased from the reported 5% among products authorised before 
the RMP became mandatory in 2005 to 29% among products approved afterwards.(44) 
Figure 3 below illustrates the dual-evidence-based approach to evaluate effectiveness of additional 
RMM, endorsed by GVP Module XVI and consistent with ICH E2E principles. It builds on two 
distinct levels of evidence: the actual implementation of the RMM (measured by process indicators) 
and the attainment of the final objective of the RMM (measured by outcome indicators)(39):  
• Process indicators: Provide evidence that the implementation steps of the additional RMMs
have been successful. They provide insight into what extent the programme has been
executed as planned and whether the intended impacts on behaviour have been observed;
• Outcome indicators: Provide an overall measure of the level of risk control that has been
achieved with the RMM. For instance, where the objective of an intervention was to reduce
the frequency and/or severity of an ADR, the ultimate measure of success shall be linked
with this objective. The assessment requires traditional epidemiologic methodology
addressing if the desired outcome was attained.
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Figure 3 – Dual-evidence-based approach to evaluate effectiveness of additional risk minimisation 
measures (RMMs). Source: European Medicines Agency. Module XVI– Risk minimisation measures: 
selection of tools and effectiveness indicators (Rev 1). EMA/204715/2012 Rev 1.(39) 
Process and outcome indicators are viewed as complementary and not alternative. Even if the 
ultimate goal of assessing effectiveness of a RMM is to determine if there was a beneficial outcome 
of the intervention, in order to understand an eventual lack of success or proactively anticipate a lack 
of success, it is important to collect data on implementation of the program (process indicators), such 
as the successful delivery to the target population, the use of those measures by the population and 
if they were correctly understood, so that they ultimately become part of the routine clinical 
practice.(39) 
The guidelines emphasise that sound scientific methods should guide the assessment of both 
indicators. For example, ‘if surveys and/or measurement scales are involved in the assessment of 
RMM appropriate methods and psychometric properties of the instruments involved should be 
considered. When RMM involve the provision of information to HCPs, resulting clinical actions 
should be measured and not only clinical knowledge”. It is also necessary to take into consideration, 
the differences in healthcare systems and all the stakeholders involved in the RMM.(39, 42) 
Specific recommendations for assessment of outcome indicators include the comparison of 
epidemiological measures of outcome of interest (e.g. incidence of hepatotoxicity or surrogate 
endpoint that anticipates a safety concern) before and after the implementation of the RMM (i.e. pre-
post design), which can be addressed by a PASS. When a pre-post design is not feasible (e.g. the 
RMM is put in place before the product is launched) then an outcome reference value (e.g. from 
literature, historical data, expected value in the population) can be used for comparison, provided it 
is duly justified.(39) 
As a result of the assessment of the effectiveness of the RMM, it may be concluded that the measures 
should remain unchanged or, that modifications need to be made to the existing activities.(39) 
Expanding the considerations from Pietro et al, and the GVP Module XVI, Banerjee et al, proposed 
a 5-level model with different evaluation levels representing increasing utility of information to 
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determine RMM effectiveness (Figure 4). The evaluation levels range from risk-minimisation tool 
coverage (level 1), evaluating the distribution of the RMM awareness and usage (level 2), assessing 
knowledge acquired (level 3), analysing the impact of knowledge on behavioural change (level 4) 
and ultimately, the effects on safety outcomes which the RMM aims to minimise (level 5). The 
authors suggest methodologies for each of these levels.(43)  
Figure 4 – A 5-level framework covers both individual risk-minimisation tools and programme 
evaluation. Source: Banerjee AK et al (2014).(43) 
Figure 5 presents an additional model, suggested by Zomerdijk et al, in which, taking a chronological 
approach, it is provided complementary information relevant for the assessment of the RMM’s 
impact on the benefit-risk balance of the drug.(46) It can be observed that the indicators of success 
are similar to those presented in the other previous described models. 
Figure 5 – Evaluation steps increase in utility of information with time after implementation. Source: 
Zomerdijk et al (2013).(46) 
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The three models discussed above constitute examples of frameworks that have been developed. It 
has been acknowledged that there are still hurdles in this area to overcome. Thus an optimal method 
to assess effectiveness of RMM is yet to be found.(42, 43, 46)  
It is important to note, as will be seen in the following chapter, that according to the legislation, a 
study measuring the effectiveness of a RMM is considered a PASS.(25) Given the anticipated 
increase in number of additional RMMs after the 2010 Pharmacovigilance legislation, an increased 
demand for studies assessing the effectiveness of RMMs is also anticipated, making it an interesting 
sub-population of PASS to study as they may reflect the performance of the overarching Risk 
Management systems. 
The previous chapter introduced the Risk Management framework describing the activities that can 
be implemented by the MAHs to identify new risks and further characterise known risks and mitigate 
the occurrence of risks through the application of RMMs which effectiveness need to be continuously 
assessed. PASS play a major role in the success of these plans by providing the methods to 
proactively investigate important safety concerns and/or assess if the implemented RMM are 
effective. They are the perfect reflection of the needs of the industry and regulators to use 
pharmacoepidemiological measures to foster understanding of the safety profile of the medicinal 
products, thus ensuring the right actions can be put in place at the right time to protect public health. 
5 Post-Authorisation Safety Studies (PASS) 
5.1 Background 
The impact assessment of the previous Pharmacovigilance legislation revealed that, PASS, an 
essential part of Risk Management activities, were frequently not conducted or completed. In 
addition, based on a 2006 industry survey, it was concluded that these studies already involved 
substantial industry resources (€356.9 million, with a lower and upper range of €202.0 and €511.8 
million, respectively). However, the studies were often of poor quality and frequently conducted for 
promotional rather than safety reasons. It was considered that under the regulatory framework at that 
time, there were no guiding principles and no adequate oversight for non-interventional safety 
studies.(22) 
According to a published review of PASS before the new Pharmacovigilance legislation, 52 of 60 
requested PASS had progressed through planning to potentially starting data collection.(47) Another 
review, also from authors from regulatory authorities and prior the new legislation, reported the 
majority of PASS protocols were not submitted or were incomplete.(23) This corroborated similar 
findings regarding the RMPs in general and their planned activities.(18) The compliance seemed to 
be very good when the studies were requested by CHMP rather than just recommended.(47) 
Blake et al recommended earlier discussions between the sponsor and the CHMP on PASS adequacy 
to avoid delays and the implementation of unfeasible studies. It was highlighted the need for “careful 
consideration of the requirements for studies and their feasibility into Risk Management planning 
before the granting of a marketing authorisation or a new indication”.(47)
The new Pharmacovigilance legislation introduced aspects which address the abovementioned 
findings as non-interventional PASS could be imposed as legally binding conditions. In addition, 
the EMA would take the role of overseeing a PASS if conducted in more than one Member State. 
These changes intended to decrease the number of poor quality studies, as well as, of studies with a 
promotional nature. Furthermore, while it was initially suggested that the authorities’ objection to a 
PASS protocol would be limited to refusing those with a promotional nature, it was decided in the 
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end, that the authorities could also object protocols based on scientific/ public health concerns, 
strengthening the role of the authorities in the scientific oversight.(22) 
5.2 A Legal Framework for the Conduct of Post-Authorisation Safety Studies (PASS) 
The new legislation set forth a firm legal background for PASS and established clear rules, from 
protocol development to final study reporting. A PASS is defined in Directive 2001/83/EC Article 
1(15) as “any study relating to an authorised medicinal product conducted with the aim of 
identifying, characterising or quantifying a safety hazard, confirming the safety profile of the 
medicinal product, or of measuring the effectiveness of Risk Management measures”.(27)  
A PASS may be initiated, managed or financed by a EU MAH voluntarily (non-imposed PASS) or 
pursuant to an obligation imposed by a competent authority (Directive 2001/83/EC Articles 21a and 
22a), in which case it is considered a condition to the marketing authorisation and are mandatory 
and subject to penalties of not implemented (imposed PASS).(27) GVP Module VIII provides 
detailed guidance on PASS.(48) 
In the Pharmacovigilance Plan section of the RMP, PASS are categorised as(48): 
• Category 1: imposed as condition to the marketing authorisation by the regulatory
authorities based on being considered key to the benefit-risk profile of the product;
• Category 2: imposed on a marketing authorisation for being a specific obligation in the
context of a conditional marketing authorisation or a marketing authorisation under
exceptional circumstances1;
• Category 3: considered voluntary in the Directive but also considered required as they are
part of the Pharmacovigilance plan agreed with the authorities;
• Other studies not required by a regulatory authority do not need to be reported in the RMP
(category 4).
Category 1 and 2 PASS are imposed PASS (mandatory and subject to penalties) and are supervised 
according to Art 107 (n)-(q) of Directive 2001/83/EC. In summary, the MAH shall submit a draft 
protocol to the PRAC or to the national competent authority, depending on if the study is to be 
conducted in more than one Member State or a single Member State, respectively. In the 60 days 
following the submission of the draft protocol, the national competent authority or the PRAC shall 
issue(27): 
(a) A letter endorsing the draft protocol;
(b) A letter of objection, which shall set out in detail the grounds for the objection, in any of the
following cases:
(i) It considers that the conduct of the study promotes the use of a medicinal product;
(ii) It considers that the design of the study does not fulfil the study objectives; or
(c) a letter notifying the MAH that the study is a clinical trial falling under the scope of EU
Clinical Trials Directive (Directive 2001/20/EC).
Additional guidance is provided in the document “Post-authorisation safety studies: questions and 
answers”, as follows: “in the instances when PRAC adopts a letter of objection, submission of an 
amended protocol may be required within X month(s) or within 14 days. In the former case, 
submission of the amended protocol is requested within X months depending on the extent of the 
revisions; the revised protocol will then follow a 30- or 60-day PRAC review procedure. In the case 
1 According to the EMA website, "exceptional circumstances" apply when the applicant can show that they 
are unable to provide comprehensive data on the efficacy and safety of the medicine for which authorisation 
is being sought, due to the rarity of the condition it is intended for, limited scientific knowledge in the area 
concerned, or ethical considerations involved in the collection of such data. 
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of a re-submission within 14 days, the PRAC will review the amended protocol within 15 days. This 
30-day timeframe for the PRAC decision is applied when the PRAC considers that the protocol 
needs to be resubmitted quickly to allow endorsement at the following PRAC meeting”.(49) 
The study may only start when the written endorsement has been issued. Then, the MAH shall 
forward the protocol to the competent authorities of the Member States in which the study is to be 
conducted, follow any specific requirements and after, the study can be initiated according to the 
endorsed protocol.(48) 
In addition, in order to support transparency on non-interventional imposed or non-imposed PASS 
and to facilitate exchange of Pharmacovigilance information between all parties, the MAHs is highly 
expected to, make study information (including for studies conducted outside the EU) available in a 
dedicated EU electronic Register of Post-Authorisation Studies (EU PAS), maintained by the 
European Network of Pharmacovigilance and Pharmacoepidemiology (ENCePP) and coordinated 
by the EMA. Any Pharmacoepidemiological and Pharmacovigilance studies can be registered. The 
application is voluntary, free of charge and can be submitted by researchers or any individual on 
their behalf. (50)  
Despite there is no legal mechanism to enforce study registration, in a non-interventional PASS 
pursuant to an obligation imposed by an EU competent authority, the date of study registration in 
the EU PAS register shall be included as a milestone in the final study report.(29) In addition, 
according to the GVP module VIII, and to incentivise transparency, it is strongly recommended that 
all PASS (imposed and non-imposed) are entered in the register, and optimally, before the start of 
data collection. The study protocol should be uploaded as soon as possible after its finalisation and 
prior to the start of data collection. Updated study protocols in case of substantial amendments, 
progress reports and the final study report should also be entered in the register (as soon as possible 
and preferably within two weeks after their finalisation).(48) 
The ENCePP aims to uphold high standards throughout the research process based on the principles 
of robust methodologies, transparency and scientific independence.(47) PASS that follow those 
principles can further qualify for obtaining an ENCePP seal.(51) 
The MAH shall submit a final study report to the national competent authority or the PRAC as 
applicable within 12 months of the end of data collection unless a written waiver has been granted 
(Directive 2001/83/EC Art 107).(27) 
 
5.3 PASS Principles and Guidance 
PASS should be designed according to strong scientific and methodological 
pharmacoepidemiological principles.  
From the previous chapters it is also clear that PASS have a distinctive purpose, interlinked with the 
overall Risk Management strategy. An immediate evidence of this particular nature stands out from 
the definition of PASS, which combines Risk Management and pharmacoepidemiological 
terms(48):  
“A post-authorisation study should be classified as a PASS when the main aim for initiating the 
study includes any of the following objectives: 
• To quantify potential or identified risks, e.g. to characterise the incidence rate, estimate the 
rate ratio or rate difference in comparison to a non-exposed population or a population 
exposed to another medicinal product or class of medicinal products as appropriate, and 
investigate risk factors, including effect modifiers; 
• To evaluate the risks of a medicinal product used in a patient population for which safety 
information is limited or missing (e.g. pregnant women, specific age groups, patients with 
renal or hepatic impairment or other relevant comorbidity or co-medication); 
• To evaluate the risks of a medicinal product after long-term use; 
• To provide evidence about the absence of risks; 
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• To assess patterns of drug utilisation that add knowledge regarding the safety of the
medicinal product or the effectiveness of a Risk Management measure (e.g. collection of
information on indication, off-label use, dosage, co-medication or medication errors in
clinical practice that may influence safety, as well as studies that provide an estimate of the
public health impact of any safety concern);
• To measure the effectiveness of a Risk Management measures”.
The fact that, the definition of a PASS is strictly related to the purpose of the study is further 
strengthened as follows: ‘Whereas the PASS design should be appropriate to address the study 
objective(s), the classification of a post-authorisation study as a PASS is not constrained by the type 
of design chosen if it fulfils the criteria as set in DIR Art 1(15). For example, a systematic literature 
review or a meta-analysis may be considered as PASS depending on its aim”.(48) 
This GVP Module also states that the development of PASS protocols should be developed by 
individuals with appropriate scientific background and experience. The different sections that need 
to be present in a PASS protocol are detailed in this guideline and leverage those also present in the 
ISPE Good Pharmacoepidemiology Practices (GPP).(48, 52) There are specific templates for PASS 
protocols and reports which establish the mandatory sections and which information each section 
should contain. In addition, there are also templates for the assessment of PASS protocols and reports 
by regulators, including guidance on how to assess the content provided in each section.(53) 
In addition, protocols need to append the ENCePP Checklist for Study protocols (available at 
http://www.encepp.eu/standards_and_guidances/index.html), which was developed to promote the 
quality of studies aligned with scientific and regulatory developments relevant to Pharmacovigilance 
and Pharmacoepidemiology, such as(54): 
• Stimulate researchers to consider important epidemiological principles when designing a
pharmacoepidemiological study and writing a study protocol;
• Promote transparency regarding methodologies used in pharmacoepidemiological studies;
• Increase awareness about developments in science and methodology in the field of
Pharmacoepidemiology.
GVP Module VIII further reference as scientific guidelines, the ENCePP Guide on Methodological 
Standards in Pharmacoepidemiology, a document covering state of the art methodological 
considerations including hyperlinks to internationally agreed recommendations and highlighting key 
points from important guidelines, published articles and textbooks.(55) 
6 Assessing the Effectiveness of Regulatory Actions 
According to the Organisation for Economic Co-operation and Development (OECD) (August 
2012), “in recent years, governments around the world have established procedures to try to analyse 
the impacts of new regulatory proposals before they are adopted. By contrast, they have paid 
remarkably little attention to analysing regulations after adoption or to evaluating the impacts of the 
procedures and practices that govern the regulatory process itself”.(56) 
Regulations are supposed to effectuate some improvement in the conditions of the world by changing 
individual or organisational behaviour in ways that generate positive impacts in terms of solving 
societal and economic problems. According to the OECD source: “at its most basic level, regulation 
is designed to work according to three main steps: (1) Regulation is implemented, which leads to 
changes in (2) The behaviour of individuals or entities targeted or affected by regulation, which 
ultimately leads to changes in (3) Outcomes, such as amelioration in an underlying problem or other 
(hopefully positive) changes in conditions in the world”.(56) 
The parallel with the considerations described in Introduction Section 4.2 on the assessment of the 
effectiveness of RMM are remarkable. As with the assessment of RMM, evaluating regulation 
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entails an inquiry, that takes place after regulation has been put in place, into how it has changed 
behaviour and ultimately if it has led to positive or negative outcomes.  
If assessing an individual RMM is already challenging, as previously described, it is not surprising 
that the process of evaluating a regulation change is extremely complex and outside the limits of any 
individual research group. In most cases, the evaluation of a regulatory framework would encompass 
the assessment of the individual rules that compose the legislative body.  
In January 2016 the PRAC adopted a strategy for measuring the impact of Pharmacovigilance 
activities including health outcomes at EU and Member States level which relies on a collaborative 
approach of all stakeholders. Measuring the impact of key Pharmacovigilance activities will allow 
regulators and stakeholders to determine which activities are most successful and to identify enablers 
and barriers for generating positive health impacts, which will contribute to the further development 
of proactive Pharmacovigilance systems and to promote best practice across the EU. It is expected 
that the strategy will support the collection of more data relevant to the health impact of the EU 
Pharmacovigilance system.(57)  
Meanwhile, there are already some published results on metrics on the new Pharmacovigilance 
processes. In May 2014, the EC published a report by the EMA on the tasks undertaken during the 
first year of application of the new legislation together with national competent authorities in 
Member States and the EC.(34) More recently, in August 2016, a new report was published to cover 
the first three years of EU legislation, based on data collected from July 2012 to December 2014 and 
discussing relevant tasks and processes over the whole 3-year period up to July 2015. Reported 
metrics supported conclusions that spontaneous reporting increased since 2012 (including an 
increased awareness of medication errors), the analysis of safety signals contributed to early updates 
of product information or other regulatory measures, hundreds of RMPs, PASS protocols and PSURs 
were centrally reviewed by the PRAC and the number of inspections increased.(36)  
In addition, the EMA considered that the new system delivers faster advice and warnings to use of 
medicines and quicker detection of safety issues. The Agency considered that patients and HCPs are 
being engaged by reporting ADRs and contributing to safety-referral procedures and that there is a 
better co-ordination and collaboration between regulators and other stakeholders, including 
academia and industry. In addition to those points, the EMA also highlights an unprecedented level 
of transparency with prompt communication on safety concerns, public access to agendas and 
minutes of the PRAC, outcomes of signals and PSURs and aggregated data on suspected ADRs.(36) 
An in-depth analysis of this metrics and the outcomes on public health will be essential to confirm 
the effectiveness of the new legislation. Smaller and/or specific evaluations of individual rules, or 
new processes from different perspectives and different stakeholders will not be enough to 
accomplish such a challenging endeavour but can, nevertheless, make small contributions and 
hopefully be of interest to complement all the other evidence. 
7 Study Rational 
The current dissertation aims to contribute to the overarching goal of understanding the impact of 
the new Pharmacovigilance legislation by focusing on the review of available data of PASS 
submitted to the EMA since the implementation of the new legislation.  
As a consequence of the effort to improve transparency, one of the main pillars of the new legal 
framework, a broad spectrum of data on the different Pharmacovigilance activities performed by the 
EMA became available, including on PASS. The availability of the large variety of information has 
provided a unique opportunity to describe the PASS landscape under the new EU Pharmacovigilance 
legislation. 
Figure 6 presents the conceptual map of the study, showing how the different concepts introduced 
in the previous chapters interact, the role of each individual component to be explored in the results 
and the dynamics between each component, which will be addressed in the discussion. 
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The grey glowing arrows symbolise the expected increased level of transparency that makes it 
possible to investigate PASS: on the top of the diagram, the MAH submits PASS protocols to the 
EMA (with a certain legal basis and at a certain point in the lifecycle of the marketing authorisation). 
There are exchanges between the stakeholders and after the final protocol is agreed, it is possible to 
estimate the duration of the overall assessment process (number of rounds of exchange, duration and 
type of feedback) represented at the bottom of the diagram. 
In the middle of the diagram, PASS are depicted as a product of Pharmacovigilance and 
Pharmacoepidemiology. By having to submit RMPs, the MAHs need to consider what is known and 
unknown about the medicinal product to establish the critical safety concerns that may affect the 
safety of the medicinal product (safety specification). For each safety concern, the MAHs need to 
establish a plan of action by considering whether routine activities are sufficient or, if additional 
activities are necessary. Some activities are designed to acquire more knowledge on the safety profile 
of the medicinal product (Pharmacovigilance activities) while others aim to mitigate the occurrence 
and/or severity of the safety concerns (RMMs).  
The consideration of the safety specification of the medicinal product by either the MAH or the 
regulators may raise questions, either related to the need to better characterise the known risks or 
detect unknown risks (investigate safety concerns, represented in orange), or concerns that the drug 
utilisation in real-world practice might differ from the expected or studied use, being important to 
monitor it actively (drug utilisation, represented in green). In addition, it is also established as part 
of the Risk Management cycle the need to investigate if the RMMs in place are being effective 
(assess effectiveness of RMM, depicted in purple). All these research questions are appropriate to 
address using Pharmacoepidemiology methods. Therefore PASS are studies with objectives derived 
from the safety specification which use pharmacoepidemiological methods to fill those gaps. 
In order to describe PASS in this dissertation, information on the type of research questions and the 
study methods were investigated. Research questions were described in line with the three 
abovementioned categories (depicted in orange, green and purple in the diagram). Methods were 
described in terms of study design, population targeted for study (inclusion based criteria), data 
collection approach (new data or leverage existing data), sample size and analysis (use of 
comparator, subgroups of interest, types of statistical methods). These characteristics were analysed 
in the light of guidelines and scientific knowledge that have been generated and disseminated to 
implement Pharmacoepidemiology in the activities of the industry and regulators. In particular, an 
in-depth analysis of the PASS aiming to assess effectiveness RMM was considered of interest given 
their position in closing the loop of a Risk Management cycle. 
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Study Objectives 
The current dissertation aimed to draw, for the first time, the PASS landscape during the first three 
years under the new Pharmacovigilance legislation, by describing the first cohort of PASS protocols 
submitted to the EMA since the first inaugural PRAC meeting in July 2012 to July 2015. 
To the best of the author’s knowledge, this is the first time that PASS submitted since the new 
Pharmacovigilance legislation are described and characterised. There are no a priori hypotheses. 
Specific objectives are: 
• To characterise PASS protocols in terms of regulatory context, study objectives, therapeutic
area, study design, source of data collection, and other methodological considerations;
• To estimate PASS protocol assessment metrics, such as, the number of rounds of review and
duration of PASS protocol assessment by the PRAC, and to identify the most common
reasons for protocol rejection;
• To determine the amount of PASS assessment comments publicly available and how many
studies were entered in the EU PAS Register;
• To understand to what extent PASS are designed as methodologically and feasibly sound
studies, by reviewing protocol content, PRAC feedback and running a more in depth
analysis of PASS assessing effectiveness of RMMs.
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Methods 
In natural and social sciences quantitative and qualitative research methods are often seen as two 
irreconcilable approaches by advocates of each style. While the methods used in quantitative 
research attempt to maximize objectivity, replicability, and generalisability of findings, and are 
typically interested in prediction, qualitative approaches focus mainly on exploring meaning, 
purpose, or reality. The question of quantitative versus qualitative measures is currently more 
assumed to be a false one, as more researchers see them as complementary approaches.(58-61)  
Quantitative approaches are often associated with the use of deductive reasoning, characterised by 
top-down logic in which, the structure of the analysis is based on previous knowledge and/or 
experience (i.e. a priori definitions and decisions about the variables) moving from the general to 
the specific. Conversely, qualitative approaches are associated with the use of inductive reasoning, 
characterised by bottom-up logic as it moves from the specific to the general, in the sense that 
particular instances are observed and combined into larger whole or general statements. Therefore, 
themes and categories emerge from the data.(62) 
The nature of this dissertation’s objectives and the available sources to address them invited the use 
of qualitative methodologies. First, the need to understand PASS in the context of the new regulatory 
framework and its background. Second, the public availability of different textual sources 
documenting PASS and their assessment by the Regulators which made them attractive data sources 
to address the objective via the scientific study of its content. 
1 Study Design 
The public availability of different textual sources documenting PASS made them a pertinent data 
source in which to conduct a documentary analysis.  
1.1 Data Sources 
The minutes of the PRAC monthly minutes provided the means to identify the different PASS 
protocols and respective rounds of revision by the PRAC. After identifying each PASS protocol, 
two other data sources were searched to find more granular information regarding the regulatory 
background and the protocol methods: the European Public Assessment Reports (EPARs) of the 
medicinal products covered in the PASS (also available in the EMA website), and the EU PAS 
Register (available in the ENCePP website). When no information was available in the 
abovementioned sources, the website ClinicalTrials.gov was searched to check if PASS were 
eventually registered there. In addition, a pool of protocols available within the author’s organisation 
was also checked in case it contained additional protocols. 
The following sections further describe each of these data sources and the type of information 
retrieved. 
1.1.1 Minutes of the PRAC Monthly Meetings(63) 
As a consequence of the efforts of the EMA to increase transparency of the regulatory processes, the 
full minutes of the PRAC monthly meetings are published, in English, every month, listing all the 
processes assessed by the PRAC in the previous month. In addition, a short description of the 
background and PRAC comments may be provided for those procedures discussed during the 
plenary meeting. These official and authentic EMA documents available online, at the EMA website, 
provided an unique opportunity to identify and track, in a chronological order, all PASS protocols 
submitted to the EMA during the first three years under the new legislation by reviewing all the 
minutes covering the period since the PRAC inaugural meeting in July 2012 until the PRAC meeting 
in July 2015.  
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As in any documentary analysis, the first step was to assess the level of information provided in 
these documents and their potential to characterise PASS.(64) Annex 1 described the structure of 
these documents and the information available regarding PASS. 
The following information was retrieved from the PRAC meeting minutes when available: name of 
active substance, MAH, whether it was an imposed or non-imposed PASS, PRAC assessment 
outcome (endorsement/ objection or need for revision/ administrative procedural information/ 
unknown). PRAC reasons for objection/ revision were further categorised by area of concern (study 
objectives and endpoints/ study design/ data source and population/ data collection and management/ 
study variables/ sample size/ data analysis/ milestones and timelines/ feasibility and bias 
considerations/ other/ missing).  
1.1.2 European Public Assessment Report (EPAR)(65) 
For each of the medicinal products studied in the PASS protocols identified from the minutes, a 
search was conducted on the EMA website to retrieve information from the EPARs using the search 
engine “Find medicine” and looking for that particular medicinal product. Annex 2 describes the 
types of information available through this search for a medical product. 
While the EPARs are only available for CAPs, medicinal products authorised through national 
authorisation procedures and subject to a referral could also be found by searching for the name of 
the active substance which would list any existent referrals under Article 20, Article 30 or Article-
107i procedures. Therefore, information about the PASS resultant from referrals could also be found 
by reviewing the outcome of these processes. 
The information from the EMA website mainly provided details on CAP medicinal products: 
marketing authorisation date, MAH, orphan drug status, the regulatory background of PASS such as 
imposed or non-imposed PASS category and life cycle stage of the medicinal product in which PASS 
was implemented. 
1.1.3 The ENCePP Website: EU PAS Register(50) 
Since July 2012 the EU PAS Register serves as the official EU register for post authorisation studies 
regardless of whether initiated, managed or financed by MAHs voluntarily or pursuant to an 
obligation, or whether conducted by research centres of the ENCePP network or any other research 
centre, including from outside the EU. Annex 3 describes the structure and data elements contained 
in the EU PAS Register (at July 2015).  
The EU PAS register was searched to identify if the PASS were registered and in those cases, if the 
protocols were made available. Since the objective of the work was to describe the PASS protocols, 
whenever available, these documents were the privileged data sources to collect the information 
about the PASS objectives and methodology.  
Main methodological characteristics retrieved from this data sources were study design, inclusion 
based criteria, data collection approach, sample size and analysis. 
1.1.4 Other Sources 
When information regarding PASS methodology was not available from the abovementioned data 
sources, an internal pool of protocols accessible to the author’s organisation was searched. No 
confidential or sensitive information was disclosed as part of this work. The data was matched with 
the data retrieved from the other public data sources. 
In addition, the ClinicalTrials.gov, a registry and results database of publicly and privately supported 
clinical studies of human participants conducted around the world, was also searched. Most of the 
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records in ClinicalTrials.gov describe interventional clinical trials but it may also include records 
describing observational studies. International sponsors less familiarised with the European data 
sources might use this data source to publish information on PASS. Therefore, this data source was 
also screened for the medicinal products and the PASS identified in the PRAC Meeting minutes.(66) 
1.2 Data Source Hierarchy 
The described data sources were mostly complementary as different PASS characteristics were 
typically retrieved from each one. However, in the cases in which the same type of information was 
available in more than one of the data sources, a hierarchy was established to decide which data 
source to privilege, as presented in Figure 7.   
Figure 7 – Hierarchy of data sources 
The protocol documents were the most reliable source of information on PASS objectives and 
methodology as they are the written documents describing the PASS plan. When this document was 
not available for a certain PASS, preference was given preference to the information recorded in the 
EU PAS Register as it contains some data structured elements from the protocol as described above. 
If the PASS protocol was not available nor registered in the EU PAS Register, then information 
about study objectives and methodology was retrieved from the minutes (a brief description was 
sometimes available, e.g. “PASS protocol for a drug utilisation study (DUS) in selected European 
countries: multinational, retrospective, observational study to assess effectiveness of risk-
minimisation measures”) or in the EPARs, as the objectives of the PASS and any requirement on 
the design were sometimes established even before the protocol is developed (e.g. “observational 
database study [cat 3]: to assess the risk of thyroid and pancreatic cancers in observational databases 
of sufficient size that provides long term longitudinal follow up of patients”). In these cases, those 
sources were considered the best estimates of the actual content that would be described in the 
protocol documents. In addition, the website ClinicalTrials.gov was also reviewed in case the studies 
were registered there. However, the data elements presented in this website, which is tailored for 
interventional studies, were less relevant to characterise PASS than those in the EU PAS Register. 
1.3 Identification of PASS Protocols 
All the PRAC monthly minutes (from July 2012 to July 2015) were included in the analysis. From 
the review of these documents in a chronological order, all the entries related to PASS protocol were 
recorded in an excel spreadsheet.  
1-Protocol documents
2-EU PAS Register
3-PRAC meeting Minutes/ EMA
website/ ClinicalTrials.gov
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Each PASS protocol could appear more than once in the consecutive meeting minutes corresponding 
to the reassessment of a revised version of the protocol resubmitted after previous PRAC 
recommendations.   
Each distinct PASS protocol assessment was sequentially recorded in different rows of the excel 
matrix. Further assessments of the same protocols were registered using the same PASS protocol 
designation, and a sequential number was assigned for each assessment/reassessment of a certain 
PASS protocol (column “round of review”).   
The process of discriminating between different PASS protocols and different rounds of assessment 
of the PASS protocols was iterative and the following rules were established to ensure consistency 
(Annex 4 contains examples in illustrate these rules): 
• Every new PASS protocol “entry” identified through the chronological review of the
minutes was considered to be the “first round” of assessment for that PASS protocol;
• If in the same, or subsequent minutes, another entry of a PASS protocol of the same
medicinal product was identified, then the text was carefully revised to decide if it was the
same PASS protocol already presented before (see Annex 4: examples 1 and 2), or if it was
a different PASS protocol for that medicinal product (see Annex 4: examples 3 and 4 and
the glycopyrronium bromide PASS protocol mentioned in example 5). Then:
o In case it was determined that it was the same PASS protocol already presented
before for the same medicinal product, this PASS protocol assessment was
considered a new round of evaluation of the same PASS protocol: recorded as a new
PASS protocol assessment round in a new row of the excel matrix using the same
PASS identification designation, with an indication that it was a subsequent round
of assessment in the respective column (i.e. “round 2” and so forth);
o Conversely, if determined that the new PASS protocol entry refers to a different
PASS for the same medicinal product, this PASS protocol was recorded in the excel
matrix with a new designation and as the first round of assessment of this new PASS
protocol (i.e. a new row assigned “round 1”);
o It should be noted that from the minutes of the meeting held on February 2014
onwards, the task was facilitated since each PASS protocol entry started presenting
additional fields, namely, the procedure number, the procedure scope and MAH,
which make it easier to identify new submissions versus resubmissions of PASS
protocols (see Annex 4 examples 5).
• When the text from a certain PASS protocol entry in the minutes indicated that two different
PASS protocols for a certain medicinal product were concomitantly assessed, even though
they were recorded in the minutes under the same subheading, they were split when recorded
in the excel matrix, in order to account for each individual PASS protocol (see Annex 4
example 6).
As a PASS protocol could be referred in more than one row of the spreadsheet, it was decided that 
all the PASS characteristics would be collected in the first row for that PASS protocol (i.e. “round 
1”). Therefore, even if resubmissions of the same PASS protocol present information about the 
PASS protocol that was unavailable before, all the information pertaining to that same PASS 
protocol was recorded in the first row for that PASS protocol (“round 1”). The investigator was 
aware of the possibility that the information provided in a subsequent round of assessment could 
contradict information provided in a previous round of the same PASS protocol. However, that 
situation did not occur as the level of information provided in different rounds was often very 
limited. 
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1.4 Data Collection 
For each different PASS protocol identified as described in Methods Section 1.3, the data sources 
(introduced in Methods Section 1.1) were searched and used according to the established hierarchy 
(see Methods Section 1.2) to collect information about PASS characteristics.  
An excel spreadsheet was used as data collection instrument. Each PASS protocol assessment, 
identified from the chronological review of the PRAC meeting minutes, was sequentially recorded 
in excel matrix rows. The columns were the characteristics of interest, some of which were 
transcribed information from data sources, while others were derived information or coded 
information that resulted from the application of the final defined rules. Please refer to Annex 5 for 
a list of variables, definitions and operational rules. The final database is provided as an electronic 
supplementary material. 
2 Data Analysis 
2.1 Iterative Development of the Coding Scheme 
The analysis of the information contained in the different documents followed the main principles 
of a content analysis technique which is defined by Krippendorf K (1980) as “a research technique 
for making replicable and valid inferences from texts (or other meaningful matter) to the contexts of 
their use”.(59) It is well accepted in this area, that, while variables and categories can be defined a 
priori and applied following a top-down rational, iterative loops of feedback from a qualitative 
review of the data may reshape the pre-defined ”classes” of data. Specially, when a researcher is 
analysing a subject for the first time, even if there are a priori expectations, new or different patterns 
may be revealed while he/she is getting familiar with the data.(62, 67)  
In light of the above considerations, it seemed pertinent to allow for flexibility when considering the 
method in the current project. Despite an initial choice on the set of variables to start PASS 
characterisation, the novel nature of the content being analysed made it necessary to further revise 
the initial coding scheme as new data emerged from the analysis. The previous variables and 
categories were not satisfactory to capture the distinctive features of the PASS and were 
progressively refined through several iterative cycles of coding and recoding until the final coding 
scheme was established (see Annex 5) containing variables capturing different PASS traits with 
exhaustive and mutually exclusive categories. The final set of rules was systematically implemented 
to all units in the excel matrix (even if they had been previously classified with previous versions 
coding rules), thus, creating the final study database.  
In addition to the general variables collected for all protocols, some more granular analyses required 
additional considerations as follows. 
2.2 Units of Analysis and Specific Considerations 
To address the different objectives of the study, it was necessary to use different sets of units, which 
could be retrieved from the excel spreadsheet using the rules described below. The analyses 
performed to address the study objectives are also described. 
2.2.1 Characterisation of PASS Entities 
To analyse the different PASS protocols (irrespective of having documents available), the excel 
spreadsheet was filtered by column G (“Rounds of PRAC evaluation =1”). As explained in Methods 
Section 1.3, the cumulative characterisation of each PASS protocol was made on its first database 
record even if some information was only available on a subsequent minutes’ entry.  
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2.2.2 Sub-analysis of PASS Protocols with Documents Available 
Some of the PASS characteristics of interest were only retrievable from the protocol documents, 
hence, a detailed characterisation was performed among the subset of PASS with protocols available. 
By filtering the spreadsheet by column AI (“Protocol available (yes/no) = yes”) it was possible to 
select the subset of PASS with the most complete information available.  
2.2.3 Sub-analysis of PASS Protocols Assessing Effectiveness of RMM 
The sub-analysis of methods used in PASS assessing effectiveness of RMM was conducted by 
filtering the excel matrix by the same columns indicated in the previous bullet point and also by 
column AT (“PASS focus: eRMM = yes”).  
The protocols of those PASS were analysed in detail and structured as shown in Annex 6 according 
to the following criteria: 
 ID: The number of the row from the excel matrix corresponding to the PASS assessing
effectiveness of RMM;
 PASS safety objectives: Information from column AQ of the excel matrix, capturing
whether the PASS objectives were exclusively dedicated to assessing effectiveness of RMM
or if those PASS protocols contained PASS objectives of the other categories;
 Study design/ data source: Whether the design was longitudinal/ cross-sectional, used
primary or secondary data collection approaches and the detail of the data source;
 Sampling frame: Details of the population targeted and included in the PASS specifying if
there was sample randomisation;
 Indicators: The types of indicators of effectiveness of RMM that seemed to be covered in
the PASS (use of RMM/ knowledge/ behaviour/ outcome);
 Interesting aspects: any observation of interest.
2.2.4 Analysis of PASS Protocol Review Process 
Each row in the matrix corresponded to a different PASS protocol assessment. In order to determine 
the number of rounds of PRAC assessment and overall duration of PRAC assessment process (from 
the first PASS protocol submission to the PRAC until the protocol was considered approved), it was 
necessary to ascertain whether the PASS protocols contained in the analyses were approved at the 
data lock point of July 2015.  
Since the information available in the minutes’ PRAC comments was often very limited, there were 
several cases were there was no explicit information on whether the PASS protocol had been finally 
endorsed. In these cases, the following assumptions were made to ascertain whether or not a certain 
PASS protocol assessment process could be considered finalised at the data lock point (July 2015): 
• The PASS was found in the EU PAS Register, which usually occurs after the protocol is
approved, or
• More than one year had elapsed since the last assessment of that PASS protocol per the
minutes (i.e. the last PASS protocol submission was recorded in the minutes of the July 2014
meeting or earlier). This was regarded as a reasonable amount of time to consider that
another PASS protocol submission was unlikely;
• In addition, PASS for which there was not enough evidence that their assessment was
initiated only after the implementation of the new Pharmacovigilance legislation, were
excluded, since for this particular analysis on the PRAC assessment process, the focus was
only on PASS protocols fully assessed within the new Pharmacovigilance legislation.
PRAC review metrics were estimated among the subset of PASS protocols that met the conditions 
enumerated above: the number of rounds of assessment for a certain PASS protocol corresponded 
to the number of entries for that PASS protocol in the excel database (number of rounds of review), 
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and the duration of protocol review was the number of months elapsed since the first and the last 
entry for a certain PASS protocol.  
2.2.5 Analysis of PASS Comments’ Text 
The PRAC comments’ text recorded in the minutes was specifically analysed with the support of the 
qualitative data analysis software MAXQDATM (2007 version) in order to characterise PRAC 
assessment outcomes. All the “PRAC comment” fields from the excel database were imported to the 
software and analysed through iterative cycles of open codification. Open Coding includes labelling 
particular sections of the text and defining and developing categories based on recurrent patterns in 
all comments. Through repeated cycles of reading and code review, different themes were identified 
as follows: 
• PRAC outcome decision (column P in the excel spreadsheet, see definition in Annex 5): to
capture whether the outcome of a certain round of a PASS protocol assessment was the need
for resubmission;
• Areas of the protocol requiring revision (column Q in the excel spreadsheet, see definition
in Annex 5): for the PASS protocol rounds in of review in which the PRAC objected or
required revision, the underlying protocol areas of concern were identified. The result of the
codification is presented in Annex 7.
• The submission and assessment timetable established by the PRAC for the protocol revision
(columns R and S in the excel spreadsheet see definition in Annex 5).
2.3 Statistical Methods 
Analyses were performed with the statistical software SPSS, Version 21.0. 
Descriptive analyses were performed among i) all the PASS protocols submitted ii) the subsample 
of PASS with protocol documents available, iii) the PASS protocols assessing effectiveness of 
RMM; iv) the PASS protocols for which the assessment process was considered concluded, v) the 
full consecutive PRAC comments published in the minutes. 
Categorical variables were summarised by the number and percentage (%) of PASS in each category, 
excluding missing data. Continuous variables were summarised using descriptive statistics (mean, 
standard deviation [SD], median, quartiles, minimum and maximum values).  
Proportions were calculated excluding missing data from the denominator. Comparisons using chi 
square (considering a significance level of 5%) were performed for categorical variables.  
All analyses were performed on actual data, with no imputations for missing data. 
1
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Results 
1 PASS Disposition 
1.1 Study Population 
In total, 353 PASS protocol assessments were identified by reviewing the minutes of the PRAC 
meetings from July 2012 to July 2015. 
Eight others were excluded due to missing data for all variables, and consequent impossibility to 
assess whether they corresponded to a submission or resubmission.  
Figure 8 below presents the disposition of the study population considering the different analysis 
datasets that address study objectives. 
Each of the 353 PASS protocol assessments was considered in terms of available information on 
PASS protocol and PRAC comments. 
The 353 PASS protocol assessments identified in the minutes corresponded to 189 different PASS 
protocols (with at least one round of assessment), with the remaining 164 PASS protocol 
assessments being related to additional rounds of assessment of those protocols (considered as 
resubmissions of PASS protocols). 
Protocols were available for approximately one third of PASS (n=57/189, 30%) allowing the most 
detailed study characterisation. The second highest hierarchical source of evidence (see Methods 
Section 1.2), the EU PAS Register, was used to classify 22% (n=42/189) of PASS, while for the 
remaining 48% (n=90/189) information was retrieved from the minutes, ClinicalTrials.gov and the 
EMA website, in the absence of more detailed sources. 
For approximately half of 189 different PASS (n=103/189, 54%) there was reasonable evidence to 
assume that the assessment process had been concluded at the data lock, July 2015 (see rules 
established in Methods Section 2.2.4): 15 had enough evidence in the minutes’ text to conclude the 
assessment was finalised, 66 others were entered in the EU PAS Register and for 22, despite the 
inexistence of registration in the EU PAS, more than one year had elapsed since the last presentation 
of the PASS protocol in the minutes up to July 2015. 
Regarding the PRAC comments, these were only available for 106 of the 353 different PASS 
assessments (n=106/353, 30%). Upon review of the 106 PRAC comments’ text, it was determined 
that PRAC outcomes were the following: 16 protocol approval (n=16/106, 15%), 71 protocol 
objection or need for revision (n=71/106, 67%) and 19 concerning other matters (n=19/106, 18%) 
such as administrative or procedural information. 
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Figure 8 – Study population 
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1.1.1 Representativeness of the Subset of PASS with Protocol Available (n=57) 
The protocol documents were available for 57 PASS. Table 1 below summarises the distribution of 
both the 189 different PASS and the subset of 57 PASS with protocol documents available by the 
main PASS characteristics.  
The proportion of PASS within each category of the variables was very similar in the two datasets. 
The highest differences were observed in terms of data collection (42% of the 189 PASS used 
secondary data collection versus 33% among the subset of 57 PASS with protocol available) and 
inclusion based criteria (70% of the 189 PASS based on single product and 21% based on multiple 
products versus 81% and 12%, respectively, among the subset of 57 PASS with protocol available). 
However, the magnitude of the differences was still small. In fact, a comparison between the PASS 
with protocol available and those without revealed no statistically significant differences (chi-square 
test, p<0.05). 
For the abovementioned reasons, the subset of 57 PASS protocols was considered representative of 
the overall 189 PASS population. Since the availability of these documents allowed a more in-depth 
characterisation of the PASS protocols, some results were based on the information contained in 
these documents and extrapolated to the overall PASS population. 
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Table 1 – Distribution of PASS characteristics (comparison of all PASS and the subset with protocol 
available) 
PASS Status 
Overall 
(n=189)* 
Protocol 
available 
(N=57) 
Regulatory Aspects n (%) n (%) 
Imposed 58 (30.7) 17 (29.8) 
Condition to MA (Cat. 1) 28 (14.8) 10 (17.5) 
Specific obligation (Cat. 2) 7 (3.7) 2 (3.5) 
Referral 23 (12.2) 5 (8.8) 
Non-imposed 131 (69.3%) 40 (70.2) 
RMP (Cat. 3) 116 (61.4) 36 (63.2) 
Other‡  15 (7.9) 4 (7.0) 
Orphan Drug Status 25 (13.2) 6 (10.5) 
Joint PASS§ 16 (12.1) 7 (12.3) 
Study specifics n (%) n (%) 
PASS focus** 
To investigate safety concerns 140 (74.1) 43 (75.4) 
Drug utilisation study 65 (34.4) 23 (40.4) 
Assess effectiveness of RMM 48 (25.4) 18 (31.6)) 
Data collection†† 
Primary 81 (57.9) 38 (66.7) 
Secondary 59 (42.1) 19 (33.3) 
Study Design‡‡  
Longitudinal follow-up 110 (80.9) 47 (82.5) 
Transversal/ cross-sectional 26 (19.1) 10 (17.5) 
Study population inclusion based criteria§§
Type of exposure 
Disease 13 (8.4) 4 (7.0) 
Multiple medicinal products 33 (21.3) 7 (12.3) 
Single medicinal product 109 (70.3) 46 (80.7)) 
Special populations focus 
Pregnant women 9 (11.5) 3 (5.3) 
Paediatric population 14 (17.9) 8 (14.0) 
Healthcare providers 17 (21.8) 9 (15.8) 
Abbreviations: MA = Marketing Authorisation; PASS = Post-Authorisation Safety Study; RMM = RMM = 
Risk Minimisation Measure; RMP = Risk Management Plan. 
Categories are mutually exclusive unless otherwise specified. 
* Percentages calculated excluding missing values.
‡ Considered to be category 4, by exclusion.
§ More than one Marketing Authorisation Holder sponsored the study. Missing data (applicable to overall
column only): imposed = 17 (29.3%), non-imposed= 40 (30.5%); total = 57 (30.2%)
**Categories not mutually exclusive.
†† Primary: collection of data specifically for the study; Secondary: use of existent data collection schemes.
Missing data (applicable to overall column only) = 49 (25.9%).
‡‡ Longitudinal: involves collection of variables at least two points in time; Transversal: involved collection of
variables at a certain point in time. Missing data (applicable to overall column only) = 53 (28.0%).
§§ Common inclusion criteria: in terms of exposure (patients with a certain disease irrespective of medicinal
products, restricted to single medicinal product exposure/ prescription or exposure/ prescription of more than
one predefined medicinal product/ treatment modalities. Missing data (applicable to overall column only) = 34
(18.0%).
Special population focus: Inclusion restricted to special groups of interest (children, pregnant women). Missing
data (applicable to overall column only) = 111 (58.7%).
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1.2 Volume of PASS Protocol Assessments 
Figure 9 presents the number of PASS protocols assessed each month during the study period, 
according to the minutes of the PRAC meetings from July 2012 to July 2015. “Number of new PASS 
protocols evaluated” refer to protocols that appeared for the first time in the concerned monthly 
minutes and “number of PASS protocols evaluated (including resubmissions)” correspond to total 
number of PASS protocols presented in the concerned monthly minutes irrespective of whether it 
was a first occurrence or a subsequent round of assessment for a PASS protocol already presented 
before.  
Overall, the number of PASS protocols assessed increased prominently after June 2013, with the 
majority of new PASS protocols (n=146/189, 77%) and the majority of overall submissions 
(n=299/353, 85%) occurring in the last two years covered in this study period. 
Figure 9 – Number of PASS protocols reviewed monthly (new submissions and resubmissions) 
More detailed information is presented in Figure 10 below. While approximately as many PASS 
overall were assessed in the second and third year (July 2013-July 2014 and July 2014-July 2015), 
the majority of new PASS protocols was assessed in the second year of the study period (n=83/189, 
44%). 
Figure 10 – Distribution of PASS protocols submissions (new and cumulative) per year in review 
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1.3 ENCePP Registration 
As of July 2015, half of the 189 PASS (n=93/189, 49%) were entered in the EU PAS Register, with 
a higher proportion among the 58 imposed PASS (n=34/58, 59%) as compared to non-imposed 
(n=59/131, 45%); chi-square test, p<0.05. Almost half of the EU PAS entries had the protocol 
documents available (n=40/93, 43%).  
Table 2 below summarises the proportion of PASS registered in July 2013, 2014 and 2015. There 
was an increased registration in the third year of the analysis as reflected by an increase in over 20% 
registration of both imposed and non-imposed PASS from July 2014 to July 2015, which had 
previously shown a negative trend from July 2012 to July 2013. 
Table 2 – Registration of PASS in EU PAS Register over the study period 
% Imposed PASS registered % Non-imposed PASS registered 
July 2012-July 2013 40% 28% 
July 2012-July 2014 35% 23% 
July 2012-July 2015 59% 45% 
Very few of the PASS registered (n=4/93, 4%) had requested and were granted an ENCePP seal, 
which recognises studies following the ENCePP principles of standards, transparency and 
independence. 
2 Description of the PASS Protocols Submitted to the PRAC during the 
Initial Three Years under the New Pharmacovigilance Legislation 
2.1 Reasons for Initiating a PASS, Regulatory Status and Sponsorship 
Figure 11 presents the regulatory basis of the 189 PASS and the lifecycle phase of the concerned 
medicinal products when PASS were planned. 
Overall, approximately one third (n=58/189, 31%) of the 189 different PASS were imposed on the 
marketing authorisation. Nearly half of them (n=28/58, 48%) were imposed as a condition to the 
marketing authorisation (category 1) and approximately one tenth (n=7/58, 12%) were imposed as 
specific obligations in the framework of a marketing authorisation under exceptional circumstance 
(category 2). In addition, despite not being part of the categorisation of imposed PASS per the 
Pharmacovigilance legislation, 40% of PASS (n=23/58, 40%) were mandated following EMA 
conclusions under the framework of an Article 107i or 20 referral procedures (benefit-risk 
reassessment procedures conducted triggered by safety concerns).  
Among the 131 non-imposed PASS, the vast majority (n=116/131, 89%) were included in the RMP 
(category 3). No information about the reason for conducting the PASS was found for the remaining 
15 non-imposed PASS (11%). Since they were not included as an annex neither to the marketing 
authorisation nor in the summary of the RMP, they were considered possibly category 4 PASS 
(voluntary PASS).  
For those PASS that were conditions to the marketing authorisation or requirements of the RMP 
(category 1 and 3), the "regulatory lifecycle event" leading to the PASS imposition or requirement 
was analysed (e.g. planned/imposed with the initial marketing authorisation; after a variation to 
extend indication to a new disease or to the use in a new approved population such as paediatric 
patients; after a renewal of the marketing authorisation; as a consequence to a variation due to a 
change in manufacturing or a new dose or route of administration; after the assessment of the PSURs, 
etc.). Approximately two thirds of either the PASS imposed as condition to the Marketing 
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Authorisation (n=18/28, 64%) or those required in the RMP (n=85/116, 73%) were planned with the 
initial marketing authorisation for the medicinal product. All category 2 PASS (n=7) were imposed 
with the initial marketing authorisation. Therefore, the majority of PASS concerned initial marketing 
authorisation (n=110/189, 58%). 
Other common triggers for requesting a PASS were variations to the marketing authorisation, mainly 
after an extension of the indication of the medicinal product to a new condition (n=5/28, 18% of 
category 1 PASS and n=13/116, 11% of category 3 PASS). An extension of the marketing 
authorisation to approve the use of the medicinal product for paediatric patients was associated with 
7% (n=2/28) of the category 1 PASS and 6% (n=7/116) of category 3 PASS.  
Figure 11 – PASS categorisation in the lifecycle of the marketing authorisation 
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Figure 12 below presents the distribution of PASS protocols assessed each year in terms of 
imposed/non-imposed status.  
The majority of the PASS protocols assessed each year were non-imposed. The proportion of 
imposed PASS assessed by year was higher in the latter two years of the analysis (approximately 
one third of the overall PASS protocols assessed in the second and third year of the study versus 
approximately one fifth of those analysed in the first year). 
Figure 12 – Distribution of PASS assessed over the three years in the study period by legal status 
Most PASS had a unique sponsor with only 12% PASS, among 132 for which there was available 
information, identified as jointly sponsored (n=16/132, 12%). The majority of the joint studies 
concerned PASS mandated as a consequence of a referral, which is generally applicable to all 
medicinal products of a certain active substance and therefore also included national authorised 
medicinal products (n=10/16, 63%). 
2.2 Characteristics of the Studied Medicinal Products 
2.2.1 Therapeutic Class 
The medicinal products covered in the PASS were diverse in terms of Anatomical Therapeutic 
Chemical (ATC) code of the active substances as summarised in Table 3 below.  
The four main ATC classes were by descending order: antineoplastic and immunomodulation agents 
(n=32/189, 17%), products acting on the alimentary tract and metabolism (n=30/189, 16%), 
antiinfectives for systemic use (n=27/189, 14%) and products acting on blood and blood forming 
organs (n=21/189, 11%).  
Similar patterns were observed among the imposed and non-imposed PASS. Substances acting on 
the cardiovascular system and on the genito-urinary system and sex hormones were slightly more 
common among imposed PASS compared with the non-imposed. In contrast, antiinfectives for 
systemic use, active substances acting on the nervous system and of the class “various” were slightly 
more common among the non-imposed PASS. 
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Table 3 – Therapeutic class of the active substance covered in the PASS 
ATC class (1st level) 
Imposed 
PASS 
(n=58) 
Non-
imposed 
PASS 
(n=131) 
Overall 
PAS 
(n=189) 
n (%) n (%) n (%) 
Antineoplastic and immunomodulating agents (L) 9 (15.5) 23 (17.6) 32 (16.9) 
Alimentary tract and metabolism (A) 7 (12.1) 23 (17.6) 30 (15.9) 
Antiinfectives for systemic use (J) 5 (8.6) 22 (16.8) 27 (14.3) 
Blood and blood forming organs (B) 8 (13.8) 13 (9.9) 21 (11.1) 
Nervous system (N) 4 (6.9) 14 (10.7) 18 (9.5) 
Cardiovascular system (C)  8 (13.8) 6 (4.6) 14 (7.4) 
Genito-urinary system and sex hormones (G) 7 (12.1) 7 (5.3) 14 (7.4) 
Various (V) 1 (1.7) 11 (8.4) 12 (6.3) 
Respiratory system (R)   5 (8.6) 4 (3.1) 9 (4.8) 
Musculo-skeletal system (M) 2 (3.4) 2 (1.5) 4 (2.1) 
Sensory organs (S) 0 (0.0) 4 (3.1) 4 (2.1) 
Dermatologicals (D) 2 (3.4) 1 (0.8) 3 (1.6) 
Systemic hormonal preparations, excluding sex 
hormones and insulins (H) 
0 (0.0) 1 (0.8) 1 (0.5) 
2.2.2 Orphan Status 
When applying for a new marketing authorisation, a MAH may apply for obtaining an orphan 
designation for the medicinal product. Orphan designation is based on the criteria laid down in 
Regulation (EC) No 141/2000 (see definition in Annex 5: description of column AB).  
Overall, 13% (n=25/189) of the PASS concerned a medicinal product with an orphan designation. 
The proportion of PASS addressing a medicinal product with an orphan designation was higher 
among the imposed PASS as compared to the non-imposed PASS (22% versus 9%, chi-square test, 
p<0.05). To note, four of the seven PASS imposed as a specific obligation to the marketing 
authorisation (category 2) concerned orphan medicinal products. 
2.2.3 Authorisation Procedure 
The vast majority of the 189 PASS presented in the PRAC minutes covered medicinal products 
authorised by a CAP (n=166/189, 88%). All but two of the 23 nationally authorised medicinal 
products’ PASS followed a decision implemented after a referral procedure. The remaining two 
PASS were imposed as a condition of the marketing authorisation and involved more than one 
Member State.  
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2.3 PASS Objectives 
PASS objectives were categorised as “to investigate safety concerns”, “to study drug utilisation“ 
and/or “to assess effectiveness of RMMs” consistent with the types of objectives that make a post-
authorisation study be considered a PASS (see Annex 5: description of column AQ). 
Figure 13 below present the results in a Venn diagram. 
Overall, the vast majority of PASS (n=140/189, 74%) had at least as one of the primary objectives, 
“to investigate safety concerns” which could be either to quantify risks, to evaluate the risks of use 
of the medicinal product in patient populations for which the information is limited or missing, to 
evaluate the risks of a medicinal product after long-term use or to provide evidence about the absence 
of risks.  
Approximately one third of the PASS (n=65/189, 34%) had, at least as one of the primary objectives, 
“to study drug utilisation”, and approximately one fourth of the PASS (n=48/189, 25%) had, at least 
as one of the primary objectives, “to assess effectiveness of RMMs”.  
Almost one third of the 189 PASS (n=58/189, 31%) combined at least two of the three PASS focus 
categories under the same protocol. In particular, half of the PASS that, had at least as one of the 
primary objectives “to study drug utilisation”, also aimed “to investigate safety concerns” (n=31/65, 
48%), or to “assess effectiveness of RMMs (n=12/65, 18%) or both (n=6/65, 9%). Therefore only 
one fourth (n=16/65, 25%) of the PASS that had at least one primary objective of “study drug 
utilisation” did not combine objectives of the other two PASS focus categories.  
In addition, the majority of the PASS that had, at least as one of the primary objectives, “to assess 
effectiveness of RMMs” (n=27/48, 56%), also combined objectives of the other PASS focus 
categories, mainly “to study drug utilisation” (n=18/48, 38%).  
Conversely, the majority of PASS which had at least one of the main focus “to investigate safety 
concerns” did not combine PASS objectives of the other categories (n=94/140, 67%). 
Figure 13 – PASS focus 
Note: Overall number of PASS with each safety concern: to investigate safety concerns (N=140); to study 
drug utilisation (N=65); to assess effectiveness of risk minimisation measures (RMMs) (N=48).  
Figure produced with the support of http://www.cmbi.ru.nl/cdd/biovenn/index.php 
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The review of the summary tables of the RMPs from the EPARs, provided showed the safety 
concerns considered in the RMPs and the planned PASS to address each of those concerns.  
Safety concerns were diverse and a comparison between those mentioned in the EPAR and those 
addressed in the protocols would have required a more complex investigation. However, it was noted 
when analysing the EPARs of the PASS that combined objectives of “investigating safety concerns” 
with at least one objective of the other categories, that there were some recurrent types of safety 
concerns. Safety concerns often analysed in PASS with those objectives were related with exposure 
in populations for which there was missing information, off-label use and the effects of long-term 
use of the medicinal product. 
The higher harmonisation observed in this subgroup of PASS made it feasible to perform an 
exploratory analysis to verify if the safety concerns deemed to be investigated in the concerned 
PASS according to the plan (EPAR) were actually reflected in the protocols objectives. 
The analysis is presented in Figure 14. 
The proportion of each of the three types of safety concerns in the PASS protocols was lower than 
it would have been expected from the EPARs.  
Figure 14 – Analysis of safety concerns described in PASS protocols and those targeted to be addressed 
in a PASS according to the EPARs  
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In addition to the safety objectives, the review of the 57 PASS with protocol documents available, 
revealed that approximately one third of those (n=20/57, 35%) also included objectives related with 
the assessment of effectiveness/benefit endpoints in addition to safety ones. Those endpoints were 
generally related with disease progression, long-term clinical response to the medicinal product, 
results from physician assessment scales, premature discontinuation and/or need to use alternative 
medicinal products.  
The proportion of PASS protocols assessing effectiveness endpoints among each therapeutic class 
was particularly high among PASS of “antineoplastic and immunomodulating agents”, as six of the 
eight PASS protocols of these active substances, assessed effectiveness as part of the study 
objectives, namely, overall survival/best overall response, progression free survival and event-free 
survival. 
2.4 PASS Methodology 
Table 4 below summarises the main PASS methodological characteristics that will be explored in 
the following subchapters.  
Table 4 – Summary of PASS methodological characteristics 
PASS Status 
Imposed 
(n=58) 
Non-
imposed 
(n=131) 
Overall 
(n=189) 
Chi-
square test 
(p-value) 
n(%) n(%) n(%) - 
Data collection†† 
Primary 25 (56.8) 56 (58.3) 81 (57.9) 0.866 
Secondary 19 (43.2) 40 (41.7) 59 (42.1) 
Study Design‡‡ 
Longitudinal follow-up 42 (89.4) 68 (76.4) 110 (80.9) 0.068 
Transversal/ cross-sectional 5 (10.6) 21 (23.6) 26 (19.1) 
Study population inclusion based criteria§§ 
Type of exposure: 
Disease 6 (11.8) 7 (6.7) 13 (8.4) 
0.319 Multiple medicinal products 13 (25.5) 20 (19.2) 33 (21.3) 
Single medicinal product 32 (62.7) 77 (74.0) 109 (70.3) 
Special populations focus: 
Pregnant women 1 (4.5) 8 (14.3) 9 (11.5) 0.226 
Paediatric population 5 (22.7) 9 (16.1) 14 (17.9) 0.491 
Healthcare providers 3 (13.6) 14 (25.0) 17 (21.8) 0.274 
Abbreviations: MA = Marketing Authorisation; PASS = Post-Authorisation Safety Study; RMP = Risk Management Plan. 
For each variable, the percentages were calculated excluding missing values. Categories are mutually exclusive unless 
otherwise specified 
†† Primary: collection of data specifically for the study; Secondary: use of existent data collection schemes. Missing data: 
imposed = 14 (24.1%), non-imposed= 35 (26.7%); total = 49 (25.9%) 
‡‡ Longitudinal: involves collection of variables at least two points in time; Transversal: involved collection of variables at a 
certain point in time. Missing data: imposed = 11 (19.0%), non-imposed= 42 (32.1%); total = 53 (28.0%) 
§§ Common inclusion criteria: in terms of exposure (patients with a certain disease irrespective of medicinal products,
restricted to single medicinal product exposure/ prescription or exposure/ prescription of more than one predefined medicinal
product/ treatment modalities. Missing data: imposed = 7 (12.1%), non-imposed= 27 (20.6%); total = 34 (18.0%)
Special population focus: Inclusion restricted to special groups of interest (children, pregnant women). Missing data: imposed
= 36 (62.1 %%), non-imposed= 75 (57.3%), total = 111 (58.7%)
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2.4.1 Study Design 
The vast majority of the PASS (n=110/136, 81%) were designed to collect data from patients from 
at least two time points (longitudinal design) with a slightly higher proportion among the imposed 
PASS versus the non-imposed (89% versus 76%) while cross-sectional designs were more common 
among the non-imposed PASS than among the non-imposed (24% versus 11%), chi-square test, 
p<0.05. Specifically, the majority of the PASS with cross-sectional design (n=16/26, 62%) were 
category 3 PASS (required in the RMP). 
The study design seemed to be associated with the PASS focus as 94% (n=97/103) of PASS with at 
least one objective of “investigating safety concerns” and design available information, had a 
longitudinal design, while 61% (n=20/33) of the PASS without objectives related to “investigate 
safety concerns” and design available information had a cross-sectional design; chi-square test, 
p<0.05.  
On the other hand, 56% (n=20/36) of the PASS with at least one objective of “assessing effectiveness 
of RMMs” and design available information had cross-sectional design, while 94% (n=94/100) of 
PASS without this objective, had a longitudinal design; chi-square test, p<.005. More specifically, 
among PASS in which the only objective was to “assess effectiveness of RMMs” (n=15), all but one 
(n=14/15, 93%) had a cross-sectional design.  
Differently from the other two categories of PASS objectives, no significant statistical differences 
were observed between the PASS with at least one objective of “assessing drug utilisation” and those 
without such objective.  
Among the 47 PASS with protocol available that had a longitudinal study design and information 
available on patient follow-up (n=39/47, 83%), the median patients’ follow-up was 3 years 
(interquartile range [IQR]: 4.0 years). It ranged from 24 hours (n=3, in PASS of medicinal products 
used in emergency care units) to 15 years (n=1, a disease registry).  
Among the imposed PASS, the median patient follow-up was 4.5 (IQR 6.0, n=13) years and among 
the non-imposed was 2.0 (IQR 3.6, n=26).  
The majority of the 34 longitudinal PASS having at least one objective of "investigating safety 
concerns” and patient follow-up duration available, had patient follow-up periods equal to or longer 
than three years (n=21/34, 62%). 
2.4.2 Selection Criteria 
The population were targeted for enrolment in the PASS based on a single medicinal product 
(exposure or prescription), multiple medicinal products (exposure or prescription) or disease 
(prevalence or incidence).  
More than two thirds of PASS with available information (n=109/155, 70%) focused on single 
medicinal product as eligibility criteria: 
• 83% (n=90/109) targeted patients exposed to the single medicinal product;
• 8% (n=9/109) targeted HCPs that prescribed or administered the single medicinal product;
• 6% (n=7/109) targeted both patients exposed and HCPs that prescribed or administered the
single medicinal product;
• 3% (n=3/109) did not contained more detailed information.
Among the 16 PASS that enrolled HCPs, 12 aimed to “assess effectiveness of RMMs”, two aimed 
to “assess drug utilisation” and the remaining two combined both those objectives in the same 
protocol. All but one of these 16 PASS had a cross-sectional study design.  
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Approximately one fifth of the PASS (n=33/155, 21%) selected the study population based on more 
than one medicinal product, all being patients with predefined exposures of interest. Among those 
33 PASS, 26 had enough information to assess whether the inclusion of the multiple medicinal 
products was for comparative purposes. In all but one, the medicinal products were used as 
comparators of the main medicinal product of interest in the PASS. In the remaining one, the 
inclusion of multiple exposures aimed to assess the safety of a combination of different medicinal 
products. 
Finally, a minority of the PASS (n=13/155, 8%) selected the study population based on disease (12 
enrolling patients with the disease of interest and the remaining targeting both patients and HCPs). 
Approximately half of these 13 PASS (n=6/13, 46%) studied medicinal products with orphan status, 
which may suggest those were rare diseases.  
However, not all orphan medicinal products were investigated in PASS with such a broad inclusion 
criteria, since among all PASS studying orphan medicinal products (n=22), the most frequent 
inclusion based criteria was single medicinal product. 
It is also of note that all the PASS selecting patients based on disease or multiple products had at 
least one study objective belonging to PASS focus “to investigate safety concerns”. In addition, 
approximately one fourth of those also included as primary objectives to “assess drug utilisation” 
(n=11/46, 24%).  
Some PASS targeted populations who are typically excluded from the clinical trials such as pregnant 
women and paediatric patients. Among 78 PASS with enough information to assess if the inclusion 
was based on one of these special populations, 12% (n=9/78) were found to be pregnancy registries 
and 18% (n=14/78) included only paediatric patients, the majority of the later, paediatric patients 
exposed to a single medicinal product (n=8), and the remaining either to multiple medicinal products 
or paediatric patients with a certain disease. 
In terms of geographic coverage, the review of the 57 PASS protocols showed that all PASS 
involved at least one European country, and that the majority of them (n=44/57, 77%) were 
conducted in European countries only, with half of those in five or fewer countries. Approximately 
one fifth (n=13/57, 23%) of PASS were to be conducted not only in Europe, but also in other 
continents, mainly in North America (US [n=9] and Canada [n=7]). 
2.4.3 Data Collection 
Among 140 PASS with information available on data collection, slightly more PASS involved the 
collection of original primary data (n=81/140, 58%), i.e. data collection scheme to address the study 
objectives was built for the purpose of the study. Conversely, the remaining PASS (n=59/140, 42%) 
leveraged data collection schemes already established for other purposes (either administrative or 
other research projects).  
There were no statistically significant differences between imposed and non-imposed PASS. 
However, data collection approach seemed to be associated with PASS focus as 58% (n=28/48) of 
PASS with at least one objective of “assessing drug utilisation” and data collection available 
information, used a secondary data collection approach, while 66% (n=61/92) of the PASS without 
objectives related to “assessing drug utilisation” and data collection available information used a 
primary data collection approach, chi-square test, p<0.005. 
Overall, among the 81 PASS with a primary data collection approach, 38 had PASS protocols 
available (n=38/81, 47%), with approximately one fifth of those (n=8/38, 21%) including Patient 
Reported Outcome (PRO) measurements such as assessments of symptoms, burden of disease and 
quality of life. 
The review of the 57 PASS with available protocols and information on informed consent 
requirements showed that informed consent was required in all PASS targeting patients for primary 
data collection (n=31) and in half of those targeting HCPs (n=6). Overall the proportion of PASS 
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requiring informed consent was higher in studies with a primary data collection approach than in 
those leveraging secondary data. (n=33/37, 89% versus n=7/19, 37%).  
Among the 59 PASS using a secondary data collection approach, 37 (n=37/59, 63%) had information 
available regarding the used data sources. They were specifically of the following types: 
• 11 (n=11/37, 30%) abstracted data from the review of local patients’ medical charts;
• 20 (n=20/37, 54%) retrieved data from existent databases (automated electronic medical
records [EMRs] and/or claims databases);
• 5 (n=5/ 37, 14%) leveraged data available from other research programs such as existing
registries;
• The remaining was a Pharmacogenomic study which used data from a clinical trial database.
The majority of the 20 PASS using existing databases were conducted in the United Kingdom 
(n=14/20, 70%) followed by Spain (n=12/20, 60%), Italy and Netherlands (n=9/20, 45% each) and 
Denmark (n=8/20, 40%). 
The most commonly used automated databases were the following: 
• Claims database: German Pharmacoepidemiological Research Database (GePaRD) from
Germany;
• EMRs: Clinical Practice Research Datalink (CPRD) and The Health Improvement Network
(THIN) from the United Kingdom; SIDIAP from Spain, the Italian Health Search Database
(HSD), and the Dutch Interdisciplinary Processing of Clinical Information (IPCI);
• Pharmacy-based medical record linkage systems: Pharmo from the Netherlands and the
Danish National Health Service Prescription Database.
The majority of PASS conducted in databases, involved multiple databases (n=16/20, 80%), five of 
which were part of the Exploring and Understanding Adverse Drug Reactions by Integrative Mining 
of Clinical Records and Biomedical Knowledge Project (EU-ADR) collaboration. However, it 
should be noted that four of these five PASS were sponsored by the same MAH and involved the 
same active substance (two protocols for the single active substance and two for a fixed combination 
of the active substance).  
The number of countries involved in these 16 multidatabase PASS ranged from two to nine, with a 
median of four. The most common medicinal product’s ATC class was respiratory system (n=5/20, 
25%), followed by cardiovascular and nervous system (n=3/20, 15% each).  
Protocols were available for one fourth of the 16 multidatabase PASS (n=4/16, 25%). Only one of 
the four protocols mentioned a method to consolidate the results from the different databases (a 
meta-analysis). In addition, while three of the four PASS had a common protocol, the remaining 
PASS presented four separate protocols, one for each of the four databases included in the PASS.  
2.4.4 Sample Size (assessed among the subset of 57 available protocols) 
The median sample size was 1000 patients (IQR 1700, n=49) and 289 HCPs (IQR 500, n=9). Ten 
of the 11 PASS protocols (n=10/11, 91%) with broader patient exposure inclusion based criteria 
(disease or multiple medicinal product) had samples equal or larger than the overall median, while 
the majority of the PASS protocols selecting patients based on single exposure (n=23/40, 58%) had 
sample sizes lower than the overall median. 
Figure 15 describes the rationale behind sample size calculation/ estimates according to the analysed 
PASS protocols.  
Approximately half of the PASS protocols based the sample size calculation on estimation of the 
parameter of interest with a certain degree of precision (n=29/57, 51%), while in approximately one 
fifth (n=11/57, 19%) of the PASS protocols sample size was chosen to give adequate power to detect 
an effect of a given magnitude. An additional fifth PASS protocols (n=12/57, 21%) provided 
practical considerations to justify sample size, such as availability of patients in the selected data 
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source and market uptake. For the remaining five PASS protocols (n=5/57, 9%) there was no 
rationale for the target sample size. 
Among the 29 PASS protocols that based the sample size calculation on a precision around an 
estimate, slightly less than half of them (n=14/29, 48%) provided support to the given estimated 
value, either based on previous studies conducted by the MAH or on literature references. The 
remaining PASS protocols did not provide a rationale for the expected value, which was set at 50% 
(most conservative estimate) or a range of options were simulated. In addition, six PASS (n=6/29, 
21%) consisting of surveys assessing effectiveness of RMMs, established the target proportion of 
correct answers to consider the RMMs successful but did not provide a justification for the chosen 
threshold.  
Amongst the 11 PASS protocols which chose a sample size that would give adequate power to detect 
an effect of a given magnitude, five (n=5/11, 45%) provided support to the assumptions used for the 
calculation, either from literature or previous studies. The majority of the remaining PASS based the 
sample size calculation on a simulation of ranges of values for the parameters needed to compute 
the size. In addition, for one of the PASS protocols, the sample size was fixed for pragmatic reasons 
but it was demonstrated that the size would give an adequate power to address the study objectives. 
Figure 15 – Sample size rational (among the 57 available PASS protocols) 
2.4.5 Analysis (assessed among the subset of 57 available protocols) 
Analysis of subgroups of patients of interest such as those for which there was missing information 
from the clinical trials and vulnerable populations, was mentioned in approximately one third of 
PASS protocols (n=20/57, 35%), the most common being elderly patients (n=11/57, 19%), hepatic 
impaired patients (n=10/57, 18%), renal impaired (n=9/57, 16%) and patients with cardiovascular 
disease (n=9/57, 16%). 
The majority of the available PASS protocols did not mention a comparator (n=38/57, 67%). Among 
the 19 PASS protocols with comparators, the majority of those were other products or standard of 
care (n=8/19, 42%), participants unexposed to the product being studied (n=5/19, 26%), comparison 
with data from external data sources (n=5/19, 26%) or comparison before and after the occurrence 
of an event of interest (n=3/19, 16%), for instance, before and after introduction of RMM and before 
Available protocols 
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and after the approval of a paediatric indication. Two of the PASS included both comparisons with 
an external data source and also with an exposed group. 
As described in Results Section 2.4.2, the majority of PASS using other medicinal products as 
comparators, included those multiple medicinal products as inclusion criteria. However, 
comparators were not necessarily established as inclusion criteria. Among 46 PASS enrolling 
participants based on a single medicinal product and for which the protocols were available, eight 
(n=8/46, 17%) included a comparator in the analysis, namely, an external data source (n=3), 
comparison pre-post an event of interest (implementation of RMM or approval of a paediatric 
indication) (n=3), an external data source and an exposed group (n=1) and one with both unexposed 
group and historical cohort (n=1). 
The majority of the 57 PASS protocols only mentioned descriptive analysis, i.e. description to show 
or summarise data in a meaningful way (n=34/57, 60%).  
Figure 16 below presents a sub-analysis of PASS protocols to explore the statistical methods used. 
Table 5 summarises the different statistical methods mentioned among the available protocols with 
a longitudinal design. 
An a priori hypothesis was only present in three (n=3/57, 5%) PASS. The remaining PASS with a 
longitudinal design but no a priori hypothesis testing and for which the analysis section was 
available (N=42), had, in general, a little detailed analytic plan. Four of them (n=4/42, 10%) 
presented only vague statements of methods that could be use after descriptive analysis, such as, 
using a “general linear model”, “performing multivariate analysis” conducting “statistical 
modelling” but not providing any granular consideration or rationale.  
Overall, statistical testing for comparison of groups was considered among approximately one fifth 
of the analysed protocols (n=8/45, 18%). Survival analysis was present in 44% of the protocols 
(n=20/45, 44%): 13 referring to Kaplan Meier and seven to Cox regression. Other models were 
mentioned among 14 (n=14/45, 31%) of the protocols, mainly Logistic regression (n=4/45, 9%), 
Poisson regression (n=4/45, 9%), and propensity scores (n=3/45, 7%).  
Sensitivity analysis were planned for one fourth of the PASS protocols for which there was enough 
information to make that assessment (n=13/52, 25%). Sensitivity analyses were significantly more 
common among the PASS protocols using secondary data collection approaches than among the 
PASS using a primary data collection approach (4% versus 14%, p<0.05). 
Figure 16 – Sub-analysis of PASS protocols’ statistical methods 
Available protocols 
(N=57)
Cross-sectional design
(N=10)
Descriptive analysis only
Longitudinal design
(N=47)
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(N=3)
No hypothesis testing 
(N=44)
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Table 5 – Statistical methods among available longitudinal PASS available protocols 
Available PASS protocols with longitudinal design 
Statistical Methods Hypothesis testing (N=3) 
No hypothesis testing 
(N=42)* 
Total 
(N=45)* 
n (%) n (%) n (%) 
Data summarisation 
only 
0 (0.0) 22 (52.4) 22 (48.9) 
Data summarisation + 
Exploratory analysis to 
be defined later 
0 (0.0) 4 (9.5) 4 (8.9) 
Group comparison 
(tests) 
3 (100.0) 5 (11.9) 8 (17.8) 
Survival analysis 2 (66.0) 18 (42.9) 20 (44.4) 
Kaplan Meier 1 (50.0) 12 (66.7) 12 (66.7) 
Cox regression 1 (50.0) 6 (33.3) 7 (35.0) 
Models 2 (66.0) 12 (28.6) 14 (31.1) 
Logistic regression 0 (0.0) 4 (33.3) 4 (28.6) 
Poisson regression 1 (50.0) 3 (25.0) 4 (28.6) 
Propensity scores 0 (0.0) 3 (25.0) 3 (21.4) 
Other†  1 (50.0) 2 (16.7) 3 (21.4) 
*Two documents with missing information on the statistical methods were excluded.
† Other included: analysis of covariance and meta-analysis (in two protocols not testing a hypothesis) and scan
statistics in a protocol testing hypothesis.
2.4.6 Sub-analysis of PASS Assessing Effectiveness of RMM 
The protocols were available for 38% (n=18/48, 38%) of the PASS assessing effectiveness of RMM. 
Detailed characteristics of these PASS are presented in Annex 6. 
Figure 17 presents a summary of the design, data collection and types of indicators assessed in the 
available 18 PASS protocols. 
In one third of the available protocols of PASS assessing effectiveness of RMMs (n=6/18, 33%), 
this was the only PASS objective. These six PASS had a cross-sectional design and used 
questionnaires as primary data collection instruments: two PASS targeted both patients and HCPs 
(separate questionnaires), and the remaining four only targeted HCPs.  
The indicators of effectiveness of RMMs present in all these six PASS were based on the assessment 
of self-reported awareness of the RMMs and understanding of the conveyed messages (knowledge). 
In addition, half also assessed self-reported behaviour to scenarios described in the surveys which 
goal was to estimate the compliance with the RMM.  
In order to determine if there were additional PASS to complement the assessment of effectiveness 
of RMM for the six abovementioned protocols, the PASS database was searched for additional PASS 
for the six active substances covered in these PASS. There were additional PASS for half of the 
substances (n=3) but two did not have a protocol available. For the remaining active substance, two 
additional PASS were found in the database with sufficient information that suggested they would 
also contribute to assessing effectiveness of RMMs for that active substance (one was a cross-
sectional survey assessing prescribing patterns and the other intended to use secondary data sources 
to assess drug utilisation before and after RMMs). 
Two thirds of the 18 PASS protocols assessing effectiveness of RMMs (n=12/18, 67%) also included 
objectives from the other “PASS focus” categories (“investigate safety concerns” [n=4], “study drug 
utilisation” [n=3] or both [n=5]). It was noted that, in these PASS, the goals related with the 
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assessment of effectiveness of RMM objectives were just vaguely described, generally stating that 
the PASS would monitor compliance with RMMs, either broadly or detailing particular messages of 
the RMMs such as assessing compliance with medical monitoring procedures highlighted by the 
RMMs, but not providing granular information.  
The majority of these 12 PASS assessing effectiveness of RMMs among other safety objectives, had 
a longitudinal design (n=8/12, 67%). Three PASS combined in the same protocol, a longitudinal 
patient follow-up with cross-sectional surveys. In these studies with a combined design, the 
assessment of effectiveness of RMMs was to be performed through the cross-sectional component 
only, based on the administration of questionnaires to patients or HCPs to assess awareness and 
understanding of the RMMs or satisfaction with the RMMs. Whether the longitudinal component of 
these three PASS would also contribute to the assessment of effectiveness of RMM in an integrated 
approach was not clear from the protocol text. 
Among the eight PASS with a longitudinal design, two consisted in the establishment of a new 
patient registry (primary data collection). The registry itself was part of the RMMs as in one of the 
cases the medical product was only distributed to sites which commit to enrol the patients in a 
registry and, in the other, a medicinal product with restricted prescription, there was emphasis in the 
educational materials of the importance to enrol patients in the registry.  
Conversely, the remaining six PASS with longitudinal designs used secondary data collection 
approaches: two retrieving drug utilisation information from existing registries and four from 
patients’ medical records/chart. Data abstraction from the medical records/chart was made at 
aggregate level in one of the PASS and at individual patient level in the other three, one reviewing 
data retrospectively and, the other two following-up the patients through prospective review of the 
charts. To note, one of these PASS protocols described a method similar to a prescription event 
monitoring approach where the patients were selected by follow-up of orders placed for the 
medicinal product with an invitation to the clinician to provide data for the PASS. 
In summary, the most common observed PASS study designs among those with at least one objective 
of assessing effectiveness of RMMs were cross-sectional primary data collection through 
questionnaire use (n=7/18, 39%), followed by longitudinal patient follow-up leveraging patient 
medical records/charts (n=4/18, 22%), PASS with longitudinal design and nested cross-sectional 
surveys (n=3/18, 17%), and finally longitudinal patient follow-up with primary data collection (ad 
hoc registries) and longitudinal patient follow-up leveraging data from existent registries (n=2/18, 
11% each). 
The most common indicators for assessing effectiveness of RMMs were related with behaviour 
(prescription patterns and treatment use) (n=15/18, 83%), followed by indicators of awareness/utility 
of the RMMs (n=11/18, 61%) and knowledge/understanding of the messages on how to correctly 
prescribe/use the medicinal product (n=9/18, 50%). Outcome indicators were rarely used (n=2/18, 
11%). The two PASS protocols describing outcome indicators were also the only PASS using a pre-
post RMM design (comparison between frequency of the off-label use before and after 
implementation of RMMs). 
It was noted that, in the PASS protocols with objectives to “investigate safety concerns” and also to 
“assess effectiveness of RMM”, some of the safety concerns’ being investigated were also those that 
the RMMs aimed to minimise. However, the PASS protocols did not clearly interlink both objectives 
and therefore there was no indication in the protocol text that the safety concerns being assessed as 
primary endpoints would be also used as outcome indicators of the success of the RMMs. In fact, 
none of the PASS assessing effectiveness of RMMs and also investigating safety concerns and/or 
assessing drug utilisation, described the criteria that would be used to determine if the RMM was 
successful.  
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In total, 10 of the 18 PASS assessing effectiveness of RMMs used questionnaires to patients and/or 
HCPs as data collection tools. The following observations summarise the methodology described in 
these protocols:  
• Countries were selected based on the justification of being sufficiently heterogeneous and
also large enough to ensure recruitment;
• The sampling frame was based on a simple or stratified random sample from available
panels of prescribers mentioning the possibility of a posteriori adjustments. There was no
evidence from the protocol text that the sampling had occurred before the protocol was
written;
• Half of these protocols mentioned that the questionnaires would be tested before their
administration. However, the level of details about the methods used for questionnaire
validation was limited, referring only to qualitative validation, such as, language and cultural
adequacy and cognitive pre-test interviews;
• Threshold for success was established as 80% or 85%, although no rational was provided
for the choice;
• The questionnaires were deemed not to take more than 20 minutes to complete and were
mostly accessible on-line;
• Only two of the protocols have the questionnaire available.
For three of these 10 PASS using questionnaires, the protocol also described that compliance with 
SmPC would be assessed by collecting drug utilisation data, which would provide a complementary 
way to assess actual behaviour. However the details on how this assessment would be 
operationalised and considered successful were missing.  
3 PRAC Assessment Process 
3.1 PRAC Comments 
Overall, PRAC comments were available in the minutes, for approximately one third of the 353 
PASS protocol submissions (n=106/353, 30%). Among the 130 submissions of imposed PASS 
protocols, 55% had PRAC comments available (n=71/130, 55%), while among the 223 assessments 
of non-imposed PASS protocols, 16% had PRAC comments available (n=35/223, 16%), chi-square 
test, p<0.05.  
Figure 18 below presents the proportion of PASS protocol submissions, recorded in the PRAC 
meeting minutes, for which there were PRAC comments available, by year in the analysis.  
Figure 18 – Yearly proportion of PRAC comments available among PASS protocols presented in the 
PRAC meeting minutes 
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Overall, the proportion of PASS submissions for which there were PRAC comments available in the 
meeting minutes, decreased significantly over time from 80% of the 45 PASS protocol submissions 
during the first year to 21% of the 154 PASS protocols submitted  during the last year of the analysis 
(chi-square test, p<0.05).  
The review of the 106 PRAC comments allowed the categorisation of the outcome of PRAC 
assessment as: 
• Protocol approved/endorsed (n=16);
• Protocol needed to be revised either through a formal objection based on the grounds of
Article 107n, for protocols pursuant to an obligation as established in Article 21a, or, without
this formal process but with PRAC recommendations to further amend the protocol (n=71);
• Other information (n=19): included comments related with the establishment of timetables
to assess subsequent protocol submissions and nomination of the PRAC Rapporteur (n=14),
recommendation to conduct joint PASS for PASS protocols that followed a referral
procedure (n=4) and one PASS protocol where the PRAC determined that the study was not
required anymore. The following rational was provided for this latter case:
“The PRAC noted that based on the evolution of the product lifecycle to gather information
on off-label use was no longer considered a public health concern. Moreover the original
recommendation to perform a Drug Utilisation Study was not driven by specific safety
concerns or due to RMMs. Therefore the need for the Drug Utilisation Study was
reappraised and the PRAC concluded that a Drug Utilisation Study should no longer be a
request within the RMP and thus no further detailed comments on the protocol were
pursued.”
Among the 71 PRAC comments indicating that the PASS protocol version being assessed, needed 
revision, 27 (n=27/71, 38%) had clear textual indication of a formal objection process (referring to 
the objection letter and/or Article 107n of Directive 2001/83/EC), typically with the following 
sentence: “the design of the study did not fulfil the study objectives”. In only one case there was 
another reason mentioned for objection, namely “it was considered that the conduct of the study 
promotes the use of a medicinal product”. All the PASS with a formal objection statement were 
imposed PASS. For the remaining 44 PRAC assessments (14 related to imposed PASS and 30 to 
non-imposed PASS), there was no direct mention to a formal objection, but the text indicated the 
PASS protocols needed to be further revised (e.g. “the protocol could be acceptable provided an 
updated protocol addressing (…) is submitted to the EMA”. 
The 71 PRAC comments related with objection/need for further revision of the protocols were 
further categorised by areas of concern. Annex 7 presents the results of the PRAC comments’ text 
analysis. 
Figure 15 presents the distribution of the areas of the protocol identified among the PRAC comments 
as responsible for the objection/need for revision of the protocol, irrespective of imposed or non-
imposed status.  
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Note: Among the 71 PASS protocol submissions for which the PRAC outcome was protocol objection or need of further 
protocol revision. Other ad hoc comments were related to data protection, change of obligation status (to imposed PASS), 
safety reporting and rational/background section. 
Figure 19 – Methodological issues raised by the PRAC and documented in public PRAC meeting 
minutes (July 2012 – July 2015)  
The following paragraphs summarise the types of comments under each protocol area, from the most 
to the least frequent. 
Study design (n=26/71, 37%): “Inadequate study design” was the standard text for objection of an 
imposed PASS and the majority of the PRAC comments did not provide more granular details. 
Among the minority which had further detail, the following reasons were listed: 
• Absence of a comparator;
• Inappropriateness of design to address different safety objectives under the same
methodology;
• Inadequate design to address the safety concerns of the RMP;
• Design not safeguarding a non-promotional and non-interventional study nature;
• Preference for an inclusion based on disease rather than single exposure.
Feasibility (n=21/71, 30%): This term grouped concerns with operational viability and scientific 
validity of the study to address its objectives. They were mainly related with the lack of evidence in 
the protocols to assure some important considerations were accounted for when designing the study. 
Those comments included:  
• Concerns with bias and confounding;
• The need to develop strategies to ensure operational feasibility;
• Requirement to demonstrate preliminary evidence or rationale to support adequacy of study
methods;
• Methodological considerations to safeguard scientific validity.
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Data analysis (n=18/71, 25%): Included requests to further detail or clarify the proposed plan. 
Almost half of the PRAC comments related to this area of concern did not provide more granular 
information. 
Data sources and/or population (n=16/71, 22%): Comprised concerns with recruitment, sampling 
strategy, and justification for the selection of certain data sources. The majority of these comments 
did not provide specific details. 
Objectives/Endpoints (n=12/71, 17%): Included the need to add/amend objectives, to have more 
measurable objectives, include better defined endpoints, or to have objectives consistent with the 
study purpose according to the RMP. 
Sample size (n=10/71, 14%): Comments were related with concerns with statistical precision or 
power, or the need to further clarify or amend the proposed sample size. 
Timelines/Milestones (n=9/71, 13%): Included recommendations to avoid study delay or 
considerations on appropriateness of timelines. 
Data collection/management (n=7/71, 10%): Included advice on specific instruments (e.g. 
inclusion of a patient’s diary), the need to collect or validate certain data or the need for further 
clarification on the data collection methods. 
Variables (n=5/71, 7%): Only one comment had details (the need to include concomitant 
medication among study variables). 
Other (n=5/71, 7%): There was a comment regarding rational and background, one regarding data 
protection, two comments regarding the need to impose a PASS that was initially non-imposed to 
stimulate the study initiation, and one comment related to the safety reporting section. 
Figure 20 presents the distribution of areas of concern by obligation status. The proportion of 
imposed PASS protocols in need for revision due to “study design” was approximately the double 
of those among the non-imposed PASS protocols. Conversely, a higher proportion of non-imposed 
PASS protocols’ assessments, had comments related with the feasibility of the study and the data 
analysis.  
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Figure 20 – Methodological issues raised by the PRAC and documented in public PRAC meeting 
minutes (July 2012 – July 2015) by PASS obligation status 
An insight from reading all the PRAC comments and also the available PASS protocols was that, 
independently of the specific section of the protocol, the level of granular detail provided in the 
protocols was limited, most of the times lacking the critical reasoning behind the methodological 
decisions. In addition, the acknowledgement of study limitations, a reflection on their impact and on 
how they would be minimised, and/or arguments to support the practical feasibility of the methods 
and their robustness to obtain valid study conclusions, were often minimal.  
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3.2 Resubmission and Reassessment Timetables 
The PRAC comments in the minutes also contained information on the timetables that would follow 
a resubmission and reassessment of a PASS protocol after being rejected. Table 6 summarises the 
timetables referred to in the PRAC comments’ text among those associated with the need for a 
further round of revision of a PASS protocol.  
The majority of the 41 imposed PASS protocol assessments with PRAC comments available needed 
to be resubmitted within 30 days (n=16/41, 39%), or 60 days (n=14/41, 34%). Less than 10% were 
urgent resubmissions (14 days). Among the 30 non-imposed PASS protocols, the majority did not 
have a timetable assigned (n=11/30, 37%) or the text only mentioned the protocol needed to be 
revised before the study started (n=8/30, 27%). 
The majority of the reassessment timetables established for the imposed PASS protocol assessments 
were of 30 days (n=16/41, 39%) while 27% (n=11/41) had a 60-day assessment timetable. Despite 
the vast majority of the non-imposed PASS protocols did not have an established assessment 
timeline, three non-imposed PASS protocol assessments were given a 30 or 60 days assessment 
timeline. 
Table 6 – PASS protocols’ submission and assessment timetables according to the PRAC comments on 
meeting minutes related to the need for protocol resubmission (N=71) 
Protocol submission timetable Protocol assessment timetable 
Imposed 
(n=41) 
Non-
imposed 
(n=30) 
Total 
(n=71) 
Imposed 
(n=41) 
Non-
imposed 
(n=30) 
Total 
(n=71) 
Time n (%) n (%) n (%) n (%) n (%) n (%) 
14 days 1 (2.4) 0 (0.0) 1 (1.4) NA NA NA 
15 days 2 (4.9) 0 (0.0) 2 (2.8) 2 (4.9) 0 (0.0) 2 (2.8) 
30 days 16 (39.0) 6 (20.0) 22 (31.0) 16 (39.0) 1 (3.3) 17 (23.9) 
60 days 14 (34.1) 2 (6.7) 16 (22.5) 11 (26.8) 2 (6.7) 13 (18.3) 
90 days 2 (4.9) 1 (3.3) 3 (4.2) NA NA NA 
“Before 
procedure 
finalisation” 
0 (0.0) 2 (6.7) 2 (2.8) NA NA NA 
“Before study 
start” 
2 (4.9) 8 (26.7) 10 (14.1) NA NA NA 
Missing 4 (9.8) 11 (36.7) 15 (21.1) 12 (29.3) 27 (90.0) 39 (54.9) 
3.3 Estimate of PASS Protocol Review Duration 
PRAC process metrics were estimated among the PASS protocols for which the PRAC review was 
assumed complete (n=103/189, 54%), see Figure 8.   
Approximately one third of the endorsed PASS protocols (n=31/103, 31%) appeared only once in 
the minutes, and the PRAC comments were not conclusive on whether they were approved on that 
round. The vast majority of those (n=25/31, 81%) were non-imposed PASS, which are not required 
to follow the same formal submission process as the imposed PASS. Therefore, it was decided not 
to compute metrics on the PRAC review process for the non-imposed PASS.  
For the imposed PASS protocols appearing more than once (n=32/38, 84% of the imposed PASS 
considered approved), the data suggested a decrease in the median number of rounds of review from 
3 (N=9) to 2 (N=6) and a mean (SD) decrease in time of review from 10.2 months (SD=4.7) to 3.8 
months (SD=1.6), when comparing PASS protocols submitted for the first time, between July 2012-
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July 2013 and those submitted for the first time between July 2014-July 2015, as shown in the Figure 
21. 
Figure 21 – Estimate of PASS protocol assessment duration since first submission until approval for 
which the PRAC review was assumed complete (N=32; year 1 = 9, year 2 = 17; year 3 = 6) 
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Discussion 
Over the last decades, numerous public health crises have shaped regulatory changes and led to the 
creation of Pharmacovigilance, along with, innovative surveillance systems and safety 
epidemiologic methods. Although those initiatives have contributed to the safer use of medicinal 
products, enforcement of additional measures was deemed necessary at the beginning of the new 
millennium. Among the new activities, PASS gained prominence as pharmacoepidemiological 
methodology offered tools to investigate uncertainties related with safety concerns. 
This review aimed to draw, for the first time, the PASS landscape during the first three years under 
the most recent Pharmacovigilance legislation. This was accomplished by describing the first cohort 
of PASS protocols submitted to the EMA since the first inaugural PRAC meeting in July 2012 to 
July 2015, charactering PASS and reflecting on the achieved levels of transparency and on the extent 
to which, PASS incorporate Pharmacovigilance and Pharmacoepidemiology principles. 
Overall, the results showed that despite the unprecedented level of transparency achieved, which 
made this study possible, there is still room for improvement in the level of information provided by 
regulators and MAHs. It was also evident that there is and some lack of communication between 
different stakeholders, which may be worsened by lack of uniform terminology.  
In addition, the results suggested some discrepancy between PASS as conceived in the RMP and the 
PASS protocols developed, highlighting the need to reinforce the bridge between 
Pharmacoepidemiology and Pharmacovigilance. To exemplify this point, a more in-depth analysis 
was conducted among the subset of PASS assessing effectiveness of RMMs. These types of PASS 
constitute a good example of the required convergence between Pharmacovigilance and 
Pharmacoepidemiology and are part of a key component of the Risk Management cycle by providing 
constructive feedback to allow the refinement of the Risk Management activities. 
The recognition of the singularity of PASS, as pharmacoepidemiological studies that have a specific 
mission within the medicinal products’ RMPs, calls for alignment of the different parties to tailor 
the best approach for each safety question. Cross-functional collaboration and communication across 
stakeholders, higher levels of transparency and a common terminology would be key to foster best 
practices that will surely contribute to a safer use of medicinal products.   
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1 The First Comprehensive Drawing of PASS Landscape 
PASS were introduced in European guidelines in 2005. Two reviews published in 2009 and 2011, 
respectively, described PASS for the first time from the perspective of the regulators making 
recommendations to streamline the regulatory review, engage earlier with the MAH to discuss the 
objectives, design and study feasibility and build more expertise and capacity in preparation for the 
upcoming Pharmacovigilance legislation.(23, 47) More than three years have now elapsed since the 
implementation of the new Pharmacovigilance legislation and no study had yet attempted to explore 
the landscape of PASS submitted under the new framework. The current dissertation aimed to 
suppress this gap by examining multiple facets of PASS. The following paragraphs outline the main 
findings describing PASS genesis, objectives and methods of PASS protocols and insights into the 
protocol review process. 
1.1 PASS in Medicinal Products’ Lifecycle: Towards a Proactive Approach 
The new legislation aimed to shift from a reactive system to a more proactive one. The 
implementation of measures such as PASS, early in the lifecycle of the medicinal products could 
swiftly address uncertainties, thus, prompting early action to prevent or minimise the occurrence of 
safety concerns.(21) Therefore, it is not surprising that the majority of the submitted PASS were 
established with the initial marketing authorisation, either as an imposition or a commitment in the 
RMP agreed with the EMA.  
However, the second most common lifecycle events originating PASS were safety referral 
procedures.2 Measures implemented as a consequence of a referral imply that some safety concerns 
have already occurred. As more proactive measures are implemented early in the lifecycle of new 
medicinal products, a decrease in the need for safety referrals may be expected. However, it is still 
early to judge the effects of the new legislation in the medicinal products already approved under 
the new regulatory framework, as recent findings indicated a referral procedure occurs on average 
18.7 years after the launch of new medicinal products.(68) 
Hopefully, early implementation of PASS will provide a continuous influx of information to 
smoothly manage the benefit-risk profile of the medicinal products without the need for a major 
reassessment of the marketing authorisation consequent to safety occurrences. In fact, the new 
legislation brings the possibility of the regulators to legally enforce the PASS, by imposing them as 
condition to the marketing authorisation when the safety question is critical to ensure the positive 
benefit-risk of the medicinal product, or, as a special obligation to the marketing authorisation for 
the situations where it is not possible to obtain comprehensive data on the efficacy and safety under 
normal conditions of use (i.e. because the condition to be treated is rare or collection of full 
information is not possible or ethical). Therefore, it is not surprising that the proportion of PASS 
addressing a medicinal product with orphan medicinal product status was higher among the imposed 
PASS as compared to the non-imposed PASS (22% versus 9%, p<0.05). Orphan medicinal products 
are those for the treatment, prevention or diagnosis of a rare disease that is life-threatening or 
chronically debilitating for which there are no therapeutic alternatives.(69) Since medical and 
scientific knowledge about rare diseases is lacking upon marketing authorisation of orphan 
medicinal products, it is not surprising that to the regulators enforce the implementation of PASS as 
condition or special obligation to maintain the marketing authorisation based on the proactive 
collection of evidence of the safety of those orphan medicinal products.  
2 A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a 
medicine or a class of medicines 
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1.2 PASS Protocol Submission and Assessment: Towards Quicker PASS 
Implementation 
Under the new legal framework, only imposed PASS must be submitted to the PRAC and having a 
specific procedure and timelines for assessment. However, our results suggested that, sponsors of 
non-imposed PASS were following the same procedures with more than two thirds of the total PASS 
mentioned in the PRAC minutes, being non-imposed.  
Notwithstanding, the majority of the PRAC comments of non-imposed PASS assessments did not 
mention a specific timetable, which is consistent with the fact that there is no formal assessment 
established for these. This may also explain why, the proportion of imposed PASS protocols in need 
for revision due to “study design” was approximately double than that of the non-imposed PASS 
protocols since there is a standard text for objection of PASS protocol according to Directive 
2001/83/EC (Article 107n), “the design of the study does not fulfil the study objectives”, which is 
applicable to imposed PASS protocols. Therefore, it is possible that this statement was generally 
used in the PRAC comments’ text to indicate rejection due to scientific reasons and not necessarily 
with the study design section of the protocol. 
The PRAC comments in the minutes also provided insight on the submission and assessment 
timetable of PASS protocols. Although the minutes may not accurately represent the formal decision 
that would be available to the MAHs, it was still informative to analyse the information provided.  
For the vast majority of the cases, the PRAC did not consider necessary to accelerate the review 
process as less than 10% of the PRAC comments on imposed PASS referred to the 30-day time 
frame (15 days for PASS resubmission followed by 15 days for PRAC assessment) which can be 
enforced when “the PRAC considers that the protocol needs to be resubmitted quickly to allow 
endorsement at the following PRAC meeting”.(49)  
The results suggested a trend towards quicker implementation of PASS protocols. When comparing 
the metrics of the PASS protocols submitted for the first time during the first year in the analysis, 
with those submitted for the first time during the third year, there was a decrease in the median 
number of rounds of assessment from 3 to 2 corresponding to an average decrease of the overall 
review process of 6 months. Even if the results are based on a small number of imposed PASS, they 
corroborated the positive trend reported during a presentation by the EMA at an Information Day on 
Post Authorisation Studies held on June 2005.(70)  
The general improvement in the assessment timeframe may be due to the more stringent regulatory 
requirements or to early engagement on study objectives and study design as recommended in the 
two reviews of PASS conducted before the new legislation.(23, 47) Ideally, PASS planning and 
feasibility should start within Risk Management planning.(47) Although this was not possible to 
assess in this study, the EMA scientific advice pilot initiated late 2015, where companies can 
voluntarily submit non-imposed PASS for early scientific advice, demonstrates the EMA’s 
commitment towards a proactive Pharmacovigilance planning.(49) 
In addition to the establishment of a defined assessment process and timelines, PRAC oversight was 
regarded with much expectation to reduce the insufficient adoption and lack of synchronisation in 
the implementation of the recommendations from the previous Pharmacovigilance Working Party, 
which had a more limited scope of influence.(21) Despite the achievement of a higher level of 
harmonisation with the creation of PRAC, which oversees PASS conducted in more than one 
Member State, PRAC recommendations still need to be endorsed by the other EMA committees and, 
afterwards, to be implemented at country level. At that stage, they may be subject to different 
requirements, which in turn, may challenge the setup and execution of multi-country and multi-
centre PASS. Two recent studies highlighted the variety of regulatory requirements by geography 
and that early determination of those are key to ensure a successful implementation of the PASS.(71, 
72) 
The upcoming 2016 new clinical trial regulation (Regulation EU No 536/2014) will hopefully 
contribute to more harmonised decisions among European Ethics Committees with regards to the 
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classification of PASS as interventional or non-interventional. However, the introduction of “low 
interventional clinical trials” definition could result in many PASS assessments no longer being led 
by the PRAC.(73) 
1.3 PASS are Not Taken as a Collective Endeavour Yet 
The PASS were typically sponsored by a single MAH. Joint sponsorship was more commonly 
observed in PASS resulting from referral procedures since those apply to multiple medicinal 
products with the same active substance or to a class of products.(68) These results seem to indicate 
that MAHs tend to collaborate more when prompted to do so as a consequence of the occurrence of 
safety concerns.  
Joint sponsorship is recommended by the new legislation.(25) Some EU initiatives represent good 
opportunities to expand joint efforts, leveraging new governance models and increasing visibility of 
existing data sources to support their use in a cross-border setting for both public health and research 
needs. The EMA patient registry initiative aims to identify and evaluate existing data sources and 
develop a methodological toolkit for establishing new registries if needed.(74) The Innovative 
Medicines Initiative (IMI) ADVANCE project is also a good example of an ongoing initiative to 
bring together multiple stakeholders in order to develop a common framework capable of rapidly 
delivering reliable data on the benefits and risks of vaccines.(75) 
1.4 Expected and Unexpected PASS Objectives 
A post-authorisation study is classified as a PASS when the main aim for initiating the study includes 
the quantification and assessment of risks or their absence, either known or for which there are 
uncertainties (e.g. in patient populations for which safety information is limited, or after long-term 
use), to assess patterns of drug utilisation that add knowledge on the safety profile of the medicinal 
product, or to measure the effectiveness of a RMM.(48) 
Therefore, a PASS is defined by its objectives and not by its design. PASS objectives were divided 
into three categories based on the above definition: to investigate safety concerns, to study drug 
utilisation and/or to assess effectiveness of RMM. Approximately one third of the PASS combined 
in the same protocol at least two of the three defined categories. In particular, the majority of studies 
assessing drug utilisation or the effectiveness of RMM also combined objectives of the other 
categories.  
In addition to safety objectives, one third of the PASS also assessed benefit endpoints. This may 
suggest that the setup of PASS represent good opportunities for MAHs to also capture routine 
effectiveness and real-world information for other stakeholders such as Health Technology 
Assessors. However, adding extra objectives is usually discouraged if they jeopardize the addressing 
of safety objectives, are too burdensome for the study conduct and possibly lead to Ethics 
Committees’ protocol rejection.(76) 
1.5 PASS Typically Enrolled European Patients Exposed to the Medicinal Product of 
Interest 
All PASS involved at least one European country and more than three quarters were conducted in 
European countries only, which represents an improvement from the situation reported in 2009 
where one third of the PASS did not include EU populations, which was considered a limitation to 
the generalisability of the results.(47) However, half of the PASS were conducted in five or less 
European countries which may raise concerns about the generalisability of the results to all European 
populations. The importance of internal versus external validity in Pharmacoepidemiology has been 
a recent topic of debate, reflected by the agenda of the recent International Conference on 
Pharmacoepidemiology & Therapeutic Risk Management.(77) From the regulatory point of view, 
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decisions are normally based on different types of evidence, representativeness being particularly 
important for assessing effectiveness of RMM, which is highly dependent on the local context where 
the RMM are applied.(78) 
More than two thirds of the PASS (70%) were restrictive in the exposure criteria used to define the 
study population, by focusing only on the exposure to the medicinal product.  
In addition, almost one third of PASS, for which the protocol documents were available, enrolled 
only patients typically excluded from clinical trials, where safety information is considered missing 
or limited, such as, paediatric patients (mainly when PASS followed an extension of the marketing 
authorisation to the paediatric population) and pregnancy registries. Another third of those PASS 
planned a sub-analysis of vulnerable populations typically excluded from clinical trials such as, 
elderly patients and patients with hepatic, renal or cardiovascular comorbidities. 
1.6 A Snapshot of PASS Methods 
The comparison between imposed and non-imposed PASS protocol across the different 
characteristics analysed in this review did not suggest any significant difference in terms of the 
assessed PASS characteristics. Overall, the vast majority of PASS (81%) were designed to collect 
data from study participants from at least two time points (longitudinal design) with an estimated 
follow-up median of 3 (IQR: 4) years. While cross-sectional designs represented the minority of 
designs for both imposed and non-imposed PASS, they were more common among the non-imposed 
ones. 
The results suggested an association between study design and PASS focus, as the vast majority of 
PASS with at least one objective related to investigate safety concerns had a longitudinal design 
(94%), while the majority of PASS not containing any objective of this category had a cross-
sectional design (61%). On the other hand, 56% of PASS with at least one objective of assessing 
effectiveness of RMM had a cross-sectional design, while 94% (n=94/100) of PASS without this 
objective, had a longitudinal design. 
In terms of data collection approaches, slightly more PASS (58%) involved the development of de 
novo data collection tools specific for the study (primary data collection) rather than leveraging data 
collection schemes already established for other purposes such as administrative or other research 
projects (secondary data collection). Data collection approach seemed to be associated with PASS 
focus as 58% of PASS with at least one objective related to studying drug utilisation were using 
secondary data collection approaches, while 66% of PASS not containing such objective were 
mainly using a primary data collection approach. 
According to the AHRQ Handbook on Registries for Evaluating Patient Outcomes, “primary data 
collection is typically used when the data of interest are not available elsewhere or, if available, are 
unlikely to be of sufficient accuracy and reliability for the planned analyses and uses. Primary data 
collection increases the probability of completeness, validity, and reliability because the particular 
study drives the methods of measurement and data collection”.(79) Those advantages may reflect 
the preference for the use of primary data collection approaches among PASS in particular if safety 
information was not routinely available in existing data sources or not collected in a homogenous 
way. In addition, among the available protocols of PASS with a primary data collection approach, 
approximately one fifth included PRO assessments. PRO provide a unique perspective that is not 
available through any other means, for instance, treatments not necessarily prescribed by clinicians 
and quality of life.(79) 
Among secondary data collection approaches, while data abstraction of information from local 
medical records still represents a common approach (30%), the use of wider systems, such as, 
automated EMRs, claims databases and data from existent patient registries, already represents the 
majority of the secondary data collection approaches. The use of electronic databases in 
Pharmacoepidemiology has increased in the past decade since they confer several advantages, 
namely, increased speed, minimise recall and reporting bias and lower costs.(80) In addition, they 
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usually contain very large patient populations including children, elderly and other groups often 
under-represented or totally excluded from clinical trials. Therefore, their large size allows the study 
of rare events and, overall, they seem to be considered representative of routine clinical care.(6, 78) 
While the use of databases is increasingly popular, particular PRAC comments related to concerns 
with selection bias highlighted the need for an appropriate consideration of the available data sources 
and justification for the selection of certain ones. 
The ENCePP Inventory of Databases provides a catalogue of data sources available in EU research 
organisations, to serve as a hub, in which researchers can identify a potential resource for their 
investigation.(81) An ongoing EMA initiative will aim to increase visibility of existing data sources 
and support their use in a cross-border setting for both public health and research needs.(74)  
In addition, there is a need to carefully consider the quality of the databases. Validation studies have 
been encouraged to ensure validity of study results, estimate the extent of misclassification and 
impact on the study results.(82) In addition, since PASS are often multi country studies, additional 
considerations on how to combine different databases are important and have been subject to intense 
research over the past years.(83-85) 
Regarding the analytic methods, the majority of PASS protocols had limited or vague information. 
This is also reflected by the PRAC comments on the data analysis section, the majority of which 
requiring a revision of this section to include more details or clarification of the planned analysis. A 
priori hypothesis were present in only 5% of the protocols. The majority of the remaining contained 
only descriptive analysis, rarely accounting for confounders or effect modifiers. 
The fact that the vast majority of PASS focused on enrolling patients or prescribers of single 
exposure of interest (70%) implied the absence of an active comparator group. However, among the 
available protocols, approximately one fifth of the single-drug exposure PASS protocols available 
contained implicit or explicit comparators such as absence of the exposure, comparison with external 
data source/ historical data or pre-post event of interest. Overall, two thirds of PASS protocols did 
not including a comparator. The particular nature of the research questions addressed by PASS may 
justify this approach as it will be further discussed in the following section. Only a case by case 
analysis of the protocol would allow an appraisal of the appropriateness of this choice. However, 
given that 2 of the 26 PRAC comments related with study design, requested a broader inclusion 
criteria than single drug exposure for comparison reasons, may suggest that the selection of single 
exposure design might not have been the most adequate approach in some PASS. 
Sensitivity analysis were documented in slightly less than one third of PASS overall and were 
significantly more common in PASS using a secondary data collection approach, which is consistent 
with recommendations to use these methods when conducting database studies.(83) 
Approximately half of the PASS protocols available based the sample size calculation on an 
estimation of the measure in question with a certain degree of precision. Among the remaining, an 
equal number of PASS based sample size on the adequate power to detect an effect of similar 
magnitude and on practical considerations such as, estimated market uptake and available patients 
in a data source. One tenth did not provide any rationale. Moreover, even among those who presented 
sample size calculations based on precision or power, only a minority provided the background for 
the given expected values and assumptions used in the calculations.  
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2 Increased Transparency but Still Some Clouds in the Way 
Lack of transparency had been identified as a major limitation to assess pharmaceutical Risk 
Management activities including PASS before the new Pharmacovigilance legislation. The lack of 
publicly available data on study protocols and their timelines were referred as limitations for 
researchers outside the EMA(18) and even within the EMA it was challenging to track the different 
processes and decisions.(47)  
The establishment of PRAC oversight, specific procedures and timelines for PASS submission, the 
publication of the monthly meeting minutes and the endorsement of the EU PAS register as the 
official database for PASS registration represent major achievements of the new legal 
framework.(86) In particular, the EU PAS register was regarded with much expectation.(18, 47) 
The fact that it was possible to track PASS protocols being discussed at the EMA from available 
meeting minutes already reflects an unprecedented level of publicly available information from the 
regulators.  
Notwithstanding, the results of this work, allowed the identification of three areas that are still 
impairing knowledge access and sharing: partial availability of information, scattered data and 
inconsistent terminology. 
 
2.1 Insufficiently Published Data 
2.1.1 At the Regulators’ Level 
PRAC feedback on the submitted protocols was very limited, restricting the possibility to learn from 
the assessment of the submitted protocols. 
Firstly, PRAC assessment comments were available in the publicly available meeting minutes for 
only one third of the submissions, and the results do not anticipate an improvement, as the 
availability of PRAC comments in the minutes was higher in the first year of the new legislation but 
decreased during the following two years.  
Secondly, within the available PRAC comments, the outcome of PRAC assessment (i.e. whether or 
not protocols were considered approved, rejected, or in need of revision) was rare and unclear, 
requiring several assumptions to be made. Granular details regarding the specific weakness and 
recommendations were very limited. Despite these limitations, the analysis of the available PRAC 
comments revealed that irrespective of the status of PASS (imposed or non-imposed), comments 
and requested revisions of protocols were consistent with previous results.(23, 87)  
 
2.1.2 At the Industry Level 
The results showed that only half of the PASS covered in the study period were entered in the EU 
PAS Registry by July 2015, suggesting a lack of adherence to the Registry from the pharmaceutical 
industry. This result has to be balanced with the fact that registration is legally binding and subject 
to financial penalties only for imposed PASS at the time of final study report. Nevertheless, 
registration of PASS in the EU PAS Register is strongly recommended by the guidelines.(48) A 
positive trend in the registration is observed though, with an increase of over 20% of both imposed 
and non-imposed PASS registration from July 2014 to July 2015. However few documents, such as, 
protocols were available. The regulators should keep emphasising the importance of this registration. 
A recent update to the EU PAS Register includes incentives for MAHs to provide dates to track the 
study milestones from “date when funding contract was signed” to “date of final study report” as 
reminders are sent after the planned date for the start of data collection, and after the planned date 
of the final study report.(88) This and upcoming updates on the guidelines or functionalities of the 
EU PAS Register will be important to strengthen the use of the Register.(50)  
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In addition, to the insufficient registration, a few general observations from the review of the 
available PASS protocols can be made regarding the level of information provided in the protocols. 
There was a limited level of detail provided, many times lacking the critical reasoning behind each 
methodological decision, the acknowledgement of study limitations and of their impact and ways to 
minimise them was often not explicit. Furthermore, there was a general lack of arguments to support 
the practical feasibility of the methods and their robustness to obtain valid study conclusions. These 
findings were corroborated by the high number of PRAC comments related with feasibility concerns, 
such as, the absence of enough evidence to support that the planned strategy was feasible, lack of 
discussion on limitations (e.g. bias) and strategies to minimise those, absence of adequate pilot study, 
lack of preliminary feasibility data and of evidence that collected data would be valid to address 
study objectives. Several comments on other protocol sections also reflected the insufficient level of 
detail provided in the analysis, the rationale for the choice of data source and the need to provide 
more specific objectives.  
In addition, PASS utilising questionnaires rarely appended the questionnaire to the protocols. Given 
that questionnaire design can affect results interpretation, there have been several claims for 
questionnaires to be available to the research community.(89)  
The lack of granular detail in the study protocols was also a finding in the review of PASS before 
the new legislation.(23) The limited level of detail in the protocols is not in line with the major 
guidelines in the area (GPP and GVP), both emphasising the need to include details on the reasoning 
behind the methodological decisions and feasibility considerations.(48, 52)  
There is clear evidence that the EMA implemented mechanisms to promote the development of well-
though and robust protocols. The specific EMA template for PASS protocols embeds text and 
guidance consistent with the guidelines. In addition, it specifies the need to complete and append the 
“ENCePP checklist for study protocols”. One of the goals of the ENCePP checklist for study 
protocols is to “promote transparency regarding methodologies used in pharmacoepidemiological 
studies”. The checklist includes a list of topics that should be taken into consideration to develop 
and demonstrate that PASS are planned with scientific quality.  
Without granular information on protocols, it is not possible for a reader to assess whether or not the 
appropriate operational and methodological considerations were taken into account. This constitutes 
a major obstacle to the assessment and communication over a certain PASS protocol and impairs 
sharing best practices and lessons learned. Increased transparency in methods has been a common 
pledge among other reviews.(83, 85, 90, 91) 
Furthermore, lack of details on the study methodology fails one of the core principles of the 
epistemological nature of the scientific method, as only by specifying a priori, the details of an 
experiment, it is possible to attempt at refusal later on. Popper stated that “the criterion of the 
scientific status of a theory is its falsifiability, or refutability, or testability”.(92) 
Therefore, despite the visible efforts implemented by the regulators to promote sufficiently detailed 
and well though studies, it is important to keep emphasising the need to provide more robust 
protocols that would allow a fruitful discussion between regulators and sponsors to increase the 
probability of the study to be able to achieve its goal. 
2.2 Broken Chain of Information 
The methods section of this dissertation reflects the complexity of tracking the different PASS 
protocols submitted through the meeting minutes and complementing the information with data from 
the EPARs and the EU PAS Register. Therefore, the same challenge identified by the EMA authors 
of a previous review that the “fragmented nature of the available data did not facilitate further 
analysis” was also felt in this review.(47) However, while these challenges were previously only felt 
by the regulators, which were the only stakeholders with access to information, they are now also 
experienced by researchers outside that context, which already represents a step forward in 
transparency, and a different reality from what was possible before.  
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From the minutes of the February 2014 meeting on, the inclusion of the EMA procedure number 
and scope facilitated the tracking of consecutive versions of the same protocol and helped to more 
quickly identify the relevant EPARs. However, it is unfortunate that there is no single document 
tracking all the different regulatory submissions by medicinal product. The document “changes since 
initial authorisation of medicine” available for each product in the EMA website records some of 
the changes to the marketing authorisation such as variations. It would be useful to integrate among 
the chronological entries, reference to other regulatory processes such as RMP and protocol 
assessments and approvals. 
 
2.3 Lack of a Common Language 
From an early stage of the project, it became apparent that different terms are used inconsistently to 
define study designs, and that a given term may be interpreted in different ways. This made the 
developing of a coding scheme very challenging and the need to create a unique coding dictionary 
to overcome the lack of consistent standards.  
The lack of consensus in terminology may lead to different interpretations of protocol content among 
different stakeholders. Therefore, rather than a mere preference on semantics, the consequences of 
lack of harmonisation severely impact the ability to collaborate and communicate among different 
parties and individuals. 
This problem seems well acknowledged in the field of Pharmacoepidemiology as illustrated by the 
following quote from one of the main textbooks in the field: “The same term is sometimes used by 
different authors to describe different concepts. Unfortunately, when reading a scientific paper, there 
is no way of determining which usage the author intended”.(6) 
Inconsistent use of language is even observed within and between guidelines and the EU PAS 
Register. 
 
2.3.1 Inconsistencies within Guidelines 
The fact that guidelines themselves are ambiguous or contradictory in the choice of terminology 
makes it challenging to promote a consistent language in the field. Some highlights are discussed 
below. 
Prospective versus Retrospective design: 
These terms are sometimes used from the perspective of how study participants are selected and 
followed-up (prospective would be the patients selected based on exposure and then followed-up 
until the outcome) or from the perspective of how data are collected for the study (if the patients are 
selected based on exposure but all data was already collected in the past, the design is considered 
retrospective in line with this viewpoint).  
Primary versus Secondary data collection: 
GVP Module VIII presents ambiguous information. On the one hand, the module’s introduction 
implies that secondary use of data consists on “database research or review of records where all the 
events of interest have already happened” and connotes primary data collection with “prospective 
observational studies and registries in which the data collected derive from routine clinical care”. 
On the other hand, the definitions given in appendix section “data sources” do not refer to “primary” 
and “secondary” data collection. Instead a distinction is made between “field studies” (collection of 
data from subject interviews or from consulting paper-based medical records) and “automated 
databases” (containing medical records and administrative ones).  
The definitions used in the introduction of the abovementioned module indicate that secondary data 
collection is synonymous to a retrospective design and primary data collection is the same as having 
a prospective design. This seems to be a common fallacy. Since in secondary data collection 
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schemes, the data collection tool is already built, retrieval of data already collected is generalised to 
retrospective data collection. Conversely, data collection tools in primary data collection studies are 
developed for the planned study and there is no data collected before the study beginning, thus being 
associated with prospective data collection.  
However, the use of the terms interchangeably results in an oversimplification of the different shades 
of study designs that can only be captured by using both pairs of terms to describe different 
characteristics. An example of a situation in which a study can use primary data collection and have 
a retrospective design, could be the collection of past exposures by interviewing patients with certain 
outcomes of interest given that there is no database or records with the available information of 
interest. Conversely, an example of a situation in which a study can use secondary data collection 
and have a prospective design, could be the collection of data from the exposure to a new medicinal 
product by real-time follow-up of patients through the monitoring of a routine EMR which already 
contains all the necessary data fields of interest. 
As seen in these examples the use of both terms provided additional information to understand the 
study design.  
In this dissertation, the lack of granular information hindered the correct ascertainment of whether a 
longitudinal design had a prospective or retrospective perspective. Therefore, study design was 
classified as “longitudinal” or “cross-sectional” and types of data collection as “primary” if data 
collection scheme was implemented de novo for the study and “secondary” if data was retrieved 
from an existing data collection scheme. 
Registry vs. cohort 
GVP Module VIII differentiates PASS study designs as “Active surveillance (Intensive monitoring 
schemes/ Prescription event monitoring/ Registries)” and “Observational studies (Cross-sectional 
study / Cohort Study/ Case-control study/ Case-only designs/ Clinical trials/ Large simple trials and 
Drug utilisation studies)”.  
The limited availability of information for most PASS prevented such a granular design 
classification. However, the use of such classification could be challenge from a practical 
perspective. For example, a registry is an organised system that uses observational methods to collect 
uniform data on specified outcomes in a population defined by a particular disease, condition or 
exposure.(48, 79) Therefore, the definition of a registry can also fit in the definition of an 
observational cohort.  
In addition, GVP also mentions that a registry can be used as a data source for other studies, which 
was the case in some of the described PASS in this review. Therefore the term registry can be both 
connoted with a study design or with data source. This may lead to an ambiguous message if there 
is no further information. In the current study, the term was used as a secondary data source to 
identify the cases in which PASS were embedded in, or collected information from, pre-existing 
registries.  
Drug utilisation study as PASS focus rather than design 
On the other hand, the term “drug utilisation study” is defined in GVP Module VIII Appendix 1 as 
a type of study design. However, none of the more common definitions of drug utilisation study3,4 
suggest that the term is bound to a particular study design and/or data collection schemes used in 
Pharmacoepidemiology. For example, given that drug utilisation information can be obtained 
                                                     
 
3 “The marketing, distribution, prescription, and use of drugs in a society, with special emphasis on the 
resulting medical, social and economic consequences” (WHO 1977) 
4 “"An eclectic collection of descriptive and analytical methods for the quantification, the understanding and 
the evaluation of the processes of prescribing, dispensing and consumption of medicines, and for the testing 
of interventions to enhance the quality of these processes."(vander Stichele and Wettermark, 2008) 
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through an organised data collection scheme, the use of the terms “registry” or “cohort” as 
incompatible deigns with “drug utilisation study” does not seem to be logical. 
In the context of PASS, the implications of the term “drug utilisation” are particularly relevant as 
the definition of PASS is based on the nature of the objectives rather than on the nature of the design. 
Among the types of objectives that define PASS there is “To assess patterns of drug utilisation that 
add knowledge on the safety of the medicinal product (e.g. indication, dosage, co-medication, 
medication errors)”. If “drug utilisation” is interpreted as a type of design/ methodology (and not as 
an objective), it may lead to the replication of a certain methodology without attention to the 
particular needs for assessing drug utilisation in different situations. 
2.3.2 Inconsistencies within the EU PAS Register 
In addition to the ambiguous terminology from the guidelines, the structure of the EU PAS register 
does not promote a greater harmonisation. Some terms are used in multiple data fields of the 
formulary, and/or are not consistent with guidelines, even with the ones from the ENCePP.  
To start with, “case-control surveillance” is an option both for “source of data” and for “study 
design”, “drug utilisation study” is both used as “scope of the study” and as “study design” which 
reflects the previous discussion concerning this term, and “prescription event monitoring” is used 
both as “source of data” and “study design”.  
In addition, “prospective patient-based data collection” is provided as an option for “source of data” 
thus, contributing to the misuse of the term as synonym to primary data collection, as already 
highlighted in the previous section. 
Moreover, the “scope of study” field in the formulary does not include one of the objectives that is 
part of PASS scope, namely, the assessment of effectiveness of RMM. 
Unfortunately, there is no glossary or description of the terms used by the EU PAS Register so the 
interpretation is left open to the registrants. For the EU PAS Register to hold promise of a greater 
transparency, by serving as a common repository to share pharmacoepidemiological research, it 
would be key to promote the use of a common language, or, at least an unequivocal interpretation 
of the data fields that an applicant need to fill.  
Such an effort for harmonisation would prove to be a difficult one as different taxonomies and 
terminologies can be found in different sources, but certainly would facilitate collaboration and the 
accuracy of communication. 
The challenges with terminology acquire a bigger proportion in the specific context of PASS as there 
seems to be some challenges in perceiving PASS as a study which is defined by its objectives rather 
than by its design. These challenges will be further discussed in the following section. 
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3 Bridging Pharmacovigilance and Pharmacoepidemiology 
In any Pharmacoepidemiology study, the choice of the methodological approach should be tailored 
to the research question to be addressed.(6) The fact that there is no “one size fits all” formula 
acquires particular relevance in the context of PASS.  
What distinguishes a PASS from other pharmacoepidemiological studies, is its specific mission 
within Pharmacovigilance. Each PASS is conceived as part of the Risk Management strategy for a 
certain medicinal product.  
It then is expected that PASS contribute to increase the knowledge on the medicinal product’s safety 
profile and fill in the most critical uncertainties, which should be determined in advance. 
In a review conducted prior to the new legislation, the RMP safety concerns of medicinal products 
approved between 2006 and 2009 were followed for 5 years. The authors concluded that 
approximately only one fifth of those uncertainties were resolved, which was considered 
insufficient. They recommended the implementation of more robust activities such as 
methodological stronger studies.(93) A different publication goes even further in their 
recommendation by considering that post marketing studies should be systematically conducted to 
assess long-term safety and detect rare ADRs as the anticipation of safety concerns is a complex 
exercise and not all safety concerns might have been foreseen.(41) However, the new 
Pharmacovigilance legislation endorsed proactivity but also proportionality of the measures put in 
place, to avoid unnecessary burden to the healthcare system. Therefore, GVP Module V considers 
that “Planning of the necessary Pharmacovigilance activities to characterise the safety profile of the 
medicinal product will be improved if it is more closely based on specific issues identified from pre- 
or post-authorisation data and from pharmacological principles”.(37) Therefore, not all medicinal 
products would necessarily require a PASS, as in most cases, routine Pharmacovigilance activities 
would be adequate to manage the uncertainties with the safety profile. (37) The most critical step to 
ensure a proportional and adequate plan is in place to manage the benefit-risk profile of the medicinal 
product (by selecting the best strategies to address each concern) is an initial adequate planning. 
Therefore, rather than conducting PASS for all new marketing authorisations it is more important to 
start developing the RMP as early as possible, engaging with the necessary stakeholders. When all 
the evidence gathered suggests that routine activities (e.g. spontaneous reporting, signal detection, 
routine monitoring of drug utilisation through database screening, etc) are not sufficient to address 
certain safety concerns, additional measures should be considered. These considerations requires a 
balance between the impact of the risk and the burden of the additional activities.(37)  
Hence, PASS are called into action to effectively provide on the spot answers to the knowledge gaps 
that the routine Pharmacovigilance activities are not able to fill, either because answers are needed 
quicker to prevent adverse occurrences, or the specific nature of the questions to be addressed are 
not routinely available. This sense of urgency and need to efficiently address the critical questions, 
could explain why some regulators are reluctant in accepting additional research questions in PASS 
protocols (e.g. effectiveness information) if they would detract the study from proficiently providing 
the necessary answers in a timely manner. In fact, some of the PRAC comments suggested PASS 
protocols containing additional information not relevant to address important safety concerns were 
considered to be unduly delaying the finalisation of the PASS protocol.  
From the above, it is clear why, according to the legislation, a post-authorisation study is classified 
as a PASS when the main aim for initiating the study includes objectives directly linked to 
uncertainties derived from the RMP. This is why their definition considers PASS aims to investigate 
safety concerns, to assess patterns of drug utilisation that add knowledge on the safety profile of the 
medicinal product or to measure the effectiveness of RMM. Thus, a PASS is defined by its objectives 
and not by its design. 
In order to assess if PASS were designed according to these principles it would have been necessary 
to have access to both protocols and RMPs and allow for an extended follow-up time to examine if 
the results of PASS effectively contributed to answer the initial uncertainties. Nevertheless, the 
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following preliminary findings suggested that there may be some disconnection between the PASS 
as conceived in the RMP and the PASS protocols developed. 
Firstly, the comparison of safety concerns planned to be addressed by the PASS (as per the RMP 
summary in the EPAR) versus the safety concerns actually addressed in PASS protocols, performed 
among the subgroup of PASS combining objectives of “investigate safety concerns” and at least one 
other safety objective (see results Section 2.3), revealed some discrepancies.  
Secondly, some PRAC comments referred as reason for protocol rejection the lack of alignment of 
the objectives in the protocol with those in the RMP.  
Lastly, approximately half of the analysed PASS protocols did not mention the RMP. This may 
suggest that the teams responsible for developing the PASS may have not leveraged all the 
information contained in the RMPs which could enrich the study design as those documents contain, 
for instance, considerations about the epidemiology of the disease, suspect or known risk factors and 
effect modifiers to the safety concerns, resultant from literature research and pre-marketing findings. 
This information can be used to account for confounders and effect modifiers thus contributing for 
more robust results. 
To achieve a harmonious articulation between the PASS mission and its methods, it would be 
important to involve pharmacoepidemiologists in the RMP development, to contribute to the 
selection of the best safety activities to put in place to address each safety concern, as they may 
provide early input into whether or not it is feasible to address certain questions with a PASS. The 
involvement of these experts only after the safety concerns and Pharmacovigilance activities are 
agreed with the regulators may result in less appropriate activities or an inconsistent Risk 
Management strategy. A recent publication has extensively reflected on the role of the 
pharmacoepidemiologist in the integrated benefit-risk assessment and its communication and 
evaluation concluding that these professionals are able to bring the methodology expertise, research 
and public health perspectives that can be instrumental in the optimisation of the benefit-risk profile 
of the medicinal products.(94) 
The following chapters reflect on some of the challenges that may need to be addressed before a 
functional bridge is considered definitely established between Pharmacovigilance and 
Pharmacoepidemiology. Further training from teams on both sides, increased collaboration and 
cross-pollination will allow for the recognition of the singularities of PASS and foster development 
of new methods and frameworks. This will help the definite establishment of PASS as fully 
functional multi-level, multi-stakeholder activities that effectively and impactful contribute to safer 
medicinal products.  
3.1 More Collaboration and Cross-pollination 
Experience and literature research has shown that people who develop RMP (who are aware of, and 
manage the benefit-risk profile of the medicinal product) will typically not be the same people 
developing the PASS. Each activity is normally executed by people with a different set of skills and 
background experience within different departments within an organisation.(94)  
Within pharmaceutical companies, safety teams developing the RMP may not be involved with the 
clinical teams conducting the pre-marketing clinical studies nor with the people in possession of the 
data on patient and provider needs (typically housed within medical affairs and the commercial 
organization). Consequently, experts in Pharmacoepidemiology may not be in close contact with all 
work streams which may have insight into the real-world use of the medicinal product (94, 95)  
If the teams who develop the PASS methodology are not aware of the safety specification and the 
overall Risk Management strategy for the medicinal product, they may lack clear understanding of 
the specific mission the PASS is supposed to accomplish. The resultant PASS may not capture the 
“missing pieces of the puzzle”, which the other Pharmacovigilance activities are not able to 
complete. As a consequence, PASS may fail to identify critical findings that would prevent the 
occurrence of ADRs with public impact. 
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It has been recognised that more awareness and engagement in Risk Management strategies could 
have important benefits. Morrato and Smith highlighted the advantage of “incorporating risk 
minimisation thinking through the development and commercialisation process” as “companies can 
be more proactive and nimble in their response should serious events requiring management 
emerge.” In addition they suggested that “pharmaceutical companies have been slow to recognise 
and embrace the significant potential these programs offer in terms of enhancing trust with HCPs 
and patients and for providing a mechanism for bringing products to the market that would not 
otherwise have been approved”.(95) 
Since leveraging data, knowledge and skills from different stakeholders may take time, earlier 
engagement, ideally before the marketing authorisation, is recommended. Early engagement with 
regulators has also been advocated by EMA.(47) 
In addition to bringing different departments and activities together, there is also a particular need 
for cross-pollination of skills such as Pharmacovigilance and Risk Management, 
Pharmacoepidemiology and also other new skills that may still be not common in the Pharmaceutical 
setting like experts in qualitative methods. 
Perhaps the most critical example is illustrated by the sub-analysis of PASS assessing effectiveness 
of RMM.  
 
3.1.1 Assessing Effectiveness of RMM: a Multi-level Multifaceted Endeavour 
Assessment of effectiveness of RMM “is an evolving area of medical sciences with no universally 
agreed standards and approaches”.(39) It is a multifarious and complex endeavour for companies 
and regulators. Firstly, because it requires a thorough understanding of the RMM put in place in a 
certain Risk Management program, their rationale, objectives and interlink with the other post 
marketing activities. Secondly, because the success of RMM depends on multiple factors such as 
their robustness, the healthcare setting where they are implemented, the success of the logistics to 
deliver them, the knowledge and motivations of HCPs and patients, among others. 
As noted in Introduction Section 4.2, different indicators have been proposed to assess effectiveness 
of the RMM, taking into consideration the various steps that may condition the success of these 
activities: from the operational implementation to the desired outcome. Some frameworks and 
models have been developed, to offer some guidance for the assessment of effectiveness of 
RMMs.(39, 43, 46) However, the analysis of protocols of PASS with at least one objective 
concerned with assessing effectiveness of RMM, suggested the published models and orientations 
have not been leveraged systematically, which is in line with other authors’ findings.(96, 97) 
Assessing Knowledge and its Impact on Behaviour: the Need for Qualitative Methodologies 
The implementations of the proposed models to assess effectiveness of RMM require the assessment 
and articulation of different indicators of success. The diversity of these indicators may require 
coupling different skills that are normally attributed to different areas of expertise such as 
Pharmacoepidemiology (typically more associated with quantitative methodologies) and social 
sciences (typically more associated with qualitative methodologies).  
On the one hand, to assess knowledge of the RMM messages and its effects on patients’ and HCPs’ 
behaviours, it is necessary to consider qualitative techniques. On the other hand, to observe patterns 
of behaviour and its effect in the desirable RMM outcome could be appropriately addressed with 
epidemiological techniques (e.g. if upon implementation of an educational program highlighting the 
need to periodically monitor patients’ liver enzymes, the number of hepatotoxicity cases attributed 
to the medicinal product decreased). 
A PASS could be a good instrument to articulate these components. However, our results did not 
suggest those factors were being taken into consideration.  
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Firstly, all PASS uniquely designed to assess effectiveness of RMM had the same design, cross-
sectional survey using questionnaires as tools to assess patient and/or HCP 
awareness/use/satisfaction/knowledge/understanding of the RMM and/or self-reported behaviour 
via answering hypothetical scenarios. While surveys may be the most appropriate tool to assess 
awareness and knowledge of the RMM by patients and HCPs, there are general limitations regarding 
self-reported behaviour information as a proxy of actual behaviour.  
In addition, while it may seem easy to design a questionnaire, the design of an appropriate 
questionnaire is not a straightforward task. (98) When looking at the 5 step model from Banerjee et 
al which, as most evaluation frameworks, follow the basic principles from Kirkpatrick's model to 
assess training programs, it can be noted that the questionnaires used in PASS mainly covered tool 
awareness and usage and risk knowledge and comprehension, but failed to assess behavioural 
modification.(99) 
Publications on implementation science have suggested that a number of constructs originating from 
social cognitive theories are the most promising for assessing behaviour change in health 
professionals.(100) Instruments to assess the impact of educational activities on physicians' 
performance have been developed based on a solid conceptual model for the study of HCPs' 
behaviours and intentions. This illustrates that determining if a RMM positively impacted patients 
and HCPs behaviour is a complex task and requires a solid understanding of these conceptual 
models. 
The adoption of best practices from Implementation Science (the study of strategies to adopt and 
integrate evidence-based health interventions and change healthcare practice patterns within specific 
settings) such as the ones described in the previous paragraph have recently been encourage in the 
field of assessing effectiveness of RMM.(45)  
Differently from these recommendations, the available protocols of PASS employing questionnaires 
did not describe a conceptual model able to assess latent constructs such as attitude and motivation. 
Less than half described critical methodological considerations such as questionnaire validation. 
Even among those that did refer to validation aspects, the level of information was very limited, 
generally only briefly referring to cognitive pre-test interviews for wording, culture adequacy and 
clarity of the message. None considered the psychometric properties of the questionnaires such as 
reliability, validity and responsiveness. Questionnaires should be developed in light of sound 
methodological qualitative and quantitative techniques and several textbooks may provide such 
guidance but may not be part of the library often used by pharmacoepidemiologists yet.(101) 
In addition, the sampling frame is of particular importance in surveys. Given that RMMs are locally 
implemented, their effectiveness is highly dependent on the healthcare context they are inserted in. 
Therefore, targeting a representative sample of subjects for which the RMM are designed to is 
critical in this context.(78) Most of the available PASS protocols using questionnaires planned for 
simple or stratified randomised samples from panels of prescribers which is consistent with GVP’s 
recommendation. However, this guideline highlights the importance of considering the 
representativeness of sponsor lists or panels of HCPs to ensure that the results would be generalisable 
to the target population.(39) Among the analysed protocols, none provided evidence that this was 
considered by the sponsors as the level of details was limited. In terms of country selection, the 
PASS protocols often did not describe considerations concerning the different healthcare systems 
and the countries involved. In addition, they generally briefly justified the selection of some of the 
biggest EU countries on the basis of anticipated larger market uptake, heterogeneity of healthcare 
systems and favourable environment to conduct research, but did not provide more granular details. 
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Assessing Behaviour and Outcomes 
A) The need for Objective-driven Pharmacoepidemiology methods
Even when questionnaires are designed according to best practices, there are limitations to the 
application of those instruments. Firstly, the results may be influenced by participation in the survey 
(such as the Hawthorne effect). Secondly, people who respond may not be representative of the 
target population given that participation is more likely amongst engaged HCPs and/or more 
motivated or educated individuals (non-responder bias). Lastly, it is subject to recall bias.(39) A 
review of effectiveness of RMM methodologies by the FDA has even recommended that methods 
should not rely solely on survey data.(97)  
Therefore, while questionnaires may be the most adequate instrument to assess the impact of a RMM 
initiative on HCPs’ or patients’ knowledge, attitudes and motivation, it would be important to 
complement those results with the observation of actual behaviour in real-world practice and 
ultimately, the effects on minimising the safety outcome targeted by the RMM. This is the rationale 
for the endorsement of a dual evidence-approach by the GVP.(39)  
When considering the three types of objectives of a PASS: to investigate safety concerns, to assess 
drug utilisation and to assess effectiveness of RMM, it can be seen that they can address the different 
facets of a safety concern and emphasises the importance of clearly understanding the rationale 
behind the PASS and the specific answers required. An example is provided below: 
Hepatotoxicity is an identified risk for a certain medicinal product but previous evidence shows that 
this ADR can be avoided by not prescribing the medicinal product to a specific subset of patients. 
The medicinal product is launched with the contraindication stated in the SmPC. However, the 
occurrence of hepatotoxity is higher than would be expected. The company decides to further 
emphasise these precautions in an educational brochure and to actively monitor the safety concern 
with a PASS. The PASS would address this safety question as follows: it will investigate the safety 
concern (hepatotoxicity) by assessing its incidence and characteristics of the cases; it will assess 
patterns of drug utilisation to evaluate compliance with the SmPC and the educational program and 
will compare the incidence of hepatotoxicity before and after the implementation of the RMM 
(educational program).  
This example intended to illustrate that a PASS can simultaneously investigate the safety concern(s) 
and also provide evidence whether or not the RMM is being effective, and if not, the information on 
how the medicinal product is being used may help redefine the RMM strategy. In different cases, 
drug utilisation can also anticipate the occurrence of ADRs.  
The analysis of 12 available PASS protocols, in which the goal was to assess effectiveness of RMM 
and to investigate safety concerns and/or assess drug utilisation, showed that, in those protocols, the 
latter two objectives seemed to drive the study methodology with little attention dedicated to 
effectiveness of RMM. This objective was generally only vaguely stated, for instance, referring that 
compliance with RMM would be assessed but lacking details on how that would be achieved, such 
as what variables and analysis will answer that particular safety question.  
These situations may again suggest some discrepancy between the purpose of PASS conceived 
within the risk management strategy, and that reflected in the PASS protocol. This can result in 
missed opportunities for a PASS to address the various facets of an overarching plan to address 
safety concerns and/or fail to provide the expected results to meet its purpose.  
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B) The need for innovative designs
Besides the correct formulation of PASS objectives aligned with the other Risk Management 
activities, there are limitations in the methodological design of studies to address these 
multidisciplinary questions. 
Only one tenth of the available protocols of PASS assessing effectiveness of RMM were following 
GVPs’ recommendations to assess outcome indicators by comparing the frequency of the outcome 
of interest before and after the implementation of the RMM or using reference values. One of the 
available PRAC comments specifically addressed this issue by requiring “amendment of the 
research question and objectives to reflect comparisons before and after” the implementation of the 
RMM. The lack of comparator/reference group and of a pre-post RMM analysis were also 
highlighted in one literature review and one presentation from the EMA about strategies to assess 
effectiveness of RMM.(96,102)  
These are recognised hurdles to successfully assess effectiveness of RMM. The lack of comparators 
is more challenging for RMMs implemented with the initial marketing authorisation. In addition, 
there are no standard outcome measures since each RMM is applicable to particular medicinal 
products with particular safety concerns. In addition, it could be challenging to operationalise an 
indicator of success of the RMM as some of their objectives may be broad and ambiguous (e.g. “use 
the drug with caution”, “carefully select patients”).(46)  
Moreover, the data to address this multifaceted mission is difficult to access. Ideally, it would require 
access to unbiased prescription and utilisation information to correlate with awareness and 
knowledge transmitted by the RMM. Then, as already mentioned, the assessment of whether the 
instructions/ recommendations from a RMM are being followed requires the interpretation and use 
of techniques more common in qualitative techniques. 
The use of secondary data sources such as EMRs including information on prescription (which can 
be considered a reflection of the HCPs’ behaviour) have been suggested as efficient ways to assess 
RMM without interfering with routine practice. The analysis of prescription records linked to other 
patients’ records, containing demographic and clinical data, may enable the assessment of 
prescribing behaviour with regards to the indication, dosage and prescriber characteristics, 
assessment of off-label use, prescription of interacting medical products, compliance with laboratory 
monitoring recommendations, etc. In addition, the available clinical information, may allow for the 
investigation of occurrence of safety outcomes in the light of the drug utilisation, which would reflect 
the patients’ and HCPs’ behaviour.(43,46, 89) 
However, not all data required to address the research questions may be available in these data 
sources. Despite the fact that, they can provide useful information to understand prescription 
behaviour, some variables may not be available, such as, whether or not particular procedures 
emphasised by an educational program were performed (e.g. regular monitoring of liver enzymes). 
In particular, indicators of knowledge resultant from the RMM would not be available in these 
databases.(39,43) 
Alternatively, more detailed and accurate data can be obtained by collecting data directly from the 
prescribers or patients. However, while specific and detailed information on patients’ or HCPs’ 
knowledge, behaviour, and medicinal products’ use can be collected in this way, it is limited by the 
issues concerning recruiting of participants, time delays and small or unrepresentative sample 
sizes.(39) In the specific case of questionnaires, as already discussed above, while these instruments 
can be particularly useful to assess knowledge, there are particular challenges such as, lack of 
objective standards to measure knowledge of risks, non-response bias and the reliance on subject’s 
ability to recall events or expectations, rather than direct measurement of how risk education affects 
behaviour. This may fail to reflect the real tool use and utility among target population, and may 
also cause an increased burden on clinical practice leading to low response to these 
surveys.(39,43,44)  
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In summary, the results suggested that the PASS assessing the effectiveness of RMM were too 
simplistic. The main focus was on knowledge assessment but without taking into account important 
considerations for the development of questionnaires able to assess the impact of knowledge on 
behaviour. Behaviour was mainly assessed through self-reported answers to hypothetical scenarios, 
despite some longitudinal PASS including assessment of effectiveness of RMM as part of the study 
goals but not providing evidence that data collected this way would be used to address that objective. 
Most of those longitudinal PASS relied on a primary data collection approach which would have 
allowed the collection of tailored information to address behaviour, but was prone to the Hawthorne 
effect, selection and non-responder bias. 
The development of combined approaches and innovative designs may provide more options to 
assess effectiveness of RMM in its multiple facets. RMM development and assessment is a multi-
level, multi-stakeholder activity, in which, the engagement of different functions and different areas 
of expertise will be essential progress levers.  
It is anticipated that, as the number of medicinal products with RMM growths, new techniques are 
applied and acceptable outcome measures established. Banerjee et al recommended “an overt 
regulatory policy on greater transparency on publication of the results of effectiveness evaluation” 
to foster development in the area. Therefore it is important to continue sharing lessons learned on 
how to assess effectiveness of RMM.(43) 
3.1.2 Patient and HCP Engagement 
Another pillar of the new Pharmacovigilance legislation was to involve patients and HCPs in the 
regulation of medicinal products, as a consequence of the perceived lack of trust by society, as 
described in some of the episodes presented in the historical background. None of the PASS 
protocols reviewed described patient or HCPs’ involvement in their development. Once again PASS 
assessing effectiveness of RMM are a good example of the need to engage HCPs and patients as it 
is necessary to understand the impact of the RMM in their knowledge, attitudes and behaviours. The 
engagement of different stakeholders is another call for collaboration within different departments 
and the integration of different skills and techniques commonly used in qualitative methods such as 
focus groups and content analysis.  
Initiatives such as the European Patients’ Academy (EU-PATI) aim to enable patients to understand 
drug development and regulations and capacitate them to collaborate in academic and industry 
research, authorities and ethics committees.(103) In the area of clinical effectiveness research, the 
Patient-Centered Outcomes Research Institute (PCORI) has already showed the ability of these 
stakeholders to provide fruitful inputs.(104) Patients and their families are generally able and 
motivated to give feedback on how treatments affect their autonomy and their satisfaction within the 
contexts of healthcare and life in which the patients are inserted.(8) 
There are also key advantages on engaging HCPs in the conduct of observational research, changing 
their self-perception as “security” agents who just comply with guidelines, to “safety” agents who 
take part in the research contributions.(8) By understanding how the collection of data would 
contribute to improve knowledge and their patients’ health, the HCPs may become more motivated, 
for instance, to provide comprehensive and accurate information.(82) 
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3.1.3 Are PASS Methodological Simplistic Studies? 
There are currently no specific tools to assess the quality of neither PASS nor 
pharmacoepidemiological safety studies in general.(105)  
From all that was discussed above, the fact that PASS are pharmacoepidemiological studies with a 
particular mission in drug regulation makes them a multifaceted object. Therefore the adequacy of 
PASS methodology needs to be assessed on a case by case basis in the context of a particular 
medicinal product with a particular safety specification and a particular action plan.  
The fact that two thirds of PASS did not include a comparator, should be considered in the light of 
particular objectives of PASS. Some PASS are established as active surveillance platforms where 
patients treated with a particular medicinal product are followed-up through a Risk Management 
system to collect long term data or detect rare ADRs as signal amplification collection platforms, 
rather than, with the objective of assessing a particular safety concerns. In addition, as with 
comparative effectiveness reviews, reasons for not including comparators may be justified, for 
instance, for hypothesis generation or due to lack of sufficient information to rationalise a 
comparative hypothesis when the medicinal product is new.(90) Therefore, to identify new risks, to 
reassure the absence of risks in the long-term, or to understand how the medicinal product is being 
used in the real-world context, it may not be necessary to include a comparator. Conversely, to 
estimate the rate ratio or rate difference of safety concerns, a comparator would be paramount, as 
would also be methods to address confounders and effect modifiers, to investigate if a certain 
outcome is due to a certain exposure. 
In addition, the vast majority of the analysed PASS protocols described more straightforward 
methods, such as purely primary or secondary data collection approaches, and were mainly using 
descriptive statistics. While this may be appropriate to a program which simply aims to monitor 
long-term use, the application of appropriate statistical methods (e.g. time series analyses, survival 
analyses, logistic regression) to a cohort of medicinal products users, may allow the assessment of 
different aspects of prescription or use and provide insights beyond purely descriptive evidence.(89) 
The previous chapter illustrated the complexity of the research purpose of a PASS and the need for 
dialogue among stakeholders involved in the safety specification definition and the Risk 
Management planning. Adequate and complete communication is also key to avoid terminology 
“traps” that may lead to misinterpretation.  
For the teams working on Risk Management and thus identifying the research topics that needed to 
be addressed by a PASS, the terms may more often be perceived as “study objectives”. For the teams 
working in Pharmacoepidemiology and thus designing study methodology, some terms maybe 
perceived as “study design”. Therefore, if the communication between teams is restricted to a small 
amount of information including ambiguous terms, there are chances the end result may miss the 
target.  
The fact that the purpose of PASS in the context of its use as a Risk Management may be perceived 
as “methodologies types” may lead to the application of “recipes” used in PASS with that perceived 
“methodology type” whereas in fact, the nature of the safety concerns and the particular needs of the 
PASS might have been significantly different. Thus, the interpretation of “study objectives” as types 
of PASS per se may threaten the ability of the study to address the questions of interest for which 
they were conceived.  
The results suggested that PASS aiming to assess RMM tended to use a cross-sectional design and 
PASS aiming to study drug utilisation tented to use secondary data collection approaches. It is 
imprudent to draw conclusions on whether or not those were the most adequate approaches without 
knowing if alternative approaches were considered. The lack of details available in the protocols 
limit such analysis, but it is worth considering the previous enunciated points regarding the 
importance of tailoring the methods of the PASS to the needs of the safety questions to investigate, 
which may include combining different approaches. Therefore, even if a given data source or data 
collection approach was successful to study drug utilisation in one particular PASS, it may not be 
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adequate for a medicinal product with a different safety specification as the key variables would not 
be the same, and consequently may not be available in certain data sources.  
In summary, given that one third of PASS were combining objectives from different PASS focus 
categories (“investigate safety concerns”, “study drug utilisation” and “assess effectiveness of 
RMM”) and, each of these PASS focus categories may encompass diverse research questions from 
diverse Risk Management systems of diverse medicinal products, it is easy to understand that rarely 
a PASS design could be replicated to another PASS without attention to the particular objectives 
that make PASS unique.  
Therefore, rather than using “recipes” based on a priori conceptions of study types and replication 
of methods applied in studies with similar underlying assumptions, it is key to tailor the design to 
the particular nature of the research question the PASS aims to address. This will foster innovative 
designs tailored to the specificities of the research questions.  
A more extensive critical appraisal of PASS methodology was limited by the insufficient granular 
information provided in each protocol. The general lack of details in PASS protocols restrains the 
ability to share knowledge and, more importantly, may reflect insufficient planning which may lead 
to the overlook of important considerations, which if taken earlier might have minimised the need 
for further PRAC revisions or remedial future actions.  
Given the complexity of the PASS mission and the need to consider multiple stakeholders and new 
skills there is no doubt that PASS should be planned as early as possible in the drug development 
process.  
The integration of Pharmacoepidemiology in the industry and regulatory activities is in its early days 
and has required adaptation of multiple stakeholders and new interactions between different teams 
and across regions. Continuous engagement between parties and efforts in the development of a 
common language and mutual understanding of the Risk Management strategy would help establish 
PASS as a solid bridge between Pharmacoepidemiology and Pharmacovigilance.  
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4 Strengths and Limitations 
The major strength of this dissertation is the comprehensive review of multiple sources of 
information about PASS submitted after the new Pharmacovigilance legislation. In addition, almost 
as a reflection of the encouragement to merge Pharmacoepidemiology with methods traditionally 
used in social sciences, the review was oriented by the principles of content analysis framework 
giving a solid methodological backbone to derive the observed results. As explained in the methods 
section, the use of a mixed methods approach provided a starting point for the classification of PASS, 
but also allowed for reshaping the coding rules and dictionary as new insights emerged during the 
review. As previously discussed, the lack of harmonisation in PASS terminology challenged the use 
of a priori conceptions, but was also an opportunity to explore the similarities and differences 
between PASS, and define new discriminant variables and categories which hopefully contribute to 
a tailored approach to understand PASS. Therefore, this work may contribute to raising awareness 
towards the singularity of PASS, which may deserve a unique taxonomy given the similarities and 
dissimilarities between PASS and other pharmacoepidemiological studies.  
One other main strength of the study was the high degree of comparability between the nested cohort 
of 57 full protocols and the overall 189 PASS protocol population that allowed the extrapolation of 
most of the methodological findings. 
Although the possibility to track numerous data on all single PASS submitted since July 2012 is the 
major strength of the review, the amount of missing and incomplete information constitutes also its 
main limitation. In particular, tracking the different PASS in the successive meeting minutes was 
complex and impacted the ability to draw robust conclusions on PRAC assessment timelines, as well 
as methodological issues raised by the PRAC.  
Another recognised limitation of the study is the fact that PASS with an interventional design and 
PASS to be implemented only in one country are not submitted to the PRAC and therefore were left 
out of the analysis. In addition, PASS discussed in PRAC plenary meetings could correspond to the 
most complex or priority ones and therefore it is possible that for those PASS there was more 
information available in the minutes. It is also possible that not all PASS protocols were captured 
by the review of the PRAC meeting minutes as some PASS protocols may be discussed within the 
RMP assessment.  
94 
95 
5 Opportunities for Future Work 
There are several opportunities to further expand this work. 
The most immediate, is the follow-up of the PASS protocols contained in this review until their 
study results are available. As a result, firstly, it will be possible to compare the reports with the 
protocols to estimate if there were differences between what was initially planned and what was later 
executed. Secondly, it would be possible to ascertain if planned PASS milestones were met and 
therefore if PASS are being completed in the timeframe agreed with the regulators, since this was a 
concern expressed by a recent review of post marketing studies imposed as specific obligations to 
the licence of conditionally authorised medicinal products in the EU. In this study, it was suggested 
that critical ethical and logistical challenges faced by the study sponsors may be compromising study 
execution and completion within the timeframe expected by the regulators, which may be less aware 
of the operational barriers faced by the MAHs.(106) 
In addition, it would be important to investigate what actions followed the publication of the results 
to understand how PASS contributed to the knowledge maturation for a certain medicinal product 
and if it would lead to preventive actions (e.g. RMM, motivating labelling changes etc.). However, 
it is anticipated that it would be difficult to assess the necessary documentation to achieve this later 
goal. 
Moreover, the current database could be supplemented with additional data fields to assess more 
granular details about the PASS (e.g. study limitations and measures to minimise them, an in-depth 
assessment of study objectives and respective methods being used). This could bring important 
insights that might help the development of a tailored tool to assess PASS quality which currently is 
not available. An example would be to assess if, given the nature of a particular objective, the design 
should contain an assessment of an exposure-outcome dyad for which considerations on confounders 
and effect modifiers should not carefully considered. 
It would also be interesting to check the Risk Management summaries of all the new marketing 
authorisations since the new Pharmacovigilance legislation was implemented and to identify plans 
for the conduct of PASS and the specific safety concerns to be addressed in order to estimate how 
many have been submitted for PRAC review (a proxy of those who reached the protocol stage). This 
approach would sustain an improvement from the situation reported before the new legislation where 
a considerable number of PASS planned according to the RMP were not being implemented and 
some did not even reach the protocol stage.(18,47)   
It will also be relevant to follow-up the trend regarding the number of PASS initiated as a 
consequence of a safety referral, as well as, if the safety concerns to be assessed in those PASS were 
already captured in the RMPs to determine how effective these are in predicting the important safety 
concerns, so that adequate measures are proactively being implemented. Given that referral 
procedures usually consist of reactive actions to safety problems that have already manifested, the 
fact that PASS are initiated earlier could reflect an increased proactivity in gaining knowledge on 
safety concerns for newly approved medicinal products. Going forward, a decrease in the number of 
safety referrals could be a pertinent indicator of a change towards a more proactive system.  
By assessing the impact of PASS on the other Pharmacovigilance activities and on the effective 
reduction of ADR burden, it would be possible to estimate the real contribution of PASS to public 
health. 
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Conclusion 
The public availability of a large variety of information on PASS has provided critical insights in 
the design and the conduct of PASS under the new EU Pharmacovigilance legislation.  
PASS are a complex by-product of the needs to bring together Pharmacovigilance and 
Pharmacoepidemiology and its multidisciplinary nature requires a broad variety of skills and 
techniques.  
The recognition of the singularity of PASS as pharmacoepidemiological studies with a specific 
mission within the post marketing plan for the medicinal product, require the alignment of different 
parties to tailor the best approach for each safety question. A clear understanding of the safety 
specification and of the critical uncertainties that PASS should be able to address are key to design 
a successful PASS. Risk Management and PASS should be planned as early as possible in the drug 
development process to allow for the involvement of different stakeholders, careful methodological 
decisions and feasibility exercises that culminate in the development of the most robust study. 
In order to foster collaboration between different stakeholders, it will be essential to further increase 
the level of information publically available, to improve visibility and tracking of regulatory 
processes, to promote the use of harmonised terminology, to develop protocols with an adequate 
level of detail, including the rationale behind the methodological decisions, and to encourage an 
effective cooperation between people working on Risk Management and those developing PASS.  
In addition, cross-pollination of skills with other areas of expertise such as qualitative methodologies 
may be critical to tackle the multidisciplinary needs of the PASS mission, in particular, in the area 
of assessing effectiveness of RMM where it is necessary to assess the impact of measures on 
patients’ and HCPs’ behaviour.  
Cross-functional collaboration and communication across stakeholders, higher levels of 
transparency and the use of a harmonised terminology would be key to develop innovative methods, 
customised to the singular and multifaceted needs of PASS, an example of which being the 
assessment of effectiveness of RMM. The anticipated result would be implementation of best 
practices that will certainly contribute to a safer use of medicinal products.  
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Annex 1 
The PRAC monthly meeting minutes contents follow the following structure: 
• Item 1: Introduction
• Items 2 and 3: EU referral procedures for safety reasons
• Item 4: Signal assessment and prioritisation
• Item 5: RMPs
• Item 6: Assessment of PSURs
• Item 7: Post-Authorisation Safety Studies
• Item 8 (introduced from March 2013); the subsequent chapters were renumbered as
consequence): Renewals of the marketing authorisation, conditional renewal and annual
assessments
• Item 9: Product-related Pharmacovigilance inspections
• Item 10: Other safety issues for discussion requested by the CHMP or the EMA
• Item 11: Other safety issues for discussion requested by the Member States
• Item 12: Organizational, regulatory and methodological matters
• Item 13: Any other business
• Annexes:
o RMP
o PSURs
o PASS
o Renewals of the marketing authorisation , conditional renewals and annual
reassessments
o List of participants
Therefore, information about PASS can either be found in the minutes’ section 7 (the one containing 
more extensive details PASS), the annex, or sporadically other sections. Those areas of the minutes 
with PASS content were typically divided in information about PASS protocol and about PASS 
reports assessed by the PRAC on the concerned month. Only PASS protocols were assessed since 
this study focused only on the PASS protocols as it aimed to describe PASS at their earlier stages 
within the new legal framework.  
Although some changes were observed in the minutes structure over the three years, item 7 typically 
presented the following elements: 
• A numbered sub header identifying a certain PASS protocol assessment by the following
elements: the active substance name, the brand name and the type of marketing authorisation
procedure (centralised or national authorisation procedures);
• Then, under each distinct PASS protocol assessment:
o A sentence summarising the reason for the introduction of that particular item in the
PRAC meeting (e.g. “evaluation of an imposed PASS protocol”);
o The PASS legal basis: imposed as subject to supervision set in Art 107 (m)-(q) of
Directive 2001/83/EC or non-imposed
o Regulatory details: identification of PRAC Rapporteur;
o Administrative details (introduced in the minutes from February 2014 onwards):
EMA procedure number, EMA procedure scope (which could contain brief
information on study background, aim and design) and the MAH;
o Background (when available) with a summary context of the PASS protocol
submitted;
o Endorsement or Refusal of the protocol / Summary of advice / PRAC comments
(when available): could provide information on the PRAC assessment outcome and
whether the PASS protocol would need to be resubmitted for new assessment after
revision by the MAH, the timetable to be applied and feedback on the main reasons
for rejecting a PASS protocol.
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For the PASS protocols presented in the minutes’ annex, the level of information was more limited 
and did not provide context or the conclusions of PRAC assessment. The following sentence was 
common to all the minutes’ annex PASS sections: “Since all comments received on the assessment 
of these studies were addressed before the plenary meeting, the PRAC endorsed the conclusion of 
the Rapporteurs on the assessment of the relevant protocol or study report for the medicines listed 
below without further plenary discussion”. Therefore PASS protocols assessed by the PRAC 
rapporteur that did not require discussion in PRAC plenary session were listed in this section but, 
there was no information on whether or not the PASS protocols were endorsed/ approved as the only 
information presented is that PRAC agreed with the rapporteurs’ conclusions.  
Examples of the data elements and structure of a PASS protocol assessment in the minutes (one for 
section 7 and other Annex) are presented below (both include in the minutes of the PRAC meeting 
held on September 2014 PRAC meeting): 
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Examples of PASS protocol assessments recorded in the minutes  
7.1.3. Strontium ranelate – PROTELOS (CAP), OSSEOR (CAP)  
• Evaluation of an imposed PASS protocol  
 
Regulatory details:  
PRAC Rapporteur: Ulla Wändel Liminga (SE)  
 
Administrative details:  
Procedure number(s): EMEA/H/C/00560/ANX 034, EMEA/H/C/00561/ANX 034  
Procedure scope: Non-interventional safety study to evaluate the effectiveness of the applied risk 
minimisation measures, including a description of the treated patient population in everyday clinical 
practice  
MAH(s):  >>>>>>>censored>>>>>>>> 
 
Background  
The requirement for the conduct of a non-interventional safety study to evaluate the effectiveness of 
the applied risk minimisation measures, including a description of the treated patient population in 
everyday clinical practice, patterns of use and cardiovascular risk, was introduced as an obligation of 
the Annex II of the marketing authorisation for Protelos and Osseor following the conclusion of the 
review conducted under referral Article 20 of Regulation (EC) No 726/2004 (see EMA/112925/2014).  
A draft protocol for such study was submitted and assessed by the rapporteur for review by the 
PRAC  
Endorsement/Refusal of the protocol  
The PRAC, having considered the draft protocol version 1.0 in accordance with Article 107n of 
Directive 2001/83/EC objected to the draft protocol as the Committee considered that the design of 
the study does not fulfil the study objectives. In particular changes in the therapeutic indication should 
be taken into consideration in the analyses of utilisation patterns as well as relevant timing regarding 
implementation of the revised product information and distribution of the related DHPC.  
The PRAC therefore recommended that:  
• The MAH should submit a revised PASS protocol within 60 days to the EMA. A 30 days-
assessment timetable will be applied.  
_______________________________________________________________________________ 
16. ANNEX I Post-authorisation Safety Studies (PASS)  
Since all comments received on the assessment of these studies were addressed before the plenary 
meeting, the PRAC endorsed the conclusion of the Rapporteurs on the assessment of the relevant 
protocol or study report for the medicines listed below without further plenary discussion.  
16.1.1. Glycopyrronium bromide, indacaterol – ULTIBRO BREEZHALER (CAP), ULUNAR 
BREEZHALER (CAP), XOTERNA BREEZHALER (CAP)  
• Evaluation of an imposed PASS protocol  
 
Regulatory details:  
PRAC Rapporteur: Torbjörn Callréus (DK)  
Administrative details:  
Procedure number(s): EMEA/H/C/002679/ANX 002.1, EMEA/H/C/003875/ANX 003, 
EMEA/H/C/003755/ANX 002.1  
Procedure scope: Evaluation of the updated PASS protocol for a multinational database cohort study 
to assess RMP specified safety outcomes in association with indacaterol/glycopyrronium bromide in 
Europe  
MAH(s): >>>>>>>censored>>>>>>>> 
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Annex 2 
The following elements were reviewed from the European Public Assessment Reports (EPAR) 
respective information tabs: 
• Authorisation details tab:
1. Anatomical therapeutic chemical (ATC) code;
2. Date of issue of marketing authorisation valid throughout the EU;
3. Identification of whether it had an orphan designation;
4. Identification whether it concerned a product subject to additional monitoring.
• Product information tab: “EPAR – Product Information” Annex IIB sections “Other
conditions and requirements of the marketing authorisation” and “Conditions or restrictions
with regard to the safe and effective use of the medicinal product” to identify any PASS
conducted as a condition or special obligation to the marketing authorisation (category 1
and 2, respectively);
• Assessment history tab: Chronological review of the EPAR(s) available in this section,
starting with the “initial marketing authorisation documents” to subsequent EPAR(s), until
the concerned PASS was identified (e.g. an EPAR on the assessment of a new indication,
etc). In particular, the section “Risk Management Plan” of the EPARs was revised as it
presented the table with the safety concerns and the Pharmacovigilance Plan of the
medicinal product. Therefore, it would normally contain the description of the planned
and/or ongoing PASS and which safety concerns they aim to address.
ANNEX 3: EU PAS REGISTER FIELDS 
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Annex 3 
An EU PAS Register record contains the following structure and data elements (at data lock: July 
2015): 
• Administrative details tab:
1. Study identification (official title, study title acronym, study type [i.e. active
surveillance, observational study, clinical trial or other], brief description of study,
if the study was requested by a regulator and if yes, which one);
2. Research centres and investigator details (coordinating study entity, details of lead
investigator, if the study is carried out within the collaboration of a research
network, other centres where the study is conducted and countries in which the study
is conducted);
3. Study timelines: initial administrative steps, progress reports and final report;
4. Sources of funding and estimates of the percentage of funding by source for the
study;
5. Contact details for public and scientific enquiries;
• Targets of the study tab:
6 Study drug information (active substance/ brand name/ multi-constituent/ATC); 
7 Medical condition to be studied; 
8 Populations under study (by age categories, gender and special population, if 
applicable, among the following possibilities: renal impaired, hepatic impaired, 
pregnant women, immunocompromised); 
9 Number of patients (estimated total number); 
10 Source of data (if an established data source is used and if yes, which one among 
the following options: Prospective patient-based data collection/ Disease/case 
registry/ Prescription event monitoring/ Administrative database, e.g. claims 
database/ Routine primary care electronic patient registry/ Exposure registry/ 
Pharmacy dispensing records/ Case-control surveillance/ Spontaneous reporting/ 
Other); 
• Methodological aspects tab:
11 Scope of the study (necessary to choose one of the following as primary scope: 
Disease epidemiology/ Risk assessment/ Drug utilisation study/ Effectiveness 
evaluation/ Other); 
12 Main objective (and if there are primary and secondary outcomes and which); 
13 Study design (Sentinel sites/ Intensive monitoring schemes/ Prescription event 
monitoring/ Cross-sectional study/ Cohort study/ Case-control study/ Case-series/ 
Case-crossover/ Self-controlled case series/ Drug utilisation study/ 
Pharmacokinetic study/ Pharmacodynamic study/ Drug interaction study/ 
Randomised controlled trial/ Non-randomised controlled trial); 
14 Follow-up of patients (if applicable); 
15 Data analysis plan (brief summary of the analysis method); 
• Documents tab:
16 ENCePP Seal; 
17 Protocol (embedded document – full or redacted); 
18 Study results (allow embedding of study report); 
19 Other relevant documents (Conflicts of interest, Composition of steering groups and 
observers, Code of conduct, ENCePP protocol checklists and others). 
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 Annex 4  
Example 1 – A typical PASS protocol entry from the first PRAC meeting minutes  
From Pharmacovigilance Risk Assessment Committee (PRAC): Minutes of the Meeting 1-3 
October 2012; Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2012/11/WC500134637.pdf 
 
7. Post-authorisation Safety Studies (PASS) 
7.1. Post-authorisation safety studies protocols 
7.1.1. Ivacaftor – KALYDECO (CAP) 
Evaluation of PASS protocol: observational study to evaluate the long-term safety of ivacaftor in 
patients with cystic fibrosis (CF) 
Regulatory details: 
PRAC Rapporteur: Miguel Angel Macia (ES) 
PRAC Co-Rapporteur: Julia Pallos (HU) 
Background 
Ivacaftor is a selective modulator of the cystic fibrosis transmembrane conductance regulator (CFTR) 
used in the treatment of cystic fibrosis. 
A PASS protocol for Kalydeco, a centrally authorised medicine containing ivacaftor, was presented 
for review by the PRAC in the context of the evaluation of the long-term safety of ivacaftor in 
patients with cystic fibrosis (title ‘An Observational Study to Evaluate the Long-Term Safety of 
ivacaftor in Patients with Cystic Fibrosis (CF)’). 
Endorsement/Refusal of the protocol 
The PRAC, having considered the draft protocol version 1.2 in accordance with Article 107n of 
Directive 2001/83/EC, objected to the draft protocol for Kalydeco (ivacaftor) as the Committee 
considered that the design of the study did not fulfil the study objectives. 
The PRAC therefore recommended that: 
The MAH should submit a revised PASS protocol within 60 days. A standard 60 day-assessment 
timetable will be applied. 
The MAH was encouraged to contact EMA within two weeks in order to receive clarification on any 
issues in advance and facilitate the resubmission of an adequate protocol. 
 
Recorded in the PASS database as follows: 
PASS database 
column name Inserted text Rationale 
ID 1 
This was the first PASS 
protocol related entry 
the PRAC meeting 
minutes. 
PASS protocol 
identification 
Glycopyrronium bromide - ENUREV 
BREEZHALER (CAP), SEEBRI 
BREEZHALER (CAP), TOVANOR 
BREEZHALER (CAP) - DUS 
In the PRAC meeting 
minutes from the 
meeting held in April 
2013, there were two 
separate entries in 
section 7 (7.1.4 and 
7.1.5) clearly 
identifying two 
different PASS 
protocols for this 
medicinal product (one 
imposed PASS protocol 
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and one Drug 
Utilisation Study 
included in the RMP). 
In the Set 2013 PRAC 
meeting minutes both 
PASS protocols are 
presented 
(corresponding to the 
second round). 
However they are 
presented in different 
sections (one dedicated 
to imposed PASS and 
other to non-imposed 
PASS). From the annex 
heading presented here 
it is clear it concerns the 
non-imposed PASS so 
the PASS protocol 
mentioned here must be 
the one previously 
referred as “Drug 
Utilisation Study” 
PRAC Meeting 
date 01-03 Oct 2012 
Date of the respective 
PRAC Meeting minute 
Rounds of PRAC 
evaluation 1 
The first entry for this 
PASS protocol  
Subject 
Evaluation of PASS protocol: 
observational study to evaluate the long-
term safety of ivacaftor in patients with 
cystic fibrosis (CF) 
Verbatim text below the 
sub header of the 
section 
Section 7.1. Post-authorisation safety studies protocols 
The header of the 
PRAC meeting minutes 
section where the PASS 
protocol is described 
PRAC Rapporteur Miguel Angel Macia (ES) --- 
Procedure number Not available 
This information was 
only introduced in 
PRAC meeting minutes 
from February 2014 
Scope Not available Same as above 
MAH Not available Same as above 
Background 
Ivacaftor is a selective modulator of the 
cystic fibrosis transmembrane 
conductance regulator (CFTR) used in the 
treatment of cystic fibrosis. 
A PASS protocol for Kalydeco, a 
centrally authorised medicine containing 
ivacaftor, was presented for review by the 
--- 
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PRAC in the context of the evaluation of 
the long-term safety of ivacaftor in 
patients with cystic fibrosis (title ‘An 
Observational Study to Evaluate the 
Long-Term Safety of ivacaftor in Patients 
with Cystic Fibrosis (CF)’). 
PRAC Comment  
The PRAC, having considered the draft 
protocol version 1.2 in accordance with 
Article 107n of Directive 2001/83/EC, 
objected to the draft protocol for 
Kalydeco (ivacaftor) as the Committee 
considered that the design of the study did 
not fulfil the study objectives. 
The PRAC therefore recommended that: 
•the MAH should submit a revised PASS 
protocol within 60 days. A standard 60 
day-assessment timetable will be applied. 
The MAH was encouraged to contact 
EMA within two weeks in order to 
receive clarification on any issues in 
advance and facilitate the resubmission of 
an adequate protocol. 
-- 
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Example 2 – Identification of a related information to the same PASS protocol already 
presented in a previous PRAC meeting minute (i.e. same unit of analysis as example 1 
but a different unit of observation) 
From Pharmacovigilance Risk Assessment Committee (PRAC): Minutes of the meeting 26-29 
Nov 2012; Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2013/01/WC500137660.pdf 
 
7. Post-authorisation Safety Studies (PASS) 
7.1. Post-authorisation safety studies protocols 
7.1.3. Ivacaftor – KALYDECO (CAP)  
Letter from the EMA Paediatric Committee (PDCO) - collection of long-term data on disease 
progression in the 5-year post-authorisation study (PASS)  
Regulatory details:  
PRAC Rapporteur: Miguel Angel Macia (ES)  
PRAC Co-Rapporteur: Julia Pallos (HU)  
Background  
The PDCO contacted the PRAC regarding a request for modification of the Paediatric Investigational 
Plan (PIP) for Kalydeco. The MAH requested the removal of a two-year placebo-controlled study 
(study D) in children with Forced Expiratory Volume in 1 second FEV1 > 90% from the PIP on the 
basis that the study was no longer feasible. The study was to evaluate the impact of ivacaftor on 
disease progression.  
The PDCO adopted a positive opinion on the PIP modification request but at the same time 
emphasised the importance of gathering long-term data on disease progression to ensure safe and 
effective use of Kalydeco in paediatric patients and recommended that the 5-year post-authorisation 
safety study (PASS) included in the Risk Management Plan be used to gather these data.  
The PRAC discussed the PDCO letter and recommendations.  
Summary of advice  
The PRAC considers the lack of long-term data on disease progression (including rate of decline of 
lung function, diabetes mellitus and distal intestinal obstruction syndrome) to be an important 
knowledge gap that is of particular cause of concern in children with cystic fibrosis.  
The PRAC therefore agreed on the need to amend the PASS protocol - for which a letter of objection 
(with recommendation for the submission of a new protocol) was agreed during the 3-5 October 2012 
meeting - to include the additional objective of obtaining long-term disease progression data and 
specific endpoints.  
A revised letter to the MAH was agreed by the PRAC requesting the MAH to further amend the 
PASS protocol and giving the MAH a one month extension to the deadline for submission of the 
revised PASS protocol.  
 
Recorded in the PASS database as follows: 
PASS database 
column name Inserted text Rationale 
ID 4 
This was the fourth 
PASS protocol related 
entry the PRAC 
meeting minutes. 
PASS protocol 
identification Ivacaftor - KALYDECO (CAP) -- 
PRAC Meeting date 26-29 Nov 2012  Date of the respective PRAC meeting minute 
110 
Rounds of PRAC 
evaluation 2 
From the text (please 
see specific segments 
highlighted in bold 
below) it is possible to 
ascertain this entry is 
related to the PASS 
protocol for Kalydeco 
presented in previous 
Meetings (ID 1) and 
therefore this entry is 
the second PRAC 
consideration regarding 
that study. 
Subject 
Letter from the EMA Paediatric 
Committee (PDCO) - collection of 
long-term data on disease progression 
in the 5-year post-authorisation study 
(PASS)  
Verbatim text below 
the subheader of the 
section 
Section 7.1. Post-authorisation safety studies protocols 
The header of the 
PRAC meeting minutes 
section where the 
PASS protocol is 
described 
PRAC Rapporteur Miguel Angel Macia (ES) --- 
Procedure number Not available 
This information was 
only introduced in 
PRAC meeting minutes 
from February 2014 
Scope Not available Same as above 
MAH Not available Same as above 
Background 
The PDCO contacted the PRAC 
regarding a request for modification of 
the Paediatric Investigational Plan (PIP) 
for Kalydeco. The MAH requested the 
removal of a two-year placebo-controlled 
study (study D) in children with Forced 
Expiratory Volume in 1 second FEV1 > 
90% from the PIP on the basis that the 
study was no longer feasible. The study 
was to evaluate the impact of ivacaftor on 
disease progression.  
The PDCO adopted a positive opinion on 
the PIP modification request but at the 
same time emphasised the importance of 
gathering long-term data on disease 
progression to ensure safe and effective 
use of Kalydeco in paediatric patients and 
recommended that the 5-year post-
authorisation safety study (PASS) 
included in the Risk Management Plan 
be used to gather these data.  
-- 
111 
The PRAC discussed the PDCO letter 
and recommendations.  
PRAC Comment 
The PRAC considers the lack of long-
term data on disease progression 
(including rate of decline of lung 
function, diabetes mellitus and distal 
intestinal obstruction syndrome) to be an 
important knowledge gap that is of 
particular cause of concern in children 
with cystic fibrosis.  
The PRAC therefore agreed on the 
need to amend the PASS protocol - for 
which a letter of objection (with 
recommendation for the submission of 
a new protocol) was agreed during the 
3-5 October 2012 meeting - to include
the additional objective of obtaining
long-term disease progression data and
specific endpoints.
A revised letter to the MAH was
agreed by the PRAC requesting the
MAH to further amend the PASS
protocol and giving the MAH a one
month extension to the deadline for
submission of the revised PASS
protocol.
-- 
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Example 3 – A typical PASS protocol entry from the last year’s PRAC meeting minutes  
From Pharmacovigilance Risk Assessment Committee (PRAC): Minutes of the meeting 06-
09/Jan015; Available at:  
http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2015/02/WC500183280.pdf 
 
7.2. Protocols of PASS non-imposed in the marketing authorisation(s)27  
7.2.1. Agomelatine – THYMANAX (CAP), VALDOXAN (CAP)  
• Evaluation of a PASS protocol  
Regulatory details:  
PRAC Rapporteur: Ingebjørg Buajordet (NO)  
Administrative details:  
Procedure number(s): EMEA/H/C/000916/MEA 023, EMEA/H/C/000915/MEA 023  
Procedure scope: Evaluation of a PASS protocol for a study using databases in four European 
countries to assess the incidence of hospitalisation for liver injury in current medical practice in 
comparison with other antidepressant drugs  
MAH(s): <<<<censored>>> 
Background  
Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist indicated in 
adults for the treatment of major depressive episodes.  
As part of the RMP for Valdoxan/Thymanax, centrally authorised products containing agomelatine 
the MAH was required to conduct a PASS using databases in four European countries in order to 
assess the incidence of hospitalisation for liver injury in current medical practice in comparison with 
other antidepressant drugs. The MAH submitted a protocol for such study (PASS for agomelatine 
and the risk of hospitalisation for acute liver injury (ALI)) which was assessed by the Rapporteur.  
Summary of advice  
• The study protocol for the proposed PASS for Valdoxan/Thymanax (agomelatine) could be 
acceptable provided an updated protocol and satisfactory responses to a list of questions agreed by 
the PRAC is submitted to the EMA within 30 days. In particular, since the expected number of 
exposed patients remains low as per the inclusion criteria, suggestions aiming at strengthening the 
study were made intended to control the potentially significant impact of exposure/outcome 
misclassification.  
• A 30 days assessment timetable will apply.  
 
Recorded in the PASS database as follows: 
 
PASS database 
column name Inserted text Rationale 
ID 263 
This was the 263th 
PASS protocol 
related entry the 
PRAC meeting 
minutes. 
PASS protocol 
identification 
Agomelatine – THYMANAX (CAP), 
VALDOXAN (CAP) – PASS 
An additional ID 
was necessary to 
add because as seen 
in the following 
example there was 
another PASS 
protocol for the 
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same medicinal 
product 
PRAC Meeting date 
 
06-09/Jan015 
Date of the 
respective PRAC 
meeting minute 
Rounds of PRAC 
evaluation 1 
This is the first time 
a PASS protocol 
related to this 
medicinal product 
was mentioned in 
the consecutive 
PRAC meeting 
minutes 
Subject Evaluation of a PASS protocol 
Verbatim text below 
the subheader of the 
section 
Section  7.2. Protocols of PASS non-imposed in the marketing authorisation(s) 
The header of the 
PRAC meeting 
minutes section 
where the PASS 
protocol is 
described 
PRAC Rapporteur Ingebjørg Buajordet (NO)  --- 
Procedure number  EMEA/H/C/000916/MEA 023, EMEA/H/C/000915/MEA 023 --- 
Scope 
Evaluation of a PASS protocol for a study 
using databases in four European 
countries to assess the incidence of 
hospitalisation for liver injury in current 
medical practice in comparison with other 
antidepressant drugs  
--- 
MAH  <<<<censored>>> --- 
Background 
Agomelatine is a melatonergic agonist (MT1 
and MT2 receptors) and 5-HT2C antagonist 
indicated in adults for the treatment of major 
depressive episodes. 
As part of the RMP for 
Valdoxan/Thymanax, centrally authorised 
products containing agomelatine the MAH 
was required to conduct a PASS using 
databases in four European countries in order 
to assess the incidence of hospitalisation for 
liver injury in current medical practice in 
comparison with other antidepressant drugs. 
The MAH submitted a protocol for such 
study (PASS for agomelatine and the risk of 
hospitalisation for acute liver injury (ALI)) 
which was assessed by the Rapporteur. 
--  
PRAC Comment  The study protocol for the proposed 
PASS for Valdoxan/Thymanax 
-- 
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(agomelatine) could be acceptable 
provided an updated protocol and 
satisfactory responses to a list of 
questions agreed by the PRAC is 
submitted to the EMA within 30 days. In 
particular, since the expected number of 
exposed patients remains low as per the 
inclusion criteria, suggestions aiming at 
strengthening the study were made 
intended to control the potentially 
significant impact of exposure/outcome 
misclassification. 
• A 30 days assessment timetable
will apply.
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Example 4 – The identification of a different PASS protocol for a medicinal protocol 
with another PASS protocol already presented  
From Pharmacovigilance Risk Assessment Committee (PRAC): Minutes of the meeting 06-
09/Jan015; Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2015/02/WC500183280.pdf 
7.2. Protocols of PASS non-imposed in the marketing authorisation(s)27 
7.2.2. Agomelatine – THYMANAX (CAP), VALDOXAN (CAP)  
• Evaluation of a PASS protocol
Regulatory details:  
PRAC Rapporteur: Ingebjørg Buajordet (NO)  
Administrative details:  
Procedure number(s): EMEA/H/C/000916/MEA 024, EMEA/H/C/000915/MEA 024  
Procedure scope: Evaluation of a PASS protocol for a non-interventional post-authorisation safety 
study/pharmacogenomic study to explore the potential liver injury and potential associated risk 
factors, risk of hepatotoxic reactions associated with agomelatine in reasonable timelines. 
Pharmacogenomic study: further explore the potential liver injury and potential associated risk 
factors, specific investigations are implemented for patients who exhibit abnormal liver enzymes 
(ALAT, ASAT or ALP value > 3 x upper limit of normal (ULN) or total bilirubin > 2 ULN) in the 
ongoing and planned clinical trials with agomelatine, with close follow-up of abnormalities until 
resolution, and determination of key variables in liver function assessment and appropriate etiological 
investigations. DNA should be taken allowing for search of the influence of different genetic 
polymorphisms  
MAH(s): <<<<censored>>>  
Background  
Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist indicated in 
adults for the treatment of major depressive episodes.  
As part of the RMP for Valdoxan/Thymanax, centrally authorised products containing agomelatine, 
the MAH was required to conduct a pharmacogenomic study to explore the potential for liver injury 
and potential associated risk factors with DNA samples to be taken allowing for investigation of the 
influence of different genetic polymorphisms. The MAH submitted a protocol for such study (human 
leukocyte antigen (HLA) alleles as genetic risk factors for evaluation of aminotransferases in 
patients treated with agomelatine) which was assessed by the Rapporteur. 
Summary of advice 
• The proposed study protocol for the for Valdoxan/Thymanax (agomelatine) pharmacogenetic study
could be acceptable provided an updated protocol with the changes regarding sampling, sequencing,
handling of missing data, inclusion of serious cases is submitted to the EMA within 30 days.
Recorded in the PASS database as follows: 
PASS database 
column name Inserted text Rationale 
ID 264 
This was the 264th 
PASS protocol 
related entry the 
PRAC Meeting 
minutes. 
PASS protocol 
identification 
Agomelatine – THYMANAX (CAP), 
VALDOXAN (CAP) - PASS/PhGen 
An additional ID was 
necessary to add to 
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distinguish from the 
previous PASS 
protocol entry which 
concerned the same 
medicinal product. 
The different 
procedure number 
and remaining text 
information clear 
indicated the PASS 
protocol concerned in 
this entry is different 
from the previous one 
PRAC Meeting date 06-09/Jan015 
Date of the respective 
PRAC Meeting 
minute 
Rounds of PRAC 
evaluation 1 
This was not the first 
time a PASS protocol 
related to this 
medicinal product, as 
seen in the example 
above. However, 
from the distinctive 
characteristics of this 
PASS protocol is 
clear it is the first 
entry for this 
particular study. 
Subject Evaluation of a PASS protocol 
Verbatim text below 
the subheader of the 
section 
Section 7.2. Protocols of PASS non-imposed in the marketing authorisation(s) 
The header of the 
PRAC meeting 
minutes section 
where the PASS 
protocol is described 
PRAC Rapporteur Ingebjørg Buajordet (NO) --- 
Procedure number EMEA/H/C/000916/MEA 024, 
EMEA/H/C/000915/MEA 024  
--- 
Scope 
Evaluation of a PASS protocol for a 
non-interventional post-authorisation 
safety study/pharmacogenomic study to 
explore the potential liver injury and 
potential associated risk factors, risk of 
hepatotoxic reactions associated with 
agomelatine in reasonable timelines. 
Pharmacogenomic study: further 
explore the potential liver injury and 
potential associated risk factors, specific 
investigations are implemented for 
patients who exhibit abnormal liver 
--- 
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enzymes (ALAT, ASAT or ALP value 
> 3 x upper limit of normal (ULN) or 
total bilirubin > 2 ULN) in the ongoing 
and planned clinical trials with 
agomelatine, with close follow-up of 
abnormalities until resolution, and 
determination of key variables in liver 
function assessment and appropriate 
etiological investigations. DNA should 
be taken allowing for search of the 
influence of different genetic 
polymorphisms 
MAH  <<<<censored>>> --- 
Background 
Agomelatine is a melatonergic agonist 
(MT1 and MT2 receptors) and 5-HT2C 
antagonist indicated in adults for the 
treatment of major depressive episodes. 
As part of the RMP for 
Valdoxan/Thymanax, centrally authorised 
products containing agomelatine, the MAH 
was required to conduct a 
pharmacogenomic study to explore the 
potential for liver injury and potential 
associated risk factors with DNA samples 
to be taken allowing for investigation of 
the influence of different genetic 
polymorphisms. The MAH submitted a 
protocol for such study (human leukocyte 
antigen (HLA) alleles as genetic risk 
factors for evaluation of aminotransferases 
in patients treated with agomelatine) which 
was assessed by the Rapporteur. 
-- 
PRAC Comment  
The proposed study protocol for the for 
Valdoxan/Thymanax (agomelatine) 
pharmacogenetic study could be 
acceptable provided an updated protocol 
with the changes regarding sampling, 
sequencing, handling of missing data, 
inclusion of serious cases is submitted 
to the EMA within 30 days. 
-- 
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Example 5 – PASS protocol entries from the annex section of PRAC meeting minutes  
From Pharmacovigilance Risk Assessment Committee (PRAC): Minutes of the meeting 02-
05/Sep2013; Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2013/10/WC500152672.pdf 
 
16. ANNEX I Post-authorisation Safety Studies (PASS)  
Since all comments received on the assessment of these measures were addressed before the plenary 
meeting, the PRAC endorsed the conclusion of the Rapporteurs on the assessment of the relevant 
protocol or study report for the medicines listed below.  
16.1. Protocols of PASS imposed in the marketing authorisation(s)39  
See section 7.  
16.2. Protocols of PASS non-imposed in the marketing authorisation(s)4  
16.2.9. Glycopyrronium bromide – ENUREV BREEZHALER (CAP), SEEBRI BREEZHALER 
(CAP), TOVANOR BREEZHALER (CAP)  
• Evaluation of a PASS protocol  
Regulatory details:  
PRAC Rapporteur: Line Michan (DK)  
 
16.2.4. Bromelain enriched proteolytic enzyme preparation from ananas comosus – NEXOBRID 
(CAP)  
• Evaluation of a PASS protocol  
Regulatory details:  
PRAC Rapporteur: Martin Huber (DE)  
 
The entries were recorded in the PASS database as follows: 
PASS database 
column name Inserted text Rationale 
ID 62 Sequential ID 
PASS protocol 
identification 
Glycopyrronium bromide - ENUREV 
BREEZHALER (CAP), SEEBRI 
BREEZHALER (CAP), TOVANOR 
BREEZHALER (CAP) - DUS 
In the PRAC meeting 
minutes from the 
meeting held in April 
2013, there were two 
separate entries in 
section 7 (7.1.4 and 
7.1.5) clearly 
identifying two 
different PASS 
protocols for this 
medicinal product (one 
imposed PASS 
protocol and one Drug 
Utilisation Study 
included in the RMP). 
In the Set 2013 PRAC 
meeting minutes both 
PASS protocols are 
presented 
(corresponding to the 
second round). 
However they are 
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presented in different 
sections (one dedicated 
to imposed PASS and 
other to non-imposed 
PASS). From the annex 
heading presented here 
it is clear it concerns 
the non-imposed PASS 
so the PASS protocol 
mentioned here must 
be the one previously 
referred as “Drug 
Utilisation Study” 
PRAC Meeting date 02-05/Sep2013 Date of the respective PRAC Meeting minute 
Rounds of PRAC 
evaluation 2 See explanation above 
Subject Evaluation of a PASS protocol 
Verbatim text below 
the subheader of the 
section 
Section  16.2. Protocols of PASS non-imposed in the marketing authorisation(s) 
The header of the 
PRAC meeting minutes 
section where the 
PASS protocol is 
described 
PRAC Rapporteur Line Michan (DK) --- 
Procedure number  Not available 
This information was 
only introduced in 
PRAC meeting minutes 
from February 2014 
Scope Not available Same as above 
MAH  Not available Same as above 
Background Missing -- 
PRAC Comment  Missing  -- 
 
PASS database 
column name Inserted text Rationale 
ID 59 Sequential ID 
PASS protocol 
identification 
Bromelain enriched proteolytic 
enzyme preparation from ananas 
comosus - NEXOBRID (CAP)  
 
PRAC Meeting date 02-05/Sep2013 Date of the respective PRAC meeting minute 
Rounds of PRAC 
evaluation 1 
This is the first time a 
PASS protocol is 
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mentioned for this 
medicinal product 
Subject Evaluation of a PASS protocol 
Verbatim text below 
the subheader of the 
section 
Section  16.2. Protocols of PASS non-imposed in the marketing authorisation(s) 
The header of the 
PRAC meeting 
minutes section where 
the PASS protocol is 
described 
PRAC Rapporteur Martin Huber (DE)  --- 
Procedure number  Not available 
This information was 
only introduced in 
PRAC meeting 
minutes from 
February 2014 
Scope Not available Same as above 
MAH  Not available Same as above 
Background Missing -- 
PRAC Comment  Missing  -- 
 
From February 2014 PRAC meeting minutes contain more information in the Annex section as seen 
in the following two examples. From Pharmacovigilance Risk Assessment Committee (PRAC) 
Minutes of the meeting 8-11/Jun015; 
Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2015/07/WC500190189.pdf 
 
16. ANNEX I Post-authorisation Safety Studies (PASS)  
Since all comments received on the assessment of these measures were addressed before the plenary 
meeting, the PRAC endorsed the conclusion of the Rapporteurs on the assessment of the relevant 
protocol or study report for the medicines listed below.  
16.1. Protocols of PASS imposed in the marketing authorisation(s)43 
16.1.1. Cholic acid– KOLBAM (CAP) - EMEA/H/C/PSP/0017  
Applicant: ASK Pharmaceuticals GmbH  
PRAC Rapporteur: Rafe Suvarna  
Scope: Evaluation of a PASS protocol for a patient registry to monitor the long term safety and 
efficacy in patients treated with cholic acid FGK  
 
16.1.2. Ivabradine – CORLENTOR (CAP), PROCOLORAN (CAP) - EMEA/H/C/PSP/0019.1  
Applicant: Les Laboratoires Servier  
PRAC Rapporteur: Menno van der Elst  
Scope: Evaluation of a revised DUS protocol for a multinational, retrospective, observational study 
to assess effectiveness of risk-minimisation measures  
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The entries were recorded in the PASS database as follows: 
PASS database 
column name Inserted text Rationale 
ID 330 Sequential ID 
PASS protocol 
identification Cholic acid– KOLBAM (CAP) -- 
PRAC Meeting date 8-11/Jun015 Date of the respective PRAC meeting minute 
Rounds of PRAC 
evaluation 1 
This is the first time a 
PASS protocol is 
mentioned for this 
medicinal product 
Subject Not applicable 
The structure of the 
minutes does not 
contain this information 
anymore, instead the 
scope, inexistent in the 
previous examples, is 
now more informative. 
Section  16.1. Protocols of PASS imposed in the marketing authorisation(s)43 
The header of the 
PRAC meeting minutes 
section where the PASS 
protocol is described 
PRAC Rapporteur Rafe Suvarna --- 
Procedure number  EMEA/H/C/PSP/0017 -- 
Scope 
Evaluation of a PASS protocol for a patient 
registry to monitor the long term safety and 
efficacy in patients treated with cholic acid 
FGK  
--- 
MAH  ASK Pharmaceuticals GmbH --- 
Background Missing -- 
PRAC Comment  Missing  -- 
 
-- Inserted text Rationale 
-- 331 Sequential ID 
-- Ivabradine – CORLENTOR (CAP), PROCOLORAN (CAP) -- 
PRAC Meeting date 8-11/Jun015 Date of the respective PRAC meeting minute 
Rounds of PRAC 
evaluation 2 
In the PRAC meeting 
minutes from the meeting 
held in May 2015, there was 
reference to a PASS 
protocol for this medicinal 
product, for which the 
procedure number was given 
(EMEA/H/C/PSP/J/0019). 
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Therefore it is clear that this 
is a subsequent presentation 
of the same PASS protocol 
(procedure number 
EMEA/H/C/PSP/0019.1)  
Subject Not applicable 
The structure of the minutes 
does not contain this 
information anymore, 
instead the scope, inexistent 
in the previous examples, is 
now more informative. 
Section  
16.1. Protocols of PASS imposed 
in the marketing 
authorisation(s)43 
The header of the PRAC 
meeting minutes section 
where the PASS protocol is 
described 
PRAC Rapporteur Menno van der Elst  --- 
Procedure number  EMEA/H/C/PSP/0019.1 -- 
Scope 
Evaluation of a revised DUS 
protocol for a multinational, 
retrospective, observational study 
to assess effectiveness of risk-
minimisation measures 
--- 
MAH  <<<censored>>> --- 
Background Missing -- 
PRAC Comment  Missing  -- 
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Example 6 – The identification of a different PASS protocol within the same PASS 
protocol entry in the PRAC meeting minutes  
From Pharmacovigilance Risk Assessment Committee (PRAC): Minutes of the meeting 4-7 March 
2013; Available at:  
http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2013/04/WC500142504.pdf 
 
7. Post-authorisation Safety Studies (PASS)  
7.1. Protocols of post-authorisation safety studies  
7.1.4. Tenofovir disoproxil fumarate – VIREAD (CAP)  
• PRAC consultation on a PASS protocol included in the Pharmacovigilance plan of the RMP in 
accordance with Article 107m of Directive 2001/83/EC  
Regulatory details:  
PRAC Rapporteur: Isabelle Robine (FR)  
The PRAC endorsed without further plenary discussion the conclusions of the Rapporteur on the 
assessment protocol synopses for a PASS of HIV-1 and HBV infected paediatric patients included in 
the version 14 of the RMP since all comments were addressed in the consultation phase.  
 
Recorded in the PASS database as two different rows as follows: 
 
PASS database 
column name Inserted text Rationale 
ID 15 
This was the 15th 
PASS protocol related 
entry the PRAC 
meeting minutes. 
PASS protocol 
identification 
Tenofovir disoproxil fumarate - 
VIREAD (CAP) - HIV 
From the text available 
it is clear that this 
PASS protocol entry 
refers to two different 
studies (please see 
segments highlighted 
in bold below). 
Therefore this entry 
was spilt in two, one 
for each PASS 
protocol. 
PRAC Meeting date 04-07/Mar2013 Date of the respective PRAC meeting minute 
Rounds of PRAC 
evaluation 1 
This was not the first 
time a PASS protocol 
related to this 
medicinal product, as 
seen in the example 
above. However, from 
the distinctive 
characteristics of this 
PASS protocol is clear 
it is the first entry for 
this particular study. 
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Subject 
PRAC consultation on a PASS 
protocol included in the 
Pharmacovigilance plan of the RMP in 
accordance with Article 107m of 
Directive 2001/83/EC 
Verbatim text below 
the subheader of the 
section 
Section 7.1. Post-authorisation safety studies protocols  
The header of the 
PRAC meeting 
minutes section where 
the PASS protocol is 
described 
PRAC Rapporteur Isabelle Robine (FR) --- 
Procedure number Not available 
This information was 
only introduced in 
PRAC meeting 
minutes from February 
2014 
Scope Not available Same as above 
MAH Not available Same as above 
Background Missing -- 
PRAC Comment 
The PRAC endorsed without further 
plenary discussion the conclusions of 
the Rapporteur on the assessment 
protocol synopses for a PASS of HIV-
1 and HBV infected paediatric 
patients included in the version 14 of 
the RMP since all comments were 
addressed in the consultation phase.  
-- 
PASS database 
column name Inserted text Rationale 
ID 16 
This was the 16th 
PASS protocol related 
entry the PRAC 
meeting minutes. 
PASS protocol 
identification 
Tenofovir disoproxil fumarate - 
VIREAD (CAP) – Hep B 
From the text available 
it is clear that this 
PASS protocol entry 
refers to two different 
studies (please see 
segments highlighted 
in bold below). 
Therefore this entry 
was spilt in two, one 
for each PASS 
protocol. 
PRAC committee 
month 04-07/Mar2013 
Date of the respective 
PRAC meeting minute 
125 
Rounds of PRAC 
evaluation 1 
This was not the first 
time a PASS protocol 
related to this 
medicinal product, as 
seen in the example 
above. However, from 
the distinctive 
characteristics of this 
PASS protocol is clear 
it is the first entry for 
this particular study. 
Subject 
PRAC consultation on a PASS 
protocol included in the 
Pharmacovigilance plan of the RMP in 
accordance with Article 107m of 
Directive 2001/83/EC 
Verbatim text below 
the subheader of the 
section 
Section 7.1. Post-authorisation safety studies protocols  
The header of the 
PRAC meeting 
minutes section where 
the PASS protocol is 
described 
PRAC Rapporteur Isabelle Robine (FR) --- 
Procedure number Not available 
This information was 
only introduced in 
PRAC meeting 
minutes from February 
2014 
Scope Not available Same as above 
MAH Not available Same as above 
Background Missing -- 
PRAC Comment 
The PRAC endorsed without further 
plenary discussion the conclusions of 
the Rapporteur on the assessment 
protocol synopses for a PASS of HIV-
1 and HBV infected paediatric 
patients included in the version 14 of 
the RMP since all comments were 
addressed in the consultation phase.  
-- 
On the subsequent PRAC meeting minutes, the abovementioned PASS protocols were presented 
separately which corroborated the need to consider PASS protocols entities separately even if they 
are grouped together in a certain minutes’ entry. 
Differently from the example above, it was also possible, for some PASS protocol entries, that only 
in a subsequent PRAC meeting minute if became apparent how many PASS protocols existed since 
the beginning for a certain medicinal product. In those cases the PASS database entry related with 
the “first round” of assessment for that medicinal product was split to capture all different PASS 
protocols.  
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rm
at
io
n 
ab
ou
t t
he
 
m
ed
ic
in
al
 
pr
od
uc
t 
st
ud
ie
s i
n 
th
e 
PA
SS
 
St
ud
y 
ca
te
go
ry
 
(P
ha
rm
ac
ov
ig
ila
nc
e P
la
n)
 - 
gr
ou
pe
d 
Th
is 
va
ria
bl
e 
pr
ov
id
es
 m
or
e 
gr
an
ul
ar
ity
 
to
 th
e 
va
ria
bl
e 
"o
bl
ig
at
io
n"
 (c
ol
um
n 
A
C)
 
by
 c
la
ss
ify
in
g 
th
e 
PA
SS
 in
 th
e 
ca
te
go
rie
s 
th
at
 d
ef
in
e 
th
em
 in
 a
 R
isk
 M
an
ag
em
en
t 
Pl
an
: c
at
eg
or
y 
1 
if 
it 
is 
a 
PA
SS
 im
po
se
d 
as
 a
 c
on
di
tio
n 
to
 th
e 
M
ar
ke
tin
g 
A
ut
ho
ris
at
io
n 
(a
rti
cl
es
 2
1a
, a
nd
 2
2a
 o
f 
D
ire
ct
iv
e 
20
01
/8
3/
EC
); 
ca
te
go
ry
 2
 if
 it
 is
 
a 
PA
SS
 im
po
se
d 
as
 a
 sp
ec
ia
l o
bl
ig
at
io
n 
w
ith
in
 a
n 
au
th
or
isa
tio
n 
un
de
r 
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om
in
al
 
Co
nd
iti
on
 
to
 M
A
 
In
fo
rm
at
io
n 
re
tri
ev
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 fr
om
 th
e 
EM
A
 
w
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sit
e:
  “
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nd
 m
ed
ic
in
e”
 / 
“P
ro
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ct
 
in
fo
rm
at
io
n”
 ta
b 
/ p
df
 d
oc
um
en
t w
ith
 th
e 
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A
R 
an
ne
xe
s /
 a
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ex
 II
B:
 C
on
di
tio
ns
 to
 
th
e 
m
ar
ke
tin
g 
au
th
or
isa
tio
n:
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 th
e 
PA
SS
 is
 
de
sc
rib
ed
 o
n 
Se
ct
io
n 
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on
di
tio
ns
 o
r 
re
str
ic
tio
ns
 w
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 re
ga
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 to
 th
e 
sa
fe
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nd
 
ef
fe
ct
iv
e 
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e 
of
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e 
m
ed
ic
in
al
 p
ro
du
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 th
e 
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ar
ke
tin
g 
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ut
ho
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at
io
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eg
or
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l c
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ire
ct
iv
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20
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ca
te
go
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 P
A
SS
 re
qu
ire
d 
in
 th
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sk
 M
an
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em
en
t p
la
n.
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dd
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SS
 m
ay
 b
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 c
on
se
qu
en
ce
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rra
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a 
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ne
fit
-ri
sk
 re
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se
ss
m
en
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pr
oc
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ur
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co
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te
d 
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A
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gg
er
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 b
y 
sa
fe
ty
 c
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ce
rn
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th
er
 
stu
di
es
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 tr
ig
ge
re
d 
by
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ny
 o
f t
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ec
ha
ni
sm
s a
bo
ve
 a
re
 c
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sid
er
ed
 
vo
lu
nt
ar
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eg
or
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at
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re
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 m
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 d
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 C
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 c
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at
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l c
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rra
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ed
 fr
om
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EM
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 m
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ic
in
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 re
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 m
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rra
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 o
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rra
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re
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 re
fe
rra
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at
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 m
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e 
"o
bl
ig
at
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 c
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 d
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 c
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 o
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 if
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l o
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at
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ith
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l c
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 o
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tio
ns
 a
bo
ve
, t
he
n 
se
ar
ch
 o
n 
th
e 
EM
A
 
w
eb
sit
e:
  “
Fi
nd
 m
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 re
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l o
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t o
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at
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 re
qu
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 c
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at
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ul
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 m
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w
ith
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m
ar
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g 
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tio
n 
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ca
tio
n 
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 n
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 d
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e 
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 th
e 
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 a
pp
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tio
n 
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ia
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c 
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re
ne
w
al
 o
f t
he
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ar
ke
tin
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A
ut
ho
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at
io
n;
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 c
on
se
qu
en
ce
 to
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ar
ia
tio
n 
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e 
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ch
an
ge
 in
 m
an
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g 
or
 a
 n
ew
 d
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e 
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ut
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fte
r t
he
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en
t o
f t
he
 P
SU
Rs
, e
tc
.) 
N
om
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 c
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n 
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M
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ro
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 re
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n 
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 p
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at
io
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 c
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r r
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in
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th
er
 
re
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rm
at
io
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 re
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ev
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m
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ev
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w
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A
Rs
 a
va
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l s
pr
ea
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at
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f r
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 th
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ta
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se
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 re
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w
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llo
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 p
ro
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A
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 a
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th
er
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ur
ce
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e 
pr
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va
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in
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w
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g 
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ta
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ur
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ar
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fe
r t
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rm
at
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n 
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at
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at
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n 
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e 
in
 th
e 
EU
 P
A
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re
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at
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at
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 m
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at
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 p
os
sib
le
. 
N
om
in
a
l 
Pr
ot
oc
ol
 
av
ai
la
bl
e 
- 
EN
Ce
PP
 
Se
le
ct
ed
 w
he
n 
th
e 
PA
SS
 p
ro
to
co
l 
do
cu
m
en
t w
as
 a
va
ila
bl
e 
in
 th
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e 
EU
 P
A
S 
Re
gi
ste
r b
ut
 it
 
w
as
 a
va
ila
bl
e 
fro
m
 o
th
er
 d
at
a 
so
ur
ce
s 
Pr
ot
oc
ol
 
no
t 
av
ai
la
bl
e 
- 
In
fo
 in
 
EN
Ce
PP
 
re
gi
str
y 
Se
le
ct
ed
 w
he
n 
th
e 
pr
ot
oc
ol
 d
oc
um
en
t w
as
 
no
t a
va
ila
bl
e 
bu
t t
he
 P
A
SS
 w
as
 re
gi
ste
re
d 
in
 th
e 
EU
 P
A
S 
Re
gi
ste
r, 
so
 th
e 
in
fo
rm
at
io
n 
av
ai
la
bl
e 
in
 it
s s
tru
ct
ur
ed
 fi
el
ds
 w
er
e 
us
ed
 
as
 p
re
fe
rre
d 
so
ur
ce
 
Pr
ot
oc
ol
 
no
t 
av
ai
la
bl
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 d
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 re
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at
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 m
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re
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f d
es
cr
ip
tio
n 
of
 th
e 
ef
fe
ct
iv
en
es
s a
ss
es
sm
en
t i
s 
pr
ov
id
ed
. 
A
V
 
Ef
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 d
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l d
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co
nt
in
en
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es
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A
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 b
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co
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rin
g 
N
A
 
U
se
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fo
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at
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n 
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Co
un
tri
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 in
 w
hi
ch
 th
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stu
dy
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ei
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 c
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du
ct
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an
d 
w
he
n 
no
t 
av
ai
la
bl
e:
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fo
rm
at
io
n 
re
tri
ev
ed
 fr
om
 
pr
ot
oc
ol
 if
 a
va
ila
bl
e 
in
te
rn
al
ly
, o
r 
in
fo
rm
at
io
n 
re
tri
ev
ed
 fr
om
 th
e 
EM
A
 
w
eb
sit
e/
 P
RA
C 
M
in
ut
es
 if
 so
m
e 
in
fo
rm
at
io
n 
w
as
 p
re
se
nt
ed
 th
er
e.
 if
 it
 w
as
 
th
er
e 
to
 c
at
eg
or
ise
 a
s “
Eu
ro
pe
 o
nl
y”
 w
he
n 
al
l c
ou
nt
rie
s a
re
 E
ur
op
ea
n,
 “
Eu
ro
pe
 a
nd
 
A
m
er
ic
as
 o
nl
y”
 w
he
n 
al
l c
ou
nt
rie
s a
re
 
fro
m
 E
ur
op
e 
an
d 
N
or
th
/ S
ou
th
 A
m
er
ic
a 
an
d 
“E
ur
op
e 
an
d/
or
 A
m
er
ic
as
 a
nd
 o
th
er
 
re
gi
on
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he
n 
th
er
e 
is 
at
 le
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t o
ne
 c
ou
nt
ry
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 o
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r A
m
er
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co
nt
in
en
ts 
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D
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en
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en
ts 
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op
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A
sia
, N
or
th
 
A
m
er
ic
a,
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ut
h 
A
m
er
ic
a,
 
A
fri
ca
, 
O
ce
an
ia
) 
Th
e 
co
nt
in
en
ts 
of
 th
e 
co
un
tri
es
 w
hi
ch
 
PA
SS
 w
as
 to
 b
e 
co
nd
uc
te
d 
(e
.g
. E
ur
op
e 
+ 
A
sia
 +
 N
or
th
 A
m
er
ic
a,
 E
ur
op
e 
+ 
A
m
er
ic
as
, A
ll 
co
nt
in
en
ts 
et
c.
) 
A
Y
 
M
et
ho
do
lo
gy
 
D
at
a 
co
lle
ct
io
n 
St
ud
ie
s w
er
e 
cl
as
sif
ie
d 
as
 p
rim
ar
y 
or
 
se
co
nd
ar
y 
ac
co
rd
in
g 
to
 th
e 
m
ai
n 
m
et
ho
d 
of
 c
ol
le
ct
io
n.
  
N
om
in
al
 
Pr
im
ar
y 
Th
e 
da
ta
 w
as
 c
ol
le
ct
ed
 d
ire
ct
ly
 fo
r t
he
 
pu
rp
os
es
 fo
r t
he
 st
ud
y 
(i.
e.
 p
hy
sic
ia
n 
re
po
rts
 d
at
a 
in
 th
e 
ca
se
 re
po
rt 
fo
rm
 a
fte
r 
ea
ch
 p
at
ie
nt
 v
isi
t) 
Se
co
nd
ar
y 
Th
e 
da
ta
 th
at
 w
as
 c
ol
le
ct
ed
 le
ve
ra
gi
ng
 p
re
-
ex
ist
in
g 
da
ta
 c
ol
le
ct
io
n 
sc
he
m
es
 (e
.g
. 
ro
ut
in
e 
cl
in
ic
al
 re
co
rd
s o
f h
ea
lth
ca
re
 u
ni
ts)
 
Pr
im
ar
y 
+ 
Se
co
nd
ar
y 
If 
th
er
e 
is 
no
 c
le
ar
 "d
om
in
an
ce
" o
f e
ith
er
 
th
e 
pr
im
ar
y 
or
 th
e 
se
co
nd
ar
y 
da
ta
 
co
lle
ct
io
n 
ap
pr
oa
ch
es
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pe
 o
f 
se
co
nd
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y 
da
ta
 
 T
he
 A
H
RQ
 b
oo
k 
w
as
 u
se
d 
as
 a
 
re
fe
re
nc
e 
to
 c
on
sid
er
 th
re
e 
m
ai
n 
ca
te
go
rie
s w
hi
ch
 c
om
pr
eh
en
siv
el
y 
in
cl
ud
e 
th
e 
di
ffe
re
nt
 o
pt
io
ns
 o
f 
se
co
nd
ar
y 
da
ta
 so
ur
ce
s:
 
-A
d 
ho
c 
ch
ar
t r
ev
ie
w
: p
rim
ar
ily
 c
on
ta
in
 
in
fo
rm
at
io
n 
co
lle
ct
ed
 a
s a
 p
ar
t o
f r
ou
tin
e 
m
ed
ic
al
 c
ar
e.
 T
he
se
 d
at
a 
re
fle
ct
 th
e 
pr
ac
tic
e 
of
 m
ed
ic
in
e 
or
 h
ea
lth
 c
ar
e 
in
 
ge
ne
ra
l a
nd
 a
t a
 sp
ec
ifi
c 
le
ve
l (
e.
g.
 
ge
og
ra
ph
ic
al
, b
y 
sp
ec
ia
lty
 c
ar
e 
pr
ov
id
er
). 
 
-A
ut
om
at
ed
 e
le
ct
ro
ni
c 
m
ed
ic
al
 re
co
rd
s 
an
d 
cl
ai
m
s d
at
ab
as
es
: C
on
sid
er
ed
 
sta
nd
ar
di
ze
d 
da
ta
ba
se
s i
n 
pl
ac
e 
in
 c
er
ta
in
 
co
un
tri
es
 w
hi
ch
 c
on
ta
in
 d
at
a 
fro
m
 m
an
y 
pr
ac
tic
es
.  
-E
xi
sti
ng
 re
gi
str
ie
s: 
W
he
n 
th
e 
PA
SS
 w
as
 
em
be
dd
ed
 in
 a
n 
on
go
in
g 
re
gi
str
y 
(e
.g
. 
di
se
as
e-
sp
ec
ifi
c 
re
gi
str
ie
s m
an
ag
ed
 b
y 
no
n-
pr
of
it 
or
ga
ni
za
tio
ns
, p
ro
fe
ss
io
na
l 
so
ci
et
ie
s o
r o
th
er
 e
nt
iti
es
). 
N
om
in
al
 
Cl
ai
m
s, 
da
ta
ba
se
, 
au
to
m
at
ed
 
EM
R 
El
ec
tro
ni
c 
m
ed
ic
al
 re
co
rd
s a
nd
 re
co
rd
 
lin
ka
ge
 o
f a
dm
in
ist
ra
tiv
e 
he
al
th
 re
co
rd
s 
ar
e 
th
e 
m
ai
n 
ty
pe
s o
f d
at
ab
as
es
. E
xa
m
pl
es
 
of
 th
e 
fir
st 
an
d 
se
co
nd
 a
re
 th
e 
CP
RD
 in
 th
e 
U
K
 a
nd
 th
e 
na
tio
na
l o
r r
eg
io
na
l d
at
ab
as
es
 
in
 th
e 
N
or
di
c 
co
un
tri
es
, I
ta
ly
, N
et
he
rla
nd
s 
an
d 
ot
he
r c
ou
nt
rie
s, 
re
sp
ec
tiv
el
y.
 
A
dm
in
ist
ra
tiv
e 
da
ta
ba
se
s (
cl
ai
m
s)
 su
ch
 a
s 
th
e 
on
es
 fr
om
 p
riv
at
e 
an
d 
m
ed
ic
al
 in
su
re
rs
 
w
er
e 
al
so
 c
on
sid
er
ed
 in
 th
is 
ca
te
go
ry
. 
A
d 
ho
c 
ch
ar
t 
re
vi
ew
 
Th
e 
te
rm
 w
as
 u
se
d 
to
 id
en
tif
y 
th
e 
us
e 
of
 
in
fo
rm
at
io
n 
co
lle
ct
ed
 a
s p
ar
t o
f r
ou
tin
e 
ca
re
 in
 a
 c
er
ta
in
 p
ra
ct
ic
e/
 p
hy
sic
ia
n 
bu
t n
ot
 
pa
rt 
of
 a
 b
ro
ad
er
 st
an
da
rd
ise
d 
da
ta
 
co
lle
ct
io
n 
da
ta
ba
se
. T
he
re
fo
re
, w
e 
in
cl
ud
ed
 u
nd
er
 th
es
e 
ca
te
go
ry
, p
ap
er
 
m
ed
ic
al
 c
ha
rts
, p
ro
vi
de
r-l
ev
el
 d
at
ab
as
es
, 
in
sti
tu
tio
na
l o
r o
rg
an
iz
at
io
na
l d
at
ab
as
es
. 
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et
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D
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se
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da
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 so
ur
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m
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da
ta
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ur
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(s
) 
m
en
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ne
d 
ab
ov
e 
(if
 a
va
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bl
e)
 
St
rin
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N
A
 
Th
e 
de
ta
il 
of
 th
e 
da
ta
 so
ur
ce
 (e
.g
. C
PR
D
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BB
 
St
ud
y 
de
sig
n 
 
Ep
id
em
io
lo
gi
ca
l d
es
ig
n 
in
 te
rm
s o
f 
w
he
th
er
 a
ll 
da
ta
 w
as
 c
ol
le
ct
ed
 a
t a
 
ce
rta
in
 p
oi
nt
 in
 ti
m
e 
(“
sn
ap
sh
ot
”)
 i.
e.
 
tra
ns
ve
rs
al
/ c
ro
ss
-s
ec
tio
na
l d
es
ig
n 
(e
xp
os
ur
e 
an
d 
ou
tc
om
es
 c
ol
le
ct
ed
 a
t t
he
 
sa
m
e 
tim
e)
, o
r i
f a
t l
ea
st 
da
ta
 w
as
 
co
lle
ct
ed
 in
 tw
o 
di
ffe
re
nt
 ti
m
e 
po
in
ts 
(n
ot
io
n 
of
 fo
llo
w
-u
p;
 e
xp
os
ur
e 
an
d 
ou
tc
om
es
 se
qu
en
tia
l) 
 i.
e.
 lo
ng
itu
di
na
l 
N
om
in
al
 
Cr
os
s-
se
ct
io
na
l 
If 
al
l t
he
 d
at
a 
is 
co
lle
ct
ed
 re
la
te
d 
to
 o
ne
 
po
in
t i
n 
tim
e 
Lo
ng
itu
di
n
al
 
If 
th
er
e 
is 
a 
fo
llo
w
-u
p/
 lo
ng
itu
di
na
l d
at
a 
co
lle
ct
io
n 
of
 a
t l
ea
st 
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o 
da
ta
 p
oi
nt
s f
or
 th
e 
pa
tie
nt
s. 
Th
is 
cl
as
sif
ic
at
io
n 
is 
in
de
pe
nd
en
t 
of
 a
ny
 p
ro
sp
ec
tiv
e/
 re
tro
sp
ec
tiv
e 
no
tio
ns
. 
BC
 
U
ni
t (
pa
tie
nt
/ 
H
C
Ps
) 
To
 id
en
tif
y 
w
he
th
er
 th
e 
ta
rg
et
ed
 
po
pu
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tio
n 
w
er
e 
pa
tie
nt
s o
r h
ea
lth
ca
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pr
of
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sio
na
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(e
.g
. h
ea
lth
ca
re
 
pr
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na
ls 
ar
e 
co
m
m
on
 in
 su
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ey
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 o
r 
if 
bo
th
 p
at
ie
nt
s a
nd
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ca
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es
sio
na
ls 
w
er
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ta
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et
ed
 (e
.g
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pl
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 p
at
ie
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nd
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r h
ea
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ca
re
 
pr
of
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sio
na
ls)
 
N
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in
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nt
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ct
ed
 w
he
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 c
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er
ia
 is
 
ap
pl
ic
ab
le
 to
 p
at
ie
nt
s 
H
CP
s 
Se
le
ct
ed
 w
he
n 
th
e 
el
ig
ib
ili
ty
 c
rit
er
ia
 is
 
ap
pl
ic
ab
le
 to
 h
ea
lth
ca
re
 p
ro
fe
ss
io
na
ls
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tie
nt
s +
 
H
CP
s 
Se
le
ct
ed
 w
he
n 
th
e 
PA
SS
 w
ill
 in
cl
ud
e 
bo
th
 
pa
tie
nt
s a
nd
 h
ea
lth
ca
re
 p
ro
fe
ss
io
na
ls 
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M
ai
n 
in
cl
us
io
n 
ba
se
d 
cr
ite
ri
a:
 
ex
po
su
re
 
U
se
d 
to
 i
de
nt
ify
 t
he
 m
ai
n 
cr
ite
ria
 t
ha
t 
de
fin
e 
th
e 
po
pu
la
tio
n 
be
in
g 
st
ud
ie
d.
 I
t 
al
lo
w
ed
 f
or
 t
he
 i
de
nt
ifi
ca
tio
n 
of
 p
at
ie
nt
 
re
gi
str
ie
s (
de
fin
ed
 a
s a
n 
or
ga
ni
se
d 
sy
ste
m
 
th
at
 u
se
s 
ob
se
rv
at
io
na
l s
tu
dy
 m
et
ho
ds
 to
 
co
lle
ct
 u
ni
fo
rm
 d
at
a (
cl
in
ic
al
 an
d 
ot
he
r)
 to
 
ev
al
ua
te
 
sp
ec
ifi
ed
 
ou
tc
om
es
 
fo
r 
a 
po
pu
la
tio
n 
de
fin
ed
 b
y 
a p
ar
tic
ul
ar
 d
is
ea
se
, 
co
nd
iti
on
 o
r e
xp
os
ur
e 
an
d 
th
at
 se
rv
es
 o
ne
 
or
 m
or
e 
pr
ed
et
er
m
in
ed
 s
ci
en
tif
ic
, c
lin
ic
al
 
or
 
po
lic
y 
pu
rp
os
es
). 
Th
er
ef
or
e,
 
it 
co
m
pr
is
es
 d
is
ea
se
 r
eg
ist
ry
 (
co
m
po
se
d 
of
 
pa
tie
nt
s w
ho
 h
av
e o
r h
av
e h
ad
 a 
di
se
as
e o
r 
co
nd
iti
on
 
of
 
in
te
re
st)
, 
dr
ug
 
re
gi
str
ie
s 
(c
om
po
se
d 
of
 p
at
ie
nt
s e
xp
os
ed
 to
 a
 h
ea
lth
 
ca
re
 p
ro
du
ct
 (d
ru
g 
or
 d
ev
ic
e)
.  
It 
cr
ea
te
 a
n 
ad
di
tio
na
l 
ca
te
go
ry
 f
or
 t
he
 
st
ud
ie
s 
w
hi
ch
 e
nr
ol
 n
ot
 a
ll 
pe
op
le
 w
ith
 a
 
ce
rta
in
 
di
se
as
e 
bu
t 
al
so
 
no
t 
us
in
g 
a 
sp
ec
ifi
c 
dr
ug
, 
so
 w
e 
ca
te
go
ris
e 
th
os
e 
as
 
“m
ul
tip
le
 d
ru
gs
” a
s t
he
y 
w
er
e i
nt
er
es
te
d 
in
 
in
cl
ud
in
g 
pa
tie
nt
s 
w
ith
 d
iff
er
en
t 
dr
ug
s/ 
cl
as
se
s 
of
 
dr
ug
s. 
A
n 
im
po
rta
nt
 
cl
ar
ifi
ca
tio
n 
is
 th
at
 n
ot
 a
ll 
PA
SS
 ta
rg
et
ed
 
th
e 
en
ro
lm
en
t 
of
 p
at
ie
nt
s, 
as
 s
ee
n 
ab
ov
e 
ot
he
rs
 
al
so
 
ta
rg
et
ed
 
he
al
th
ca
re
 
pr
of
es
sio
na
ls
 a
nd
 c
ou
ld
 b
e 
in
te
re
ste
d 
in
 
N
om
in
al
 
Si
ng
le
 
pr
od
uc
t 
Se
le
ct
ed
 w
he
n 
th
e 
stu
dy
 fo
cu
s o
f o
nl
y 
th
e 
m
ed
ic
in
al
 p
ro
du
ct
 st
ud
ie
d 
in
 th
e 
PA
SS
 
(e
.g
. i
nc
lu
sio
n 
of
  p
at
ie
nt
s o
nl
y 
ex
po
se
d 
to
 
th
at
 m
ed
ic
in
al
 p
ro
du
ct
 o
r a
 c
ro
ss
-s
ec
tio
na
l 
su
rv
ey
 to
 a
ss
es
s t
he
 u
nd
er
sta
nd
in
g 
of
 th
e 
he
al
th
ca
re
 p
ro
fe
ss
io
na
ls 
re
ga
rd
in
g 
th
e 
co
rre
ct
 u
se
 o
f t
ha
t s
in
gl
e 
m
ed
ic
in
al
 
pr
od
uc
t) 
M
ul
tip
le
 
dr
ug
s 
Se
le
ct
ed
 w
he
n 
th
e 
stu
dy
 fo
cu
s n
ot
 o
nl
y 
on
 
th
e 
m
ed
ic
in
al
 p
ro
du
ct
 st
ud
ie
d 
in
 th
e 
PA
SS
 
bu
t a
lso
 o
th
er
s w
hi
ch
 a
re
 o
f i
nt
er
es
t f
or
 th
e 
ob
je
ct
iv
es
 o
f t
he
 st
ud
y 
(e
.g
. e
nr
ol
s p
at
ie
nt
s 
ex
po
se
d 
to
 th
e 
m
ed
ic
in
al
 p
ro
du
ct
 o
f 
in
te
re
st 
X
 a
nd
 m
ed
ic
in
al
 p
ro
du
ct
 Y
 a
s 
th
er
e 
is 
a 
pa
rti
cu
la
r i
nt
er
es
t i
n 
co
m
pa
rin
g 
th
em
 o
r a
 c
la
ss
 o
f m
ed
ic
in
al
 p
ro
du
ct
s Z
 
et
c.
). 
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em
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V
ar
ia
bl
e 
N
am
e 
V
ar
ia
bl
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ef
in
iti
on
  
V
ar
ia
bl
e t
yp
e 
C
at
eg
or
y 
C
od
in
g 
ru
le
s 
BD
 
M
et
ho
do
lo
gy
 
M
ai
n 
in
cl
us
io
n 
ba
se
d 
cr
ite
ri
a:
 
ex
po
su
re
 
ot
he
r 
as
pe
ct
s 
of
 t
he
 m
ed
ic
in
al
 p
ro
du
ct
 
su
ch
 as
 u
nd
er
sta
nd
in
g 
of
 th
e c
or
re
ct
 u
se
 o
f 
a 
m
ed
ic
in
al
 p
ro
du
ct
 e
tc
. 
Th
er
ef
or
e 
th
is 
va
ria
bl
e m
ea
su
re
s t
he
 o
bj
ec
t(s
) o
f f
oc
us
 o
f 
th
e 
stu
dy
 i
n 
te
rm
s 
of
 s
in
gl
e 
pr
od
uc
t, 
m
ul
tip
le
 p
ro
du
ct
s 
of
 i
nt
er
es
t 
or
 d
ise
as
e 
(th
e 
br
oa
de
r a
nd
 m
os
t i
nc
lu
si
ve
 c
rit
er
ia
). 
N
om
in
al
 
D
ise
as
e 
Se
le
ct
ed
 w
he
n,
 d
es
pi
te
 th
e 
PA
SS
 is
 
co
nc
er
ne
d 
w
ith
 a
 c
er
ta
in
 m
ed
ic
in
al
 
pr
od
uc
t, 
th
e 
in
te
re
st 
is 
in
 st
ud
yi
ng
 a
ll 
th
e 
pa
tie
nt
s w
ith
 a
 c
er
ta
in
 d
ise
as
e 
(n
ot
 
ta
rg
et
in
g 
sp
ec
ifi
c 
m
ed
ic
in
al
 p
ro
du
ct
s)
. 
Th
er
ef
or
e 
th
is 
is 
th
e 
m
os
t i
nc
lu
siv
e 
cr
ite
ria
.  
BE
 
In
te
re
st
 in
 
sp
ec
ia
l 
po
pu
la
tio
n(
s)
 
(u
se
 fo
rm
at
 
"i
nc
lu
sio
n/
"s
u
bg
ro
up
" 
- 
"t
yp
e o
f 
po
pu
la
tio
n 
of
 
in
te
re
st
")
 
A
 d
iff
er
en
t w
ay
 o
f c
ap
tu
rin
g 
th
e 
fo
cu
s o
n 
th
e 
stu
dy
 is
 in
 te
rm
s o
f s
pe
ci
al
 
po
pu
la
tio
ns
 o
f i
nt
er
es
t. 
Th
is 
co
ul
d 
in
cl
ud
e 
PA
SS
 e
nr
ol
lin
g 
on
ly
 p
at
ie
nt
s o
f 
a 
sp
ec
ia
l p
op
ul
at
io
n 
(e
.g
. p
re
gn
an
t 
w
om
en
 o
r p
ae
di
at
ric
 p
at
ie
nt
s)
 o
r e
ve
n 
he
al
th
ca
re
 p
ro
fe
ss
io
na
ls 
as
 se
en
 a
bo
ve
 
(o
n 
th
e 
va
ria
bl
e 
un
it)
. O
th
er
s d
o 
no
t 
re
str
ic
t t
he
 in
cl
us
io
n 
cr
ite
ria
 to
 c
er
ta
in
 
po
pu
la
tio
ns
 b
ut
 th
ey
 c
ou
ld
 b
e 
in
te
re
ste
d 
in
 st
ud
yi
ng
 sp
ec
ifi
c 
su
bg
ro
up
s o
f 
pa
tie
nt
s a
s p
rim
ar
y 
or
 se
co
nd
ar
y 
ob
je
ct
iv
e 
an
d 
th
er
ef
or
e 
th
ey
 a
re
 a
na
ly
se
d 
se
pa
ra
te
ly
. T
hi
s v
ar
ia
bl
e 
in
cl
ud
es
 b
ot
h 
sit
ua
tio
ns
 (t
he
 in
cl
us
io
n 
of
 sp
ec
ia
l 
po
pu
la
tio
ns
 o
r t
he
 a
na
ly
si
s o
f s
pe
ci
al
 
po
pu
la
tio
ns
). 
Th
e 
la
te
r w
as
 o
nl
y 
po
ss
ib
le
 
N
om
in
al
 
+ 
str
in
g 
In
cl
us
io
n 
- 
X
 
W
he
n 
sp
ec
ia
l p
op
ul
at
io
n(
s)
 is
 p
ar
t o
f t
he
 
el
ig
ib
ili
ty
 c
rit
er
ia
 fo
r t
he
 st
ud
y.
 T
he
 fu
ll 
lis
t o
f p
os
sib
ili
tie
s i
s: 
"I
nc
lu
sio
n 
- 
Pr
eg
na
nt
", 
"I
nc
lu
sio
n 
- P
ae
di
at
ric
", 
"I
nc
lu
sio
n 
- h
ea
lth
ca
re
 p
ro
fe
ss
io
na
ls"
, 
"I
nc
lu
sio
n 
- P
at
ie
nt
s +
 h
ea
lth
ca
re
 
pr
of
es
sio
na
ls
" (
w
he
n 
th
e 
stu
dy
 in
cl
ud
es
 
bo
th
 a
 sa
m
pl
e 
of
 h
ea
lth
ca
re
 p
ro
fe
ss
io
na
ls 
an
d 
ot
he
r o
f p
at
ie
nt
s t
ha
t w
ill
 a
dd
re
ss
 
di
ffe
re
nt
 o
bj
ec
tiv
es
/ a
na
ly
si
s (
e.
g.
 d
ru
g 
ut
ili
sa
tio
n 
as
se
ss
ed
 in
 th
e 
sa
m
pl
e 
of
 
pa
tie
nt
s a
nd
 su
rv
ey
 to
 a
ss
es
s e
ffe
ct
iv
en
es
s 
of
 ri
sk
 m
in
im
isa
tio
n 
m
ea
su
re
s a
m
on
g 
he
al
th
ca
re
 p
ro
fe
ss
io
na
ls)
 o
r e
ve
n 
"I
nc
lu
sio
n 
- P
ae
di
at
ric
 +
 h
ea
lth
ca
re
 
pr
of
es
sio
na
ls
" o
r "
In
cl
us
io
n 
- P
re
gn
an
t +
 
he
al
th
ca
re
 p
ro
fe
ss
io
na
ls"
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Th
em
e 
V
ar
ia
bl
e 
N
am
e 
V
ar
ia
bl
e d
ef
in
iti
on
 
V
ar
ia
bl
e t
yp
e 
C
at
eg
or
y 
C
od
in
g 
ru
le
s 
BE
 
M
et
ho
do
lo
gy
 
In
te
re
st
 in
 
sp
ec
ia
l 
po
pu
la
tio
n(
s)
 
(u
se
 fo
rm
at
 
"i
nc
lu
sio
n/
"s
u
bg
ro
up
" 
- 
"t
yp
e o
f 
po
pu
la
tio
n 
of
 
in
te
re
st
")
 
fo
r t
he
 P
A
SS
 fo
r w
hi
ch
 th
er
e 
w
as
 a
cc
es
s 
to
 th
e 
fu
ll 
pr
ot
oc
ol
.  
It 
w
as
 im
po
rta
nt
 to
 d
ist
in
gu
ish
 st
ud
ie
s 
in
cl
ud
in
g 
a 
sp
ec
ia
l p
op
ul
at
io
n 
as
 
in
cl
us
io
n 
cr
ite
ria
 (e
.g
. a
 P
A
SS
 in
cl
ud
in
g 
on
ly
 p
re
gn
an
t w
om
en
 o
bv
io
us
ly
 h
as
 a
 
sp
ec
ia
l i
nt
er
es
t i
n 
stu
dy
in
g 
pr
eg
na
nt
 
w
om
en
) t
o 
ot
he
r P
A
SS
 in
cl
ud
in
g 
al
l 
po
pu
la
tio
n 
co
ul
d 
al
so
 b
e 
in
te
re
ste
d 
in
 
an
al
ys
in
g 
th
e 
pr
eg
na
nt
 w
om
en
. T
he
 
ca
te
go
rie
s s
pe
ci
fy
 w
he
th
er
 th
e 
sp
ec
ia
l 
po
pu
la
tio
n 
is 
re
fle
ct
ed
 in
 th
e 
in
cl
us
io
n 
cr
ite
ria
 o
r i
n 
th
e 
an
al
ys
is 
(“
in
cl
us
io
n”
, 
“s
ub
gr
ou
ps
”)
 fi
nd
 th
e 
ty
pe
 o
f s
pe
ci
al
 
po
pu
la
tio
n 
 
Ex
am
pl
es
: I
nc
lu
sio
n 
pa
ed
ia
tri
c;
 
Su
bg
ro
up
 –
 e
ld
er
ly
, p
ae
di
at
ric
, c
ar
di
ac
 
im
pa
ire
d 
N
om
in
al
 
+
str
in
g
Su
bg
ro
up
s 
-X
Id
en
tif
ie
d 
w
he
n 
re
ad
in
g 
th
e 
fu
ll 
pr
ot
oc
ol
. 
W
he
n 
th
e 
stu
dy
 o
bj
ec
tiv
es
 a
nd
/o
r a
na
ly
sis
 
se
ct
io
ns
  s
om
e 
of
 th
es
e 
su
bg
ro
up
s o
f 
in
te
re
st 
an
d 
co
ns
id
er
ed
 a
s i
nd
iv
id
ua
l 
ca
te
go
rie
s t
ho
se
 w
ho
 a
pp
ea
re
d 
in
 5
 o
r 
m
or
e 
stu
di
es
 a
nd
 o
th
er
 fo
r t
he
 re
m
ai
ni
ng
 
le
ss
 fr
eq
ue
nt
 su
bg
ro
up
s 
BF
 
C
om
pa
ra
to
r 
O
nl
y 
th
e 
PA
SS
 w
ith
 p
ro
to
co
l a
va
ila
bl
e 
ar
e 
co
de
d 
w
ith
 th
is 
va
ria
bl
e.
 W
he
n 
re
ad
in
g 
th
e 
pr
ot
oc
ol
, i
f t
he
 P
A
SS
 
sp
ec
ifi
ca
lly
 m
en
tio
ns
 th
at
 a
 c
om
pa
ris
on
 
be
tw
ee
n 
gr
ou
ps
 o
f s
ub
je
ct
s w
ou
ld
 b
e 
m
ad
e.
 A
fte
r a
na
ly
sin
g 
al
l t
he
 d
iff
er
en
t 
co
m
pa
ra
to
rs
 w
e 
id
en
tif
ie
d 
th
e 
fo
llo
w
in
g 
m
ai
n 
ca
te
go
rie
s a
s d
et
ai
le
d 
in
 th
e 
ne
xt
 
co
lu
m
ns
. 
N
om
in
al
 
N
o 
N
o 
co
m
pa
ris
on
 w
ill
 b
e 
m
ad
e 
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ef
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yp
e 
C
at
eg
or
y 
C
od
in
g 
ru
le
s 
BF
 
M
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gy
 
C
om
pa
ra
to
r 
C
om
pa
ra
to
r 
N
om
in
al
 
O
th
er
 
tre
at
m
en
ts
 
St
ud
ie
s w
he
re
 p
at
ie
nt
s w
ith
 d
iff
er
en
t 
ex
po
su
re
s (
dr
ug
s, 
de
vi
ce
s, 
ot
he
r t
re
at
m
en
t, 
sta
nd
ar
d 
of
 c
ar
e)
 w
er
e 
co
m
pa
re
d 
U
ne
xp
os
ed
 
To
 id
en
tif
y 
stu
di
es
 w
er
e 
pa
tie
nt
s w
ith
 a
 
ce
rta
in
 tr
ea
tm
en
t e
xp
os
ur
e 
w
er
e 
co
m
pa
re
d 
to
 p
at
ie
nt
s i
n 
w
hi
ch
 th
e 
on
ly
 c
rit
er
ia
 w
as
 
no
t b
ei
ng
 e
xp
os
ed
 to
 th
at
 sp
ec
ifi
c 
tre
at
m
en
t/ 
ex
po
su
re
 (e
xp
os
ed
 v
er
su
s 
un
ex
po
se
d 
pa
tie
nt
s)
 
ex
te
rn
al
 
da
ta
 
so
ur
ce
s 
If 
th
e 
re
su
lts
 fo
r t
he
 p
op
ul
at
io
n 
in
 th
e 
PA
SS
 w
er
e 
co
m
pa
re
d 
to
 re
su
lts
 o
f a
 
po
pu
la
tio
n 
in
 o
th
er
 d
at
a 
so
ur
ce
 
in
de
pe
nd
en
t o
f t
he
 st
ud
y 
(e
.g
. o
th
er
 
re
gi
str
y 
or
 e
pi
de
m
io
lo
gy
 d
at
a 
so
ur
ce
) 
Pr
e 
an
d 
po
st 
a 
ce
rta
in
 
ou
tc
om
e 
of
 
in
te
re
st 
Co
m
pa
ris
on
 o
f a
 p
op
ul
at
io
n 
be
fo
re
 a
nd
 
af
te
r c
er
ta
in
 o
cc
ur
re
nc
e 
(e
.g
. i
nt
ro
du
ct
io
n 
of
 a
 e
du
ca
tio
na
l p
ro
gr
am
) 
BG
 
C
om
pa
ra
to
r 
sim
pl
ifi
ed
 
V
ar
ia
bl
e 
de
riv
ed
 fr
om
 a
bo
ve
 (y
es
/n
o 
co
m
pa
ra
to
r i
nd
ep
en
de
nt
 o
f t
he
 ty
pe
 o
f 
co
m
pa
ra
to
r)
 
N
om
in
al
 
Y
es
/ N
o 
Th
is 
w
ill
 h
av
e 
th
e 
sa
m
e 
va
lu
e 
as
 a
bo
ve
 
w
ith
ou
t (
Y
es
/ N
o)
 w
ith
ou
t p
re
se
nt
in
g 
an
y 
ad
di
tio
na
l d
et
ai
ls 
BH
 
PR
O
 
in
st
ru
m
en
t 
O
nl
y 
th
e 
PA
SS
 w
ith
 p
ro
to
co
l a
va
ila
bl
e 
ar
e 
co
de
d 
w
ith
 th
is 
va
ria
bl
e.
 It
 id
en
tif
ie
d 
if 
Pa
tie
nt
 R
ep
or
te
d 
O
ut
co
m
es
 (P
RO
) a
re
 
us
ed
 in
 th
e 
PA
SS
. 
N
om
in
al
 
Y
es
/ N
o 
If 
on
e 
or
 m
or
e 
PR
O
 is
 m
en
tio
ne
d 
"Y
es
" i
s 
se
le
ct
ed
. I
nt
o 
br
ac
ke
ts 
th
e 
na
m
e 
or
 ty
pe
 o
f 
PR
O
 is
 p
re
se
nt
ed
 (e
.g
. S
F-
36
/ b
ur
de
n 
of
 
di
se
as
e 
/ q
ua
lit
y 
of
 li
fe
) e
tc
. 
BI
 
PR
O
 
in
st
ru
m
en
t 
sim
pl
ifi
ed
 
V
ar
ia
bl
e 
de
riv
ed
 fr
om
 a
bo
ve
 (y
es
/n
o 
co
m
pa
ra
to
r i
nd
ep
en
de
nt
 o
f t
he
 ty
pe
 o
f 
PR
O
) 
N
om
in
al
 
Y
es
/ N
o 
Th
is 
w
ill
 h
av
e 
th
e 
sa
m
e 
va
lu
e 
as
 a
bo
ve
 
w
ith
ou
t (
Y
es
/ N
o)
 w
ith
ou
t p
re
se
nt
in
g 
an
y 
ad
di
tio
na
l d
et
ai
ls 
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M
et
ho
do
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gy
 
Sa
m
pl
e s
iz
e 
N
um
be
r o
f p
at
ie
nt
s o
r H
CP
s (
de
pe
nd
in
g 
on
 th
e 
un
it 
of
 a
na
ly
sis
) t
he
 st
ud
y 
ai
m
s t
o 
re
cr
ui
t. 
If 
th
er
e 
is 
a 
sa
m
pl
e 
siz
e 
fo
r b
ot
h 
pa
tie
nt
s a
nd
 H
CP
s (
a 
stu
dy
 th
at
 ta
rg
et
 
bo
th
 u
ni
ts)
 th
en
 in
cl
ud
e 
bo
th
 in
 th
e 
fo
llo
w
in
g 
fo
rm
at
: s
am
pl
e 
siz
e 
fo
r H
CP
s 
+ 
sa
m
pl
e 
siz
e 
fo
r p
at
ie
nt
s 
Sc
al
e 
nu
m
be
r (
or
 
nu
m
be
r +
 
nu
m
be
r) 
Re
tri
ev
ed
 fr
om
 th
e 
pr
ot
oc
ol
 o
r w
he
n 
no
t 
av
ai
la
bl
e 
bu
t r
eg
ist
er
ed
 in
 th
e 
EU
 P
A
S 
Re
gi
ste
r, 
fro
m
 th
is 
re
gi
ste
r (
fie
ld
 "9
. 
N
um
be
r o
f p
at
ie
nt
s"
). 
W
he
n 
an
 in
te
rv
al
 is
 
pr
ov
id
ed
 (e
.g
. i
nc
lu
sio
n 
of
 3
00
 to
 6
00
 
pa
tie
nt
s)
, t
he
 a
ve
ra
ge
 n
um
be
r i
s p
re
se
nt
ed
 
(e
.g
. 4
50
 in
 th
is 
ca
se
). 
W
he
n 
th
e 
PA
SS
 
in
cl
ud
es
 b
ot
h 
pa
tie
nt
s a
nd
 h
ea
lth
ca
re
 
pr
ov
id
er
s (
e.
g.
 1
00
0 
pa
tie
nt
s a
nd
 2
50
 
he
al
th
ca
re
 p
ro
fe
ss
io
na
ls)
 th
e 
nu
m
be
rs
 a
re
 
pr
es
en
te
d 
in
 th
e 
fo
llo
w
in
g 
fo
rm
at
 (n
um
be
r 
of
  h
ea
lth
ca
re
 p
ro
fe
ss
io
na
ls 
+ 
nu
m
be
r o
f 
pa
tie
nt
s, 
i.e
. 2
50
 +
 1
00
0)
 
BK
 
Sa
m
pl
e s
iz
e 
(H
C
Ps
) 
D
er
iv
ed
 fr
om
 "s
am
pl
e 
siz
e"
:  
pr
es
en
tin
g 
ju
st 
th
e 
nu
m
be
r o
f h
ea
lth
ca
re
 
pr
of
es
sio
na
ls
 
Sc
al
e 
nu
m
be
r 
D
er
iv
ed
 fr
om
 th
e 
va
ria
bl
e 
ab
ov
e.
 If
 th
e 
PA
SS
 in
vo
lv
e 
 h
ea
lth
ca
re
 p
ro
fe
ss
io
na
ls 
(c
he
ck
 v
ar
ia
bl
e 
"U
ni
t (
pa
tie
nt
s/H
CP
s"
), 
co
py
 th
e 
sa
m
e 
nu
m
be
r, 
if 
no
t, 
se
le
ct
ed
 
"N
A
" 
BL
 
Sa
m
pl
e s
iz
e 
(p
at
ie
nt
s)
 
D
er
iv
ed
 fr
om
 "s
am
pl
e 
siz
e"
: p
re
se
nt
in
g 
ju
st 
th
e 
nu
m
be
r o
f p
at
ie
nt
s 
Sc
al
e 
nu
m
be
r 
D
er
iv
ed
 fr
om
 th
e 
va
ria
bl
e 
ab
ov
e.
 If
 th
e 
PA
SS
 in
vo
lv
e 
pa
tie
nt
s (
i.e
. n
on
-h
ea
lth
ca
re
 
pr
of
es
sio
na
ls)
, c
he
ck
 v
ar
ia
bl
e 
"U
ni
t 
(p
at
ie
nt
s/H
CP
s"
). 
Co
py
 th
e 
sa
m
e 
nu
m
be
r, 
if 
no
t, 
se
le
ct
ed
 "N
A
" 
BM
 
Sa
m
pl
e s
iz
e 
(p
at
ie
nt
s +
 
H
C
Ps
) 
D
er
iv
ed
 fr
om
 "s
am
pl
e 
siz
e"
: p
re
se
nt
in
g 
th
e 
nu
m
be
rs
 o
f b
ot
h 
pa
tie
nt
s a
nd
 
he
al
th
ca
re
 p
ro
fe
ss
io
na
ls
 
Sc
al
e 
nu
m
be
r+
 
nu
m
be
r 
D
er
iv
ed
 fr
om
 th
e 
va
ria
bl
e 
ab
ov
e.
 If
 th
e 
PA
SS
 in
vo
lv
e 
bo
th
 p
at
ie
nt
s a
nd
 h
ea
lth
ca
re
 
pr
of
es
sio
na
ls 
(c
he
ck
 v
ar
ia
bl
e 
"U
ni
t 
(p
at
ie
nt
s/H
CP
s"
). 
Co
py
 th
e 
sa
m
e 
nu
m
be
rs
, 
if 
no
t, 
se
le
ct
ed
 "N
A
" 
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3 
Th
e 
da
ta
ba
se
 is
 p
ro
vi
de
d 
as
 e
le
ct
ro
ni
c 
su
pp
le
m
en
ta
ry
 m
at
er
ia
l (
CD
-R
O
M
) 
M
at
ri
x 
co
lu
m
n 
id
en
tif
i
ca
tio
n 
Th
em
e 
V
ar
ia
bl
e 
N
am
e 
V
ar
ia
bl
e d
ef
in
iti
on
  
V
ar
ia
bl
e t
yp
e 
C
at
eg
or
y 
C
od
in
g 
ru
le
s 
BN
 
M
et
ho
do
lo
gy
 
Pa
tie
nt
 
fo
llo
w
-u
p 
(y
ea
rs
) 
Th
e 
pa
tie
nt
/H
CP
 fo
llo
w
-u
p 
in
 y
ea
rs
. I
f 
m
or
e 
th
an
 o
ne
 u
ni
t (
H
CP
 a
nd
 p
at
ie
nt
) i
s 
ta
rg
et
ed
 th
en
 th
e 
sa
m
e 
de
no
m
in
at
io
n 
as
 
ab
ov
e 
sh
ou
ld
 b
e 
us
ed
 (i
.e
. f
ol
lo
w
-u
p 
of
 
he
al
th
ca
re
 p
ro
fe
ss
io
na
ls 
+ 
fo
llo
w
-u
p 
of
 
pa
tie
nt
s)
. 
Sc
al
e 
nu
m
be
r 
Re
tri
ev
ed
 fr
om
 th
e 
pr
ot
oc
ol
 o
r w
he
n 
no
t 
av
ai
la
bl
e 
bu
t r
eg
ist
er
ed
 in
 th
e 
EU
 P
A
S 
Re
gi
ste
r, 
fro
m
 th
is 
re
gi
ste
r (
fie
ld
 "1
4.
 
Fo
llo
w
-u
p 
of
 p
at
ie
nt
s"
). 
W
he
n 
an
 in
te
rv
al
 
is 
pr
ov
id
ed
 (e
.g
. 3
 to
 5
 y
ea
rs
), 
th
e 
av
er
ag
e 
nu
m
be
r i
s p
re
se
nt
ed
 (e
.g
.4
.5
 y
ea
rs
). 
W
he
n 
th
e 
PA
SS
 in
cl
ud
es
 b
ot
h 
pa
tie
nt
s a
nd
 
he
al
th
ca
re
 p
ro
vi
de
rs
  t
he
 fo
llo
w
-u
p 
fo
r 
ea
ch
 g
ro
up
 a
re
 p
re
se
nt
ed
 in
 th
e 
fo
llo
w
in
g 
fo
rm
at
 (n
um
be
r o
f f
ol
lo
w
-u
p 
fo
r 
he
al
th
ca
re
 p
ro
fe
ss
io
na
ls 
+ 
nu
m
be
r o
f 
fo
llo
w
-u
p 
pa
tie
nt
s, 
i.e
. 1
 +
 5
 o
r N
A
+ 
5 
if 
th
er
e 
is 
no
 fo
llo
w
-u
p 
fo
r o
ne
 o
f t
he
 g
ro
up
s)
 
BO
 
IC
F 
O
nl
y 
th
e 
PA
SS
 w
ith
 p
ro
to
co
l a
va
ila
bl
e 
ar
e 
co
de
d 
w
ith
 th
is 
va
ria
bl
e.
 If
 a
cc
or
di
ng
 
to
 th
e 
PA
SS
 p
ro
to
co
l, 
in
fo
rm
ed
 c
on
se
nt
 
w
ill
 b
e 
re
qu
es
te
d 
or
 n
ot
. 
N
om
in
al
 
Y
es
/ N
o 
If 
an
 in
fo
rm
ed
 c
on
se
nt
 p
ro
ce
ss
 is
 
m
en
tio
ne
d 
th
en
 “
Y
es
" i
s s
el
ec
te
d.
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ta
 so
ur
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Sa
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am
e 
In
di
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to
rs
 
In
te
re
st
in
g 
as
pe
ct
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5 
D
H
PC
 
an
d 
up
da
te
d 
Sm
PC
 
A
ss
es
s 
ef
fe
ct
iv
en
es
s 
of
 
ris
k 
m
in
im
is
at
io
n 
m
ea
su
re
s+
D
ru
g 
U
til
isa
tio
n 
St
ud
y 
  
Cr
os
s-
se
ct
io
na
l/ 
Pr
im
ar
y 
da
ta
 
co
lle
ct
io
n:
 
Q
ue
sti
on
na
ire
 
to
 
pr
es
cr
ib
er
s 
   
St
ra
tif
ie
d 
ra
nd
om
 
sa
m
pl
e 
fro
m
 
pr
ov
id
er
’s
 
pr
es
cr
ib
er
s l
ist
.  
U
se
 o
f R
M
M
 
K
no
w
le
dg
e 
Be
ha
vi
ou
r 
(a
gg
re
ga
te
 
pa
tie
nt
 d
at
a 
to
 b
e 
pr
ov
id
ed
 b
y 
th
e 
pr
es
cr
ib
er
s)
 
    
O
n-
lin
e 
qu
es
tio
nn
ai
re
s 
fo
r 
ph
ys
ic
ia
ns
;  
Pr
e-
te
st
 
in
 
6-
8 
ph
ys
ic
ia
ns
 
(u
nd
er
sta
nd
in
g 
an
d 
w
or
di
ng
). 
Ph
ys
ic
ia
ns
’ 
co
m
m
en
ts
 
w
ill
 
be
 
im
pl
em
en
te
d 
in
 th
e 
fin
al
 v
er
si
on
. 
Ba
ck
 
an
d 
fo
rth
 
tra
ns
la
tio
n 
m
et
ho
d;
 
D
ur
at
io
n 
of
 q
ue
sti
on
na
ire
: 1
0-
15
 
m
in
ut
es
; 
O
ut
co
m
e m
ea
su
re
: N
ot
 p
ro
vi
de
d;
 
O
th
er
 P
A
SS
 in
 th
e 
da
ta
ba
se
? 
Y
es
 
(to
 a
ss
es
s 
dr
ug
 u
til
isa
tio
n 
us
in
g 
se
co
nd
ar
y 
da
ta
 s
ou
rc
es
 b
ef
or
e 
an
d 
af
te
r R
M
M
). 
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Sm
PC
 
an
d 
pa
tie
nt
s’
 
ed
uc
at
io
na
l 
br
oc
hu
re
 
A
ss
es
s 
ef
fe
ct
iv
en
es
s 
of
 
ris
k 
m
in
im
is
at
io
n 
m
ea
su
re
s+
To
 
in
ve
sti
ga
te
 
RM
P 
sa
fe
ty
 
co
nc
er
ns
+D
ru
g 
U
til
isa
tio
n 
St
ud
y 
Lo
ng
itu
di
na
l/ 
Se
co
nd
ar
y 
da
ta
 
co
lle
ct
io
n:
 
Ex
ist
in
g 
re
gi
str
y 
(P
oo
le
d 
an
al
ys
is 
of
 
in
di
vi
du
al
 
pa
tie
nt
 d
at
a 
fro
m
 
co
ho
rts
 
pa
rti
ci
pa
tin
g 
in
 
th
e 
EP
PI
CC
 
re
gi
str
y:
 
be
fo
re
 
an
d 
af
te
r 
ap
pr
ov
al
 
of
 
R
M
M
) 
  
A
ll 
pa
tie
nt
s i
n 
th
e 
ex
ist
en
t 
co
ho
rts
 
m
ee
tin
g 
el
ig
ib
ili
ty
 c
rit
er
ia
 
Be
ha
vi
ou
r 
   
M
ea
su
re
s 
to
 a
ss
es
s 
su
cc
es
s 
of
 
RM
M
 n
ot
 p
ro
vi
de
d;
 
Pa
tie
nt
s 
w
ill
 b
e 
de
sc
rib
ed
 b
as
ed
 
on
 o
n-
of
f/l
ab
el
 st
at
us
; 
O
ut
co
m
e 
m
ea
su
re
: 
N
ot
 e
xp
lic
it 
bu
t 
ra
tio
na
l 
su
gg
es
ts
 
of
f-l
ab
el
 
w
ill
 b
e 
as
se
ss
ed
 b
ef
or
e 
an
d 
af
te
r 
RM
M
; 
O
th
er
 P
A
SS
 in
 th
e 
da
ta
ba
se
? 
N
o.
 
16
 
Sm
PC
 
an
d 
ed
uc
at
io
na
l 
br
oc
hu
re
 
A
ss
es
s 
ef
fe
ct
iv
en
es
s 
of
 
ris
k 
m
in
im
is
at
io
n 
m
ea
su
re
s+
To
 
in
ve
sti
ga
te
 
RM
P 
sa
fe
ty
 
co
nc
er
ns
+D
ru
g 
U
til
isa
tio
n 
St
ud
y 
Lo
ng
itu
di
na
l/ 
Se
co
nd
ar
y 
da
ta
 
co
lle
ct
io
n:
 
re
tro
sp
ec
tiv
e 
ch
ar
t 
re
vi
ew
 
(th
re
e 
qu
es
tio
nn
ai
re
s 
se
nt
 to
 p
hy
si
ci
an
s 
ov
er
 t
hr
ee
 y
ea
rs
 
to
 
re
qu
es
t 
ag
gr
eg
at
e 
da
ta
) 
Ta
rg
et
 
al
l 
H
BV
 
tre
at
in
g 
ph
ys
ic
ia
ns
 c
ar
in
g 
fo
r 
pa
ed
ia
tri
c 
pa
tie
nt
s 
(n
o 
in
fo
rm
at
io
n 
on
 
ho
w
 th
ey
 w
ill
 b
e 
id
en
tif
ie
d)
 
Be
ha
vi
ou
r 
   
N
o 
de
ta
ils
 
on
 
ho
w
 
th
e 
ef
fe
ct
iv
en
es
s 
of
 R
M
M
 w
ill
 b
e 
as
se
ss
ed
.  
O
ut
co
m
e m
ea
su
re
: N
ot
 p
ro
vi
de
d;
 
O
th
er
 P
A
SS
 in
 th
e 
da
ta
ba
se
? 
N
o.
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Ed
uc
at
io
na
l 
pr
og
ra
m
 f
or
 
ph
ys
ic
ia
ns
 
an
d 
pa
tie
nt
s 
Ef
fe
ct
iv
en
es
s o
f 
ris
k 
m
in
im
is
at
io
n 
m
ea
su
re
s 
Cr
os
s-
se
ct
io
na
l/ 
Pr
im
ar
y 
da
ta
 
co
lle
ct
io
n:
 
Q
ue
sti
on
na
ire
s 
to
 
pr
es
cr
ib
er
s 
an
d 
pa
tie
nt
s 
 
-U
p 
to
 
5 
Eu
ro
pe
an
 
co
un
tri
es
  
-R
an
do
m
 s
am
pl
e 
(s
im
pl
e 
or
 
st
ra
tif
ie
d)
 
fro
m
 
ph
ys
ic
ia
n 
pa
ne
l 
or
 p
re
sc
rib
er
 l
ist
 
(a
s 
av
ai
la
bl
e 
an
d 
ta
ki
ng
 
in
to
 
ac
co
un
t 
ge
og
ra
ph
ic
 
lo
ca
tio
n 
an
d 
se
tti
ng
) 
an
d 
re
as
se
ss
ed
 
af
te
r 
pr
od
uc
t 
is 
la
un
ch
ed
 
-P
at
ie
nt
s 
w
ill
 b
e 
re
cr
ui
te
d 
w
he
n 
re
tu
rn
in
g 
to
 
se
co
nd
 
vi
sit
 
in
 
pr
ac
tic
es
 
pr
es
cr
ib
in
g 
th
e 
pr
od
uc
t 
Re
ce
ip
t o
f R
M
M
 
K
no
w
le
dg
e 
Se
lf-
re
po
rte
d 
be
ha
vi
ou
r 
  
O
n-
lin
e 
qu
es
tio
nn
ai
re
s 
fo
r 
ph
ys
ic
ia
ns
 
an
d 
in
te
rv
ie
w
 
w
ith
 
tra
in
ed
 p
er
so
na
l f
or
 p
at
ie
nt
s; 
Q
ue
sti
on
na
ire
s 
te
ste
d 
th
ro
ug
h 
co
gn
iti
ve
 
in
te
rv
ie
w
s 
in
 
ph
ys
ic
ia
ns
 a
nd
 p
at
ie
nt
s 
in
 l
oc
al
 
co
un
tri
es
 (
w
ith
 e
xp
er
ie
nc
e 
w
ith
 
th
e 
pr
od
uc
t);
 
D
ur
at
io
n 
of
 q
ue
sti
on
na
ire
: 
N
ot
  
pr
ov
id
ed
; 
Th
re
sh
ol
d 
fo
r 
su
cc
es
s: 
85
%
 f
or
 
ph
ys
ic
ia
ns
 a
nd
 5
0%
 p
at
ie
nt
s 
(f
or
 
sa
m
pl
e 
si
ze
 c
al
cu
la
tio
n)
; 
Ph
ys
ic
ia
ns
 o
f 
th
e 
pr
ac
tic
es
 t
ha
t 
in
cl
ud
e 
pa
tie
nt
s 
w
ill
 c
om
pl
et
e 
qu
es
tio
nn
ai
re
 
(f
or
 
ex
pl
or
at
or
y 
an
al
ys
is,
 
no
t 
in
cl
ud
ed
 
in
 
th
e 
an
al
ys
is)
; 
Q
ue
sti
on
na
ire
 n
ot
 a
va
ila
bl
e;
 
O
ut
co
m
e m
ea
su
re
: N
ot
 p
ro
vi
de
d;
 
O
th
er
 
PA
SS
 i
n 
th
e 
da
ta
ba
se
? 
O
th
er
 P
A
SS
 f
or
 t
hi
s 
m
ed
ic
in
al
 
pr
od
uc
t 
is
 r
ec
or
de
d 
in
 d
at
ab
as
e 
bu
t n
o 
de
ta
ils
 a
va
ila
bl
e 
to
 a
cc
es
s 
w
he
th
er
 it
 c
om
pl
em
en
ts
 th
is 
on
e.
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51
 
Pa
tie
nt
s’
 
ed
uc
at
io
na
l 
m
at
er
ia
ls 
A
ss
es
s 
ef
fe
ct
iv
en
es
s 
of
 
ris
k 
m
in
im
is
at
io
n 
m
ea
su
re
s+
D
ru
g 
U
til
isa
tio
n 
St
ud
y 
Co
m
bi
ne
d:
 
Lo
ng
itu
di
na
l 
pr
im
ar
y 
da
ta
 
co
lle
ct
io
n 
(p
ro
sp
ec
tiv
e 
co
ho
rt)
 +
 C
ro
ss
-
se
ct
io
na
l p
rim
ar
y 
da
ta
 
co
lle
ct
io
n 
(Q
ue
sti
on
na
ire
 to
 
a 
su
bs
et
 
of
 
pa
tie
nt
s 
fr
om
 t
he
 
co
ho
rt)
 
Se
le
ct
io
n 
of
 
st
ud
y 
sit
es
 w
ill
 b
e 
de
te
rm
in
ed
 a
t t
he
 
co
un
try
 l
ev
el
 i
n 
or
de
r 
to
 o
bt
ai
n 
a 
re
pr
es
en
ta
tiv
e 
sa
m
pl
e 
of
 
sit
es
 
re
fle
ct
iv
e 
of
 t
he
 
tre
at
m
en
t 
pa
tte
rn
s 
w
ith
in
 
ea
ch
 c
ou
nt
ry
 (
no
 
de
ta
ils
 p
ro
vi
de
d)
 
Pa
tie
nt
s: 
Re
ce
ip
t 
K
no
w
le
dg
e 
Pa
tie
nt
s 
to
 
be
 
co
nt
ac
te
d 
af
te
r 
ad
m
in
is
tra
tio
n 
of
 p
ro
du
ct
 (e
-m
ai
l 
or
 te
le
ph
on
e 
pr
ef
er
en
ce
); 
N
o 
de
ta
ils
 
on
 
qu
es
tio
nn
ai
re
 
de
ve
lo
pm
en
t a
nd
 v
al
id
at
io
n;
 
N
o 
de
ta
ils
 
on
 
qu
es
tio
nn
ai
re
 
de
ve
lo
pm
en
t a
nd
 v
al
id
at
io
n;
 
Th
e 
pr
os
pe
ct
iv
e 
da
ta
 c
ol
le
ct
io
n 
se
em
 
in
de
pe
nd
en
t 
fro
m
 
th
e 
pa
tie
nt
s’
 a
ns
w
er
s; 
O
ut
co
m
e m
ea
su
re
: N
ot
 p
ro
vi
de
d;
 
O
th
er
 P
A
SS
 in
 th
e 
da
ta
ba
se
? 
N
o;
 
Th
e 
dr
ug
 
ut
ili
sa
tio
n 
st
ud
y 
co
m
po
ne
nt
 is
 n
ot
 d
isc
us
se
d 
as
 a
 
co
m
po
ne
nt
 
to
 
ad
dr
es
s 
ef
fe
ct
iv
en
es
s o
f R
M
M
. 
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Ed
uc
at
io
na
l 
pr
og
ra
m
 f
or
 
ph
ys
ic
ia
ns
 
an
d 
pa
tie
nt
s 
A
ss
es
s 
ef
fe
ct
iv
en
es
s 
of
 
ris
k 
m
in
im
is
at
io
n 
m
ea
su
re
s 
Cr
os
s-
se
ct
io
na
l/ 
Pr
im
ar
y 
da
ta
 
co
lle
ct
io
n:
 
Q
ue
sti
on
na
ire
s 
to
 
pr
es
cr
ib
er
s, 
pa
tie
nt
s 
an
d 
ca
re
gi
ve
rs
 
Li
st
of
 
pr
es
cr
ib
er
s 
to
 b
e 
pr
ov
id
ed
 
by
 
M
A
H
 - 
 q
uo
ta
s o
f 
ta
rg
et
 
pa
rti
ci
pa
nt
s 
(e
.g
. 
by
 sp
ec
ia
lis
t) 
w
ill
 
be
 
ra
nd
om
is
ed
 
w
ith
in
 st
ra
tu
m
 
Re
ce
ip
t 
an
d 
us
ag
e 
K
no
w
le
dg
e 
Se
lf-
re
po
rte
d 
be
ha
vi
ou
r 
Th
re
e 
(p
hy
si
ci
an
/p
at
ie
nt
/ 
ca
re
gi
ve
r) 
se
ts 
of
 
w
eb
-b
as
ed
 
su
rv
ey
s;
 
D
ur
at
io
n 
of
 
qu
es
tio
nn
ai
re
: 
25
 
m
in
 fo
r H
CP
s a
nd
 1
5-
20
 m
in
ut
es
 
fo
r p
at
ie
nt
s; 
Th
re
sh
ol
d 
fo
r s
uc
ce
ss
: 8
5%
; 
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 c
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at
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at
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ns
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in
g 
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e 
ta
rg
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 b
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l 
/ 
Se
co
nd
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io
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re
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pe
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en
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N
et
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ct
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iv
e 
tre
at
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tie
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 p
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 p
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de
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 a
re
 p
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 m
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n 
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ab
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 d
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l p
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ro
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pr
es
cr
ib
e 
pr
od
uc
t –
 st
at
ed
 a
 
fe
as
ib
ili
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 m
at
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 p
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at
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r o
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 c
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rie
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da
rd
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th
in
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al
ou
d”
. 
Pr
ot
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tio
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 d
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 p
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pr
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at
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 c
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at
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m
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m
e m
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 p
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pr
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at
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at
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ra
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at
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ra
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at
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at
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 b
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ra
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 m
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rg
er
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 b
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w
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ed
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m
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ou
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nt
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 d
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cr
ib
e 
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e 
pa
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rn
s 
of
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 in
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l c
ar
e 
an
d 
ev
al
ua
te
 th
e 
ef
fe
ct
iv
en
es
s o
f r
isk
 m
in
im
isa
tio
n 
in
te
rv
en
tio
ns
. P
ro
pe
rly
 im
pl
em
en
te
d,
 
a 
na
tu
ra
lis
tic
 d
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ig
n 
ca
n 
de
cr
ea
se
 th
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im
pa
ct
 o
f t
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aw
th
or
ne
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ffe
ct
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 th
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nd
en
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f p
eo
pl
e 
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ct
 a
ty
pi
ca
lly
 w
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n 
th
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 k
no
w
 th
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re
 b
ei
ng
 o
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er
ve
d.
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 C
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m
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e 
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e 
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g 
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y 
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ot
oc
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 sh
ou
ld
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te
rfe
re
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ith
 u
su
al
 c
ar
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tre
at
m
en
t o
f p
at
ie
nt
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th
at
 a
 c
rit
ic
al
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vi
ew
 o
f p
hy
sic
ia
n 
pr
ac
tic
e 
is 
no
t a
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je
ct
iv
e 
of
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pr
oj
ec
t. 
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 p
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s t
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at
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 c
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Re
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at
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 b
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t r
ev
ie
w
) 
A
 m
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 d
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 p
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 f
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 p
ro
vi
de
d 
(c
om
pl
ia
nc
e 
w
ith
 R
M
M
); 
O
th
er
 P
A
SS
 in
 th
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at
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ra
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ra
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 b
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 c
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D
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at
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e m
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 p
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 p
ro
du
ct
: 
on
e 
cr
os
s—
se
ct
io
na
l 
su
rv
ey
 
as
se
ss
in
g 
pr
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 d
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itu
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 f
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 p
re
sc
rib
in
g 
th
e 
m
ed
ic
in
al
 
pr
od
uc
t).
 
Th
e 
pr
es
cr
ib
er
s w
ill
 b
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 p
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at
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 r
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re
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 b
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at
ie
nt
s 
pr
os
pe
ct
iv
e 
co
ho
rt)
 +
 C
ro
ss
-
se
ct
io
na
l p
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at
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b l
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at
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 p
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re
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at
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 f
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at
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 t
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l d
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Th
is 
an
ne
x 
di
sp
la
ys
 th
e 
ar
ea
s o
f c
on
ce
rn
 c
on
sid
er
ed
 re
sp
on
sib
le
 fo
r t
he
 re
je
ct
io
n/
ob
je
ct
io
n 
of
 th
e 
PA
SS
 p
ro
to
co
ls 
by
 th
e 
PR
A
C.
 T
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 v
er
ba
tim
 
te
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 p
re
se
nt
ed
 g
ro
up
ed
 b
y 
su
bc
at
eg
or
y 
co
nt
ai
ni
ng
 s
im
ila
r c
om
m
en
ts 
(b
ul
le
t p
oi
nt
s)
 a
nd
 th
e 
hi
gh
-le
ve
l c
at
eg
or
y 
la
be
l a
ttr
ib
ut
ed
 to
 s
im
ila
r 
co
m
m
en
ts 
w
ith
 th
e 
nu
m
be
r o
f c
om
m
en
ts 
in
 e
ac
h 
on
e.
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de
sig
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(n
=2
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 o
f c
om
pa
ra
to
r (
“d
es
pi
te
 c
ha
lle
ng
es
 p
os
ed
 b
y 
re
cr
ui
tm
en
t, 
a 
co
m
pa
ra
to
r a
rm
 w
as
 n
ec
es
sa
ry
 si
nc
e 
hi
sto
ric
al
 c
on
tro
ls 
w
er
e 
us
ed
 in
 
th
e 
cl
in
ic
al
 d
ev
el
op
m
en
t ”
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ap
pr
op
ria
te
ne
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 to
 a
dd
re
ss
 d
iff
er
en
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af
et
y 
ob
je
ct
iv
es
 u
sin
g 
th
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sa
m
e 
m
et
ho
do
lo
gy
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sin
gl
e 
pr
ot
oc
ol
 to
 a
dd
re
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 b
ot
h 
th
e 
re
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ire
m
en
t 
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 co
nd
uc
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 d
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e r
eg
ist
ry
 a
nd
 to
 p
er
fo
rm
 a 
re
tro
sp
ec
tiv
e c
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rt 
re
vi
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 to
 a
ss
es
s o
ff-
la
be
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ra
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 re
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 c
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 c
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 d
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 c
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 p
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at
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at
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 re
sid
ua
l s
ou
rc
es
 o
f b
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at
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 c
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l c
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ef
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 f
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ba
se
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 d
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ex
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 r
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 p
at
ie
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w
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ro
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 b
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eg
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e 
re
as
on
s 
in
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ud
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lo
w
in
g 
co
nt
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 c
ol
le
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in
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at
ie
nt
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 s
w
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be
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ee
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m
en
ts
, a
ss
es
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en
t o
f c
om
pa
ra
tiv
e 
sa
fe
ty
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ev
al
ua
tio
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of
 lo
ng
-te
rm
 sa
fe
ty
 in
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 m
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e 
co
m
pl
et
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w
ay
.”
 
• 
N
o 
sp
ec
ifi
c 
de
ta
ils
 p
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t p
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su
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 c
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 b
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 p
ro
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ra
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 d
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 b
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ra
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 o
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at
io
n 
on
 p
at
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r m
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 d
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 p
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 p
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e m
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 d
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 p
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 re
su
lts
”,
 “r
eq
ue
ste
d 
m
ea
su
re
s t
o 
gu
ar
an
te
e t
ha
t t
he
re
 is
 n
o 
in
te
rfe
re
nc
e b
et
w
ee
n 
th
e p
ro
sp
ec
tiv
e P
A
SS
 an
d 
th
e r
et
ro
sp
ec
tiv
e D
U
S”
,
“a
pp
ro
ac
h 
to
 m
in
im
ise
 se
le
ct
io
n 
bi
as
 a
nd
 p
ro
vi
di
ng
 a
 c
la
rif
ic
at
io
n 
th
at
 th
e 
ap
pr
oa
ch
 b
ei
ng
 u
se
d 
w
ou
ld
 b
e 
ab
le
 to
 se
le
ct
 a
 re
pr
es
en
ta
tiv
e
sa
m
pl
e 
of
 th
e 
el
ig
ib
le
 p
at
ie
nt
 p
op
ul
at
io
n”
, “
co
nc
er
ns
 w
er
e 
ex
pr
es
se
d 
on
 th
e 
fe
as
ib
ili
ty
 o
f t
he
 p
ro
po
se
d 
stu
dy
 c
on
sid
er
in
g 
th
at
 th
e 
da
ta
so
ur
ce
 s
el
ec
te
d 
w
ou
ld
 n
ot
 d
el
iv
er
 th
e 
ex
pe
ct
ed
 r
es
ea
rc
h 
qu
es
tio
ns
 w
ith
in
 th
e 
sp
ec
ifi
ed
 ti
m
ef
ra
m
e 
du
e 
to
 li
m
ite
d 
sta
tis
tic
al
 p
ow
er
”,
“c
ha
lle
ng
es
 a
ss
oc
ia
te
d 
w
ith
 th
e 
stu
dy
 d
es
ig
n’
s 
ab
ili
ty
 to
 a
dd
re
ss
 c
on
ce
rn
s 
ab
ou
t t
he
 s
af
et
y 
of
 th
e 
hi
gh
er
 lo
ad
in
g 
do
se
”,
 “
de
sig
n 
an
d
co
nd
uc
t o
f t
he
 s
tu
dy
 th
at
 c
ou
ld
 th
re
at
en
 th
e 
va
lid
ity
 o
f t
he
 re
su
lts
”,
 “
cl
ar
ifi
ca
tio
ns
 o
n 
m
ea
su
re
s 
to
 m
on
ito
r a
nd
 a
vo
id
 s
el
ec
tio
n 
bi
as
”,
“m
ea
su
re
s t
o 
m
in
im
ise
 c
on
fo
un
di
ng
 b
y 
in
di
ca
tio
n.
”,
 “
re
du
ce
 re
sid
ua
l s
ou
rc
es
 o
f b
ia
s”
, “
 su
gg
es
tio
ns
 a
im
in
g 
at
 st
re
ng
th
en
in
g 
th
e 
stu
dy
w
er
e 
m
ad
e 
in
te
nd
ed
 to
 c
on
tro
l t
he
 p
ot
en
tia
lly
 s
ig
ni
fic
an
t i
m
pa
ct
 o
f e
xp
os
ur
e/
ou
tc
om
e 
m
isc
la
ss
ifi
ca
tio
n”
, “
PR
A
C 
ex
pr
es
se
d 
co
nc
er
n
th
at
 th
is 
da
ta
ba
se
 w
ill
 su
ffe
r f
ro
m
 se
le
ct
io
n 
bi
as
 b
as
ed
 o
n 
th
e 
fig
ur
es
 p
ro
vi
de
d.
 “
•
Pr
el
im
in
ar
y 
ev
id
en
ce
 to
 su
pp
or
t f
ea
sib
ili
ty
 “
pr
es
en
ta
tio
n 
of
 a
 fi
rs
t a
na
ly
sis
 o
f t
he
 re
ac
tio
ns
 to
 b
e 
stu
di
ed
 in
 o
rd
er
 to
 d
ef
in
e 
th
e 
ba
sis
 o
f
ca
lc
ul
at
io
n”
, “
PR
A
C 
re
qu
es
te
d 
th
e 
M
A
H
 to
 c
on
si
de
r a
 p
ilo
t t
o 
te
st 
da
ta
 c
ol
le
ct
io
n 
m
et
ho
ds
” 
(n
=2
)
•
N
o 
sp
ec
ifi
c 
de
ta
ils
 p
ro
vi
de
d 
(n
=1
, 6
%
)
18
0 
D
at
a 
an
al
ys
is 
(n
=1
8)
: 
•
M
os
t c
om
m
en
ts 
ha
d 
in
su
ffi
ci
en
t d
et
ai
l t
o 
un
de
rs
ta
nd
 th
e n
at
ur
e o
f t
he
 re
qu
ire
d 
re
vi
sio
n 
sta
tin
g 
th
e n
ee
d 
to
 p
ro
vi
de
 fu
rth
er
 d
et
ai
ls 
(n
=2
),
cl
ar
ifi
ca
tio
ns
 (n
=3
), 
th
e 
ne
ed
 to
 s
ub
m
it 
a 
sta
tis
tic
al
 a
na
ly
sis
 p
la
n 
(n
=1
) r
eg
ar
di
ng
 th
e 
pr
es
en
te
d 
an
al
ys
is.
 O
nl
y 
th
re
e 
pr
es
en
te
d 
m
or
e
de
ta
ile
d 
in
fo
rm
at
io
n 
(“
ha
nd
lin
g 
of
 m
iss
in
g 
da
ta
”,
 “
 p
ar
tic
ul
ar
 c
ha
ng
es
 in
 th
e 
th
er
ap
eu
tic
 in
di
ca
tio
n 
sh
ou
ld
 b
e 
ta
ke
n 
in
to
 c
on
sid
er
at
io
n
in
 th
e 
an
al
ys
es
 o
f 
ut
ili
sa
tio
n 
pa
tte
rn
s 
as
 w
el
l a
s 
re
le
va
nt
 ti
m
in
g 
re
ga
rd
in
g 
im
pl
em
en
ta
tio
n 
of
 th
e 
re
vi
se
d 
pr
od
uc
t i
nf
or
m
at
io
n 
an
d
di
str
ib
ut
io
n 
of
 th
e 
re
la
te
d 
D
H
PC
” 
an
d 
“s
et
 th
e 
m
in
im
um
 a
cc
ep
ta
bl
e 
pe
rc
en
ta
ge
 o
f H
ea
lth
ca
re
 P
ro
fe
ss
io
na
ls 
pr
ov
id
in
g 
co
rre
ct
 a
ns
w
er
s
fo
r e
ac
h 
of
 th
e 
stu
dy
 o
bj
ec
tiv
es
 in
 o
rd
er
 to
 c
on
sid
er
 th
e 
ov
er
al
l p
ro
gr
am
m
e 
to
 b
e 
ad
eq
ua
te
ly
 su
cc
es
sf
ul
 fo
r e
ac
h 
of
 th
e 
ris
ks
”)
•
N
o 
sp
ec
ifi
c 
de
ta
ils
 p
ro
vi
de
d 
(n
=8
/1
8,
 4
4%
)
D
at
a 
so
ur
ce
/ p
op
ul
at
io
n 
(n
=1
6)
 
•
Re
cr
ui
tm
en
t/ 
sa
m
pl
in
g 
str
at
eg
y 
“I
n 
ad
di
tio
n 
to
 re
cr
ui
tm
en
t o
f s
tu
dy
 p
ar
tic
ip
an
ts 
vi
a 
gy
na
ec
ol
og
ist
s, 
th
e 
stu
dy
 is
 a
lso
 to
 re
cr
ui
t s
tu
dy
pa
rti
ci
pa
nt
s v
ia
 g
en
er
al
 p
ra
ct
iti
on
er
s”
, “
in
cl
us
io
n 
of
 se
rio
us
 c
as
es
”
•
A
de
qu
ac
y 
of
 d
at
a 
so
ur
ce
: “
co
nc
er
n 
th
at
 th
is 
da
ta
ba
se
 w
ill
 s
uf
fe
r f
ro
m
 s
el
ec
tio
n 
bi
as
 b
as
ed
 o
n 
th
e 
fig
ur
es
 p
ro
vi
de
d.
 T
he
 M
A
H
 s
ho
ul
d
pr
ov
id
e 
ju
sti
fic
at
io
n 
on
 t
he
 p
ro
po
rti
on
 o
f 
gy
na
ec
ol
og
ist
s 
in
cl
ud
ed
 i
n 
th
e 
da
ta
ba
se
 i
n 
th
e 
di
ffe
re
nt
 c
ou
nt
rie
s”
, t
he
 P
RA
C 
th
er
ef
or
e
re
co
m
m
en
de
d 
th
e 
M
A
H
 to
 p
ro
vi
de
 a
 n
ew
 s
tu
dy
 p
ro
to
co
l f
or
 th
e 
sa
fe
ty
 e
va
lu
at
io
n,
 w
hi
ch
 s
ho
ul
d 
in
cl
ud
e:
 A
 th
or
ou
gh
 o
ve
rv
ie
w
 o
f a
ll
EU
 d
at
a 
so
ur
ce
s p
ot
en
tia
lly
 a
bl
e 
to
 d
et
ec
t e
lig
ib
le
 p
at
ie
nt
s”
, “
ju
sti
fic
at
io
n 
fo
r u
se
 o
f a
 se
le
ct
ed
 p
op
ul
at
io
n 
ov
er
 th
e 
to
ta
l p
op
ul
at
io
n 
of
th
e 
se
le
ct
ed
 d
at
ab
as
e”
•
N
o 
sp
ec
ifi
c 
de
ta
ils
 p
ro
vi
de
d 
(n
=1
1/
16
, 6
9%
)
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 O
bj
ec
tiv
es
/ e
nd
po
in
ts
 (n
=1
2)
 
• 
N
ee
d 
to
 c
on
sid
er
 a
dd
iti
on
al
/a
m
en
d 
ob
je
ct
iv
es
 “
th
e 
pr
ot
oc
ol
 s
ho
ul
d 
in
cl
ud
e 
on
ly
 t
re
at
m
en
ts 
on
-la
be
l 
as
 m
ai
n 
ob
je
ct
iv
es
, t
he
 s
tu
dy
 
ob
je
ct
iv
es
 sh
ou
ld
 b
e 
re
vi
se
d”
, ,
 a
m
en
dm
en
t o
f t
he
 re
se
ar
ch
 q
ue
sti
on
 a
nd
 o
bj
ec
tiv
es
 to
 re
fle
ct
 c
om
pa
ris
on
s b
ef
or
e 
an
d 
af
te
r t
he
 re
fe
rra
l”
, 
“t
o 
in
cl
ud
e 
th
e 
ad
di
tio
na
l o
bj
ec
tiv
e 
of
 o
bt
ai
ni
ng
 lo
ng
-te
rm
 d
ise
as
e 
pr
og
re
ss
io
n 
da
ta
 a
nd
 sp
ec
ifi
c 
en
dp
oi
nt
s”
 
• 
N
ee
d 
to
 c
on
sid
er
 m
or
e 
m
ea
su
ra
bl
e 
ob
je
ct
iv
es
/ e
nd
po
in
ts 
de
fin
iti
on
 “
M
A
H
 sh
ou
ld
 tr
an
sla
te
 th
e 
ov
er
al
l g
oa
ls 
of
 th
e 
PA
SS
 a
nd
 D
U
S 
in
to
 
m
or
e 
sp
ec
ifi
c 
m
ea
su
ra
bl
e 
ob
je
ct
iv
es
”,
 “
pr
ov
id
e 
cl
ar
ifi
ca
tio
n 
on
 th
e 
pr
im
ar
y 
an
d 
se
co
nd
ar
y 
en
d-
po
in
ts”
 
• 
O
bj
ec
tiv
es
 n
ot
 a
dd
re
ss
in
g 
th
e 
pu
rp
os
e 
of
 t
he
 s
tu
dy
 s
et
 i
n 
th
e 
RM
P 
“t
he
 s
tu
dy
 w
as
 i
nc
lu
de
d 
in
 t
he
 R
M
P 
to
 a
dd
re
ss
 o
th
er
 n
on
-
ca
rd
io
va
sc
ul
ar
 s
af
et
y 
co
nc
er
ns
. N
ev
er
th
el
es
s, 
th
es
e 
sa
fe
ty
 c
on
ce
rn
s 
ar
e 
no
t a
de
qu
at
el
y 
ad
dr
es
se
d 
in
 th
e 
pr
ot
oc
ol
, t
he
re
fo
re
 th
e 
PR
A
C 
su
gg
es
te
d 
th
at
 su
ch
 a
dd
iti
on
al
 e
nd
po
in
ts 
sh
ou
ld
 b
e 
m
on
ito
re
d 
ap
pr
op
ria
te
ly
” 
• 
N
o 
sp
ec
ifi
c 
de
ta
ils
 p
ro
vi
de
d 
(n
=5
/1
2,
 4
2%
) 
 
Sa
m
pl
e s
iz
e 
(n
=1
0)
: 
• 
St
at
ist
ic
al
 p
re
ci
sio
n 
“e
xp
an
d 
th
e g
eo
gr
ap
hi
ca
l s
co
pe
 o
f t
he
 st
ud
y 
(a
nd
/o
r e
xt
en
d 
th
e o
bs
er
va
tio
n 
tim
e i
n 
or
de
r t
o 
ga
in
 st
at
ist
ic
al
 p
re
ci
sio
n 
fo
r t
he
 st
ud
y 
re
su
lts
” 
• 
St
at
ist
ic
al
 p
ow
er
 “
co
nc
er
ns
 w
er
e 
ex
pr
es
se
d 
co
ns
id
er
in
g 
th
at
 th
e 
pr
op
os
ed
 d
at
a 
so
ur
ce
 d
ue
 to
 li
m
ite
d 
sta
tis
tic
al
 p
ow
er
.”
, “
stu
dy
 si
ze
 a
nd
 
po
w
er
” 
• 
Cl
ar
ifi
ca
tio
n/
 n
ee
d 
to
 a
m
en
d 
sa
m
pl
e 
siz
e 
“d
isc
us
sio
n 
on
 p
ro
po
se
d 
lo
st 
to
 fo
llo
w
-u
p 
ra
te
 (5
 %
), 
up
da
tin
g 
ac
co
rd
in
gl
y 
th
e 
nu
m
be
r o
f 
pa
tie
nt
s t
o 
be
 e
nr
ol
le
d 
(if
 a
pp
lic
ab
le
)”
, “
fu
rth
er
 ju
sti
fic
at
io
n 
is 
ne
ed
ed
 o
n 
th
e 
pr
op
os
ed
 sm
al
l s
am
pl
e 
siz
e”
, “
Th
e 
PR
A
C 
co
ns
id
er
s t
ha
t 
3,
00
0 
pa
tie
nt
s i
s t
he
 re
qu
ire
d 
sa
m
pl
e 
siz
e 
fo
r t
hi
s d
ru
g 
ut
ili
sa
tio
n 
stu
dy
 a
nd
 th
er
ef
or
e 
do
es
 n
ot
 a
gr
ee
 w
ith
 th
e 
M
A
H
’s
 p
ro
po
sa
l t
o 
on
ly
 
in
cl
ud
e 
1,
00
0 
pa
tie
nt
s.”
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•
N
o 
sp
ec
ifi
c 
de
ta
ils
 p
ro
vi
de
d 
(n
=4
/1
0,
 4
0%
)
T i
m
el
in
es
/ M
ile
st
on
es
 (n
=9
) 
•
Co
nc
er
ns
 t
o 
av
oi
d 
stu
dy
 d
el
ay
 “
Th
e 
PR
A
C 
co
ns
id
er
ed
 t
ha
t 
a 
stu
dy
 w
ith
 r
es
ul
ts 
de
liv
er
ed
 i
n 
20
15
 w
as
 e
ss
en
tia
l 
fo
r 
th
e 
fu
rth
er
ch
ar
ac
te
ris
at
io
n 
of
 th
e 
ve
no
us
- 
an
d 
ar
te
ria
l t
hr
om
bo
tic
 r
isk
 o
f 
th
e 
pr
od
uc
t. 
Th
e 
PR
A
C 
th
er
ef
or
e 
ad
vi
se
d 
th
at
 th
e 
CH
M
P 
im
po
se
 a
n
ob
lig
at
io
n 
fo
r p
os
t-a
ut
ho
ris
at
io
n 
sa
fe
ty
 st
ud
y”
, “
th
e s
tu
dy
 fo
cu
s o
f t
he
 P
A
SS
 sh
ou
ld
 b
e t
he
 p
rim
ar
y 
en
dp
oi
nt
 v
en
ou
s t
hr
om
bo
em
bo
lis
m
,
an
d 
th
us
 th
er
e 
sh
ou
ld
 n
ot
 b
e 
fu
rth
er
 d
el
ay
 to
 st
ar
t t
he
 st
ud
y 
in
 re
la
tio
n 
to
 a
dd
iti
on
al
 se
co
nd
ar
y 
en
dp
oi
nt
s”
, “
Th
e 
M
A
H
 is
 re
qu
es
te
d 
by
th
e 
PR
A
C 
to
 st
ar
t t
he
 su
rv
ey
 a
s s
oo
n 
as
 p
os
sib
le
 ”
•
Co
ns
id
er
at
io
ns
 o
n 
ap
pr
op
ria
te
ne
ss
 o
f t
im
el
in
es
 “
th
e 
ap
pr
op
ria
te
ne
ss
 o
f t
he
 e
xt
en
de
d 
tim
el
in
e 
w
ill
 b
e 
pr
ov
id
ed
 u
po
n 
pr
ov
isi
on
 o
f t
he
se
da
ta
”,
 “
a 
re
vi
sio
n 
of
 th
e 
tim
el
in
es
 to
 ta
ke
 in
to
 a
cc
ou
nt
 th
e 
di
ss
em
in
at
io
n 
of
 e
du
ca
tio
na
l m
at
er
ia
l”
•
N
o 
sp
ec
ifi
c 
de
ta
ils
 p
ro
vi
de
d 
(n
=4
/9
, 4
4%
)
D
at
a 
co
lle
ct
io
n/
 m
an
ag
em
en
t (
n=
7)
: 
•
Re
co
m
m
en
da
tio
n 
of
 s
pe
ci
fic
 in
str
um
en
ts 
“t
he
 M
A
H
 s
ho
ul
d 
su
pp
or
t t
he
 k
ee
pi
ng
 o
f a
 tr
ea
tm
en
t d
ia
ry
 f
or
 a
ll 
pa
tie
nt
s 
w
ho
 h
av
e 
be
en
in
cl
ud
ed
 in
 th
e 
stu
dy
 to
 e
ns
ur
e 
a 
su
ffi
ci
en
t d
oc
um
en
ta
tio
n 
of
 a
ny
 a
dv
er
se
 e
ve
nt
 d
ur
in
g 
ho
m
e 
tre
at
m
en
t”
,
•
N
ee
d 
to
 c
ol
le
ct
 c
er
ta
in
 d
at
a/
 d
at
a 
va
lid
at
io
n 
“ 
th
e 
M
A
H
 sh
ou
ld
 b
e 
re
qu
es
te
d 
to
 su
bm
it 
a 
su
m
m
ar
y 
of
 th
e 
da
ta
 li
ke
ly
 to
 b
e 
av
ai
la
bl
e 
on
ot
he
r k
ey
 a
sp
ec
ts 
of
 th
e 
sa
fe
ty
 p
ro
fil
e 
to
 a
ss
es
s 
w
he
th
er
 th
ey
 m
ee
t t
he
 re
qu
ire
m
en
ts 
in
cl
ud
ed
 in
 th
e 
RM
P”
, “
cl
ar
ify
 d
at
a 
on
 e
xp
os
ur
e
th
at
 w
ill
 b
e 
re
co
rd
ed
, a
nd
 to
 p
ro
vi
de
 a
 d
at
a 
va
lid
at
io
n 
pl
an
”
•
N
ee
d 
fo
r c
la
rif
ic
at
io
n 
“c
la
rif
y 
th
at
 th
e 
da
ta
 c
ol
le
ct
io
n 
w
ill
 b
e 
pe
rfo
rm
ed
 in
 a
 c
om
pl
et
el
y 
re
tro
sp
ec
tiv
e 
w
ay
 b
as
ed
 o
n 
ch
ar
t r
ev
ie
w
s”
•
O
th
er
 “
ph
ar
m
ac
og
en
et
ic
 st
ud
y 
co
ul
d 
be
 a
cc
ep
ta
bl
e 
pr
ov
id
ed
 a
n 
up
da
te
d 
pr
ot
oc
ol
 w
ith
 th
e 
ch
an
ge
s r
eg
ar
di
ng
 sa
m
pl
in
g,
 se
qu
en
ci
ng
”
 18
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• 
N
o 
sp
ec
ifi
c 
de
ta
ils
 p
ro
vi
de
d 
(n
=2
/7
, 2
9%
) 
 V
ar
ia
bl
es
 (n
=5
): 
O
nl
y 
on
e 
co
m
m
en
t r
eg
ar
di
ng
 th
e 
ne
ed
 to
 d
es
cr
ib
e 
co
nc
om
ita
nt
 m
ed
ic
at
io
ns
 “
in
cl
ud
in
g 
a 
de
sc
rip
tio
n 
of
 a
ny
 c
on
co
m
ita
nt
 c
om
bi
ne
d 
ho
rm
on
al
 
co
nt
ra
ce
pt
iv
e 
(C
H
C)
 u
se
, w
hi
ch
 is
 c
on
tra
in
di
ca
te
d”
 
N
o 
de
ta
ils
 p
ro
vi
de
d 
(n
=4
/5
, 8
0%
). 
 O
th
er
: 
• 
Ra
tio
na
l a
nd
 b
ac
kg
ro
un
d 
“t
o 
cl
ar
ify
 th
e 
ra
tio
na
le
 a
nd
 b
ac
kg
ro
un
d,
” 
• 
D
at
a 
pr
ot
ec
tio
n 
“T
he
 P
RA
C 
re
qu
es
ts 
in
cl
ud
e 
in
fo
rm
at
io
n 
on
 h
ow
 th
e 
us
e 
of
 a
no
ny
m
is
ed
 d
at
a 
w
ill
 b
e 
en
su
re
d”
 
• 
PA
SS
 o
bl
ig
at
io
n 
“T
he
 P
RA
C 
co
ns
id
er
ed
 th
at
 a
 st
ud
y 
w
ith
 re
su
lts
 d
el
iv
er
ed
 in
 2
01
5 
w
as
 e
ss
en
tia
l f
or
 th
e 
fu
rth
er
 c
ha
ra
ct
er
is
at
io
n 
of
 th
e 
ve
no
us
- 
an
d 
ar
te
ria
l 
th
ro
m
bo
tic
 r
isk
 o
f 
th
e 
pr
od
uc
t. 
Th
e 
PR
A
C 
th
er
ef
or
e 
ad
vi
se
d 
th
at
 t
he
 C
H
M
P 
im
po
se
 a
n 
ob
lig
at
io
n 
fo
r 
po
st-
au
th
or
isa
tio
n 
sa
fe
ty
 st
ud
y 
in
 ac
co
rd
an
ce
 w
ith
 A
rti
cl
e 1
0a
 o
f t
he
 R
eg
ul
at
io
n 
(E
C)
 N
o 
72
6/
20
04
.”
, “
Th
e P
RA
C 
co
nf
irm
ed
 th
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